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KYNURENINASE: SYNTHESIS OF SUBSTRATE ANALOGUES ANDMECHANISTIC STUDIES.
Kynureninase (EC.3.7.1.3) is an unusual pyridoxal 5'-phosphate (PLP) dependent 
enzyme which catalyses the p-y hydrolytic cleavage of kynurenine to give anthranilic acid 
and alanine. The enzyme is a potential therapeutic target for controlling the levels of 
metabolites, quinolinic acid and kynurenic acid, that are important in a variety of 
neurodegenerative and inflammatory disorders, such as Alzheimer's disease, AIDS, Lyme 
disease and poliovirus. Studies have been carried out to elucidate the mechanism of the 
enzyme.
A phosphinic acid analogue of kynurenine, designed as a putative transition state mimic 
for the reaction, has been prepared. This was found to be a competitive inhibitor, with a 
K iof 4.19 mM when its interaction with kynureninase, isolated from Pseudomonas 
fluorescens^ was examined. The corresponding methyl phosphinate was also prepared. 
This was found to be a more potent inhibitor, with a Kj of 0.88 mM. It is proposed that 
méthylation of the acid removes a destabilising interaction between the negative charge of 
the ionised phosphinic acid and some group of the active site.
A number of analogues of kynurenine were prepared in order to obtain information on the 
specificity of the enzyme and the interactions at the active site. A racemic mixture of 
desaminokynurenine was found to have a Ki of 23.2 p.M. Cyclohexyl and naphthyl 
amino acid derivatives prepared by the same method were found to be weak competitive 
inhibitors of the enzyme with Ki values of 844 p,M and 207 |iM repectively. 
Desaminokynurenine was found to be a substrate with a rate of reaction twenty times 
slower than that of kynurenine. The naphthyl amino acid derivative was also found to be 
a substrate. The results suggested that interactions with the aromatic ring are important 
and that the naphthyl amino acid derivative may be too large for the active site.
The synthesis of 25-[2-^H]-kynurenine is described using two different routes. 
Diacetylation / racémisation of racemic kynurenine in deuterium oxide followed by acylase 
catalysed resolution is the most direct route. The alternative is to prepare 2S-[2-'^E]- 
tryptophan by a similar procedure and then to convert this to 26^-[2-%]-kynurenine via 
ozonolysis. This compound has been used in isotope studies to gain an understanding of 
the mechanism of the enzyme catalysed reaction. The primary deuterium isotope effect, 
= 0.98 and ^(V/K) = 3.6, showed that for the kynureninase catalysed reaction, a-H 
abstraction is partially rate limiting. A solvent isotope effect, = 4.4 and ^(V/K) = 4.6 
was also determined, showing that a proton transfer is also partially rate limiting.
CHAPTER
1. INTRODUCTION.
1.1 BACKGROUND.
Kynureninase (EC 3.7.1.3) is a pyridoxal 5' phosphate (PLP) dependent enzyme which 
catalyses the p,y-hydrolytic cleavage of 25'-kynurenine (1) to give anthranilic acid (2) and 2S- 
alanine (3)^ (Scheme 1.1). The enzyme has been purified from a number of sources 
including Pseudomonas marginalis^ Neurospora crassa ,^rat liver^ and porcine liver.^
CO2-
PLP CO2*
NH3+ " Y "  'NH3+ ^  NH3+
Scheme 1.1
The enzyme also catalyses the hydrolysis of 3-hydroxykynurenine (4) and the relative rates of 
the two substrates have been observed to vary with enzyme preparations from different 
sources. For example, the pseudomonad enzyme hydrolyses kynurenine five times faster 
than 3-hydroxykynurenine,^ while the liver enzyme hydrolyses the hydroxy derivative twice 
as rapidly as kynurenine."^
Kynurenine is a major metabolite of tryptophan (5), on one of its three major pathways of 
metabolism (Scheme 1.2) (The other two are the serotonin and the tryptamine pathways). 
The metabolites on the kynurenine pathway include 25-kynurenine (1), 3-hydroxykynurenine 
(4), 3-hydroxyanthranilic acid (6), anthranilic acid (2), quinolinic acid (7), picolinic acid, 
xanthurenic acid, nicotinic acid and nicotinamide to mention those that have been investigated 
most.^
C0 2 H
TRYPTOPHAN METABOLIC PATHWAY
ÇO2 H
r II NH2
A.
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KYNURENIC ACID
HgO
CO2 H
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^ N ^ C O a H  
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,-------- \  NAD
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Scheme 1.2
(10)
Although kynurenic acid was recognised long ago as a tryptophan metabolite, it was not until 
about 1947 that the kynurenine pathway was recognised as a major route for the conversion 
of tryptophan to nicotinamide and its nucleotide conjugates.^ It was some years later that 
quinolinic acid was accepted as an intermediate. Interest in the kynurenine pathway was long 
centred around its importance as a source of nicotinamide and as a major disturbed pathway in 
cases of vitamin B6 d e f ic ie n c y b e in g  an essential cofactor for several of the kynurenine 
enzym es.However, more recently interest has been reawalcened due to the discovery of the 
neurological importance of some metabolites on the pathway.^
1.2 THE TRYPTOPHAN METABOLIC PATHWAY.
The kynurenine pathway is the major route of tryptophan catabolism. However, as it 
provides the pyridine nucleus of the nicotinamide nucleotide coenzymes it must also be 
regarded as an important biosynthetic pathway.
The first step of the pathway is oxidative cleavage of the heterocyclic ring of tryptophan by 
either tryptophan 2,3-dioxygenase (EC 1.13.11.11) or by indolamine 2,3-dioxygenase (EC 
1.13.11.17). The immediate product of this is AT-formyl kynurenine (8) which is rapidly 
hydrolysed to kynurenine (1) by a formamidase enzyme (EC 3.5.1.9). In mammals, fungi 
and many micro-organisms kynurenine has three fates. It can undergo hydrolysis to 
anthranilic acid (2) catalysed by kynureninase (EC 3.7.1.3). The anthranilic acid is used as a 
precursor for the synthesis of aromatic amino acids. Alternatively, it can undergo 
transamination to kynurenic acid (9) which is the biosynthetic precursor of some of the 
quinolines. This is catalysed by the enzyme kynurenine aminotransferase (KAT, EC 
2.6.1.7). Finally, it can undergo hydroxylation to give 3-hydroxykynurenine (4) catalysed 
by kynurenine 3-hydroxylase (EC 1.14.13.9). This last is the major fate of kynurenine 
arising from the oxidation of physiological amounts of tiyptophan and leads into the pathway 
of nicotinamide nucleotide sy n th esis .K y n u ren in ase  is also able to hydrolyse 3-
hydroxykynurenine to give 3-hydroxyanthranilic acid (6). Rearrangement then yields 
quinolinic acid, the most neurologically important metabolite on the pathway. This is 
catalysed by 3-hydroxyanthranilate oxidase (EC 1.13.11.6). Quinolinic acid is then 
converted to nicotinic acid mononucleotide (10) by quinolinate phosphoribosyl transferase 
(QPRTase, EC 2.4.2.19). Further transformations may then follow, leading to the 
nicotinamide coenzymes.
1.2.1 Oxidative Cleavage of Tryptophan.
There appear to be two distinct enzymes which catalyse the oxidative cleavage of the indole 
ring of tryptophan and they are both haem dependent. Tryptophan dioxygenase (EC 
1.13.11.11) in the liver and indolamine 2,3-dioxygenase (EC 1.13.11.17) in most other 
tissues.^^
1.2.1.1 Tryptophan 2.3-Dioxvgenase.
Tryptophan dioxygenase is rate limiting for the entry of tryptophan into the irreversible 
pathway of catabolism of what is, for mammals, an essential amino acid. The mammalian 
enzyme has a short half life (of the order of two hours) and is subject to regulation by several 
different mechanisms.
The enzyme from fungi and bacteria appears to be essentially the same as that from 
mammalian liver. Both are tetramers with a unit molecular weight of 103 000 and two haem 
groups per tetramer.^^ The enzyme is haem dependent. Tryptophan binds to the activated 
form of the holo-enzyme (enzyme-haem complex) and the complex then binds oxygen. The 
enzyme activity is increased by tryptophan and a number of tryptophan analogues such as a- 
methyl tryp tophan .T hese act by stabilising the holo-enzyme and promote conjugation of 
the apo-enzyme with the haem complex. They do not compete with tryptophan at the catalytic 
site but bind to a regulatory site which is distinct from the catalytic site.^^ Ascorbate is used
as the reductant in vitro to increase activity although it is possible that the ultimate reductant in 
vivo is superoxide.
Wiseman et al. carried out isotope effect studies on tryptophan dioxygenase and proposed a 
mechanism from the results (Scheme 1.3).^^
R
jEnz—B
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H (11) 
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Scheme 1.3
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- — - 4R ^2
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A primary solvent deuterium isotope effect of 4.4 at pH 7.0 implied that abstraction of the 
indole proton was at least partially rate limiting. An inverse secondary isotope effect of 0.96 
at pH 7.0 was observed indicitive of a change in hybridisation from sp^ to sp3 at position 2. 
This is consistent with C-O bond formation at C-2. Since the secondary isotope effect 
increased with pH as the solvent isotope effect decreased, proton transfer and bond formation 
at C-2 must represent different steps in the reaction mechanism. Furthermore, the proton
transfer step must precede C-O formation. Variation of oxygen concentration did not 
significantly effect the secondary isotope effect and this can be taken as indication of a 
predominantly ordered binding pattern with oxygen binding first. Stepwise rather than 
concerted formation of the oxetane (11) was proposed as the initial deprotonation of the indole 
would make the concerted pathway energetically inaccessible. The final product arises via 
decomposition of the oxetane, consistent with labelling studies that show both of the new 
oxygen atoms in the product are derived from molecular oxygen.
The activity of tryptophan dioxygenase is readily and rapidly modified by substrate 
availability. The enzyme is sensitive to induction by both glucocorticoid hormones and 
glucagon whereas insulin prevents induction.^ High concentrations of the nicotinamide 
nucleotide coenzymes, especially NADPH both inhibit preformed tryptophan synthase and 
repress its synthesis by binding at the regulatory site of the enzyme.
Seifert described a tryptophan dioxygenase assay which used liver slices as the source of 
the enzyme and simultaneous HPLC determination of the formyl kynurenine and kynurenine 
formed from tryptophan. This assay has a major advantage of being able to discriminate 
between formyl kynurenine and kynurenine in defining tryptophan dioxygenase activity as 
both products could be detected spectroscopically after their separation on a reversed-phase 
Ci8 column.
1.2.1.2 Indolamine 2.3-Dioxvgenase.
Indolamine dioxygenase is a monomeric haem containing glycoprotein with a moleculai" 
weight of 41 000. Unlike tryptophan dioxygenase this enzyme is a superoxide dependent 
enzyme which requires the presence of free radical generating systems, such as ascorbate and 
methylene blue, for activity in vitro. In vivo the role of the dye is thought to be assumed by 
either a flavin (eg FMNH2 ) or tetrahydrobiopterin, for which there is likely to be a specific
binding site.^^ Superoxide dismutase inhibits the enzyme and superoxide is the oxygenating 
agent. The enzyme has a broad specificity and acts on 2S- and 2/?- tryptophan, 2S- and 2R- 
5-hydroxytryptophan, tryptamine, serotonin and m elatonin .Indolam ine dioxygenase is 
widely distributed in mammalian tissues, having been identified not only in the distial ileum, 
but also in the stomach, lung and brain. However it is not present in either liver or Iridney. 
The human enzyme is found in a variety of tissues with especially high activity in lung, small 
intestine and placenta. The enzyme is not induced by the same mechanisms as tryptophan 
dioxygenase and contains no activating site for tryptophan analogues. There are few 
mechanistic data on the reaction and no isotope effects have been measured. However, a 
similar mechanism to that of tryptophan dioxygenase is likely as they are both haem- 
dependent enzymes.
Whereas tryptophan dioxygenase is induced by a number of physiological factors as 
discussed above, indolamine dioxygenase appears to respond to pathological stress and it is 
induced by y-interferon. Induction of the enzyme results in depletion of available tryptophan,
which is the least abundant of the essential amino acids required for cellular integrity. Such a 
restriction of available tryptophan would more severely effect rapidly dividing cells, such as 
microbial pathogens and tumour cells, as tryptophan is required for replication. As a result 
the enzyme has apparent antimicrobial and antitumour properties.^® Nitiic oxide, the product 
of nitric oxide synthase initiated arginine degradation, is a regulator of haem enzymes. It has 
been found that both exogenous and endogenous NO is capable of inhibiting indolamine 
dioxygenase activity in y-interferon primed mononuclear phagocytes m vitro. A  plausible 
mechanism by which NO inhibits indolamine dioxygenase is via interaction with the haem 
iron present at the active site of the enzyme because NO has a high affinity for haem ii'on. 
Such binding may interfere with the conversion of ferric to ferrous iron required for 
indolamine dioxygenase catalysis.^^ Oxidative arginine and tryptophan metabolism in y- 
interferon primed mononuclear phagocytes are therefore functionally related. This provides
an insight into how cells may use these methods to regulate their antimicrobial and anti-tumor 
activities.
1.2.1.3 Inhibitors of Dioxygenases.
Bender has studied the effect of three drugs on tryptophan metabolism in the rat. 
Benserazide (12), Carbidopa (13) and Isoniazid (14) are potent inhibitors of tryptophan 
oxygenase and kynureninase.
HO OH 
H2N. " /
N-N” C
(12)
CH3HO
.H2 0
NHNH2 CONHNH2
( 13) (14)
As inhibitors of tryptophan oxygenase they would be expected to reduce the entry of 
tryptophan into the pathway of nicotinamide nucleotide synthesis. The anti-Parkinsonian 
dmgs Benserazide and Carbidopa are thought to be inhibitors because their phenolic nature 
allows them to interact with the haem binding site. Isoniazid is not phenolic but it is possible 
that it is capable of interacting with the regulatory site of tiyptophan oxygenase. It has been 
shown that a number of hydrazine derivatives of tryptophan analogues are more potent 
inhibitors of tryptophan oxygenase than are the parent compounds and suggested that the 
hydrazines can interact with the haem binding site of the enzyme, thus preventing activation of 
apo-tryptophan oxygenase.^^ A number of indole derivatives and p-carboline derivatives 
have also been tested with both enzymes. Peterson^^ has prepared a number of derivatives 
and analogues of tryptophan to elucidate the structural requirements of tryptophan
10
dioxygenase. Cady and Sono tested l-methyl-2/?5-tryptophan (15), p“(3-benzofuranyl)- 
2i?5-alanine (16, the oxygen analogue of tiyptophan) and p-(3-benzo(Z?)thienyl)-2i?5-alanine 
(17, the sulphur analogue of tryptophan), each of which was found to be a competitive 
inhibitor for tryptophan dioxygenase. However, none of these compounds acted as 
substrates, indicating that the free form of the indole nitrogen is an important physical and / or 
electronic structural requirement for tiyptophan to be metabolised by the enzyme.
CHg
(15) X = 0(16)X = S(17)
Eguchi^^ and Peterson have tested a number of p-carboline derivatives including 
norharman (18). Norharman is the most potent inhibitor known for both enzymes from 
mammalian sources. It is a non-competitive inhibitor of indoleamine dioxygenase^^ and 
competitive inhibitor of tryptophan dioxygenase.Peterson  has reported 3-butyl-|3- 
carboline (19) as the most potent inhibitor of indoleamine dioxygenase with a Ki of 3.3 fxM 
(the Km of 25'-tryptophan is 13 pM).
Y=H (18) 
Y="Bu (19)
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1.2.2 ICyEisresîine Formamidase.
The immediate product of oxidative cleavage of the indole ring of tryptophan, catalysed by 
either tryptophan dioxygenase or indoleamine dioxygenase is iV’-formyl kynurenine. This is 
rapidly hydrolysed to kynurenine by kynurenine formamidase (EC 3.5.1.9) with release of 
formate. The enzyme from all sources is essentially the same, however there are some 
differences in substrate specificity and sensitivity to inhibitors. Kynurenine formamidase has 
a relatively broad substrate specificity and will hydrolyse a number of aryl formylamines, 
including 2S- and 2/?-/V’-formyl kynurenine, N’-formyl hydroxykynurenine and iV’-formyl 
anthranilate.
Kynurenine formamidase will not hydrolyse N-formyl kynurenine and this forms the basis of 
an assay for the enzyme. If iV’, iV-diformyl kynurenine (20) is employed as the substrate the 
product is iV-formyl kynurenine which accumulates in the medium and its concentration can 
be monitored.
O CO2H
M"/ °O (20)
1.2.2.1 Inhibitors of Kvnurenine Formamidase.
Penwim and Seifert^^ have shown that kynurenine formamidase is inhibited very strongly by 
organophosphorus and methylcarbamate insecticides. These compounds altered the formation 
of several 25-tryptophan metabolites associated with the 25-kynurenine pathway in mice. 
Liver kynurenine formamidase was inhibited almost completely by Diazinon (21), which is 
one of its most potent inhibitors in vivo?^ Diazinon and related compounds show toxicity 
due to cholinesterase inhibition but also have a degree of non-cholinergic toxicity.
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The structural requirements for optimal kynurenine formamidase inhibition were studied by 
testing a number of organophosphorus compounds Q 2)P
E tO ^
EtO
R‘0
R'O
(22)
R"
R'=Allcyl, X = S orO  
R" = AUcyl or Aryl
Pyrimidinyl phosphorothioates followed by crotonamide phosphates were the most potent 
compounds. Replacement of sulphur by oxygen in the phosphorothioate Diazinon reduced in 
vivo liver kynurenine fomamidase inhibition. The aryl phosphorothioates may be thought of 
as transition state mimics for the hydrolysis reaction and therefore bind tightly to the enzyme 
active site thus explaining the potent inactivation (Scheme 1.4).^^
O COgH
Formamidase
L  JL  NHg Î3=»
"H
B— Enz
O COgH
^HB'^Enz
+ HCO2H
Scheme 1.4
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1.2.3. Kynurenmase.
Moriguchi, Yamamoto and Soda have purified and crystallised kynureninase from 
Pseudomonas marginalis? The enzyme is composed of two identical subunits and the 
molecular weight determined by electrospray ionisation mass spectrometry was 45 484 per 
subunit for kynureninase isolated from Pseudomonas fluorescens Note that Pseudjomonas 
fluorescens was formerly known as Pseudomonas marginalis?^ The partial amino acid 
sequence has also been determined from this source as well as the sequence from rat liver 
kynureninase.^^ In addition, Alberatigiani et al. have isolated human kynureninase.^^ One 
mole of pyridoxal phosphate is bound per mole of enzyme. The enzyme exhibits absorption 
maxima at 280,337 and 430 nm (see Graph 1.1).
Absorption spectrum of the enzyme in 0.01 M potassium phosphate buffer, pH 7.2.
0.5
o o o
VO
T t
wavelengtli
Graph 1.1
Moriguchi et at. ^  obtained a UV spectrum indicative of a bound pyridoxal phosphate for pig 
liver kynureninase. A peak in the 430 range is characteristic of a pyridoxal phosphate bound
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to the enzyme as a Schiff s base with an amino group. This characteristic spectrum and also 
the isolation of £-iV-pyridoxyllysine from the hydrolysate of borohydride reduced enzyme 
show that PLP is bound to an e-amino group of a lysine residue of the protein through an 
aldimine linkage.
The enzyme was found to be stable in the pH range 5.8-8.0 when heated at 50 °C for five 
minutes (see graph 1.2). The enzyme has an optimum reactivity at about pH 8 , when 
examined in the presence of Tris-HCl buffer and potassium phosphate buffer (see graph 
1.3).3‘‘
too
g 00
>-H"
=! 60CO<1—CO 40Hi>
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0
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Graph 1.2: Effect of pH on enzyme stability Graph 1.3: Effect of pH on kynureninaseactivity
The buffers used were acetate 
(@) for pH 4.7-5.8 , potassium phosphate 
(O) for pH 5.8-7.8,Tris-HCl (A) for 
pH 7.6-9.0 and glycine-NaOH (A) for 
pH 8.8-10.5.
The buffers used were acetate
(©) for pH 4.7-5.8 , potassium phosphate
(O) for pH 5.8-8.0, Tris-HCl
(A) for pH 7.6-9.0 and glycine-
NaOH (A) for pH 8.8-10.5.
15
A paper by Hayaishi and Stanier stated that the activity of kynureninase may be measured 
conveniently either by spectrophotometric or manometric methods. Manometric assays of 
kynureninase were made by measuring carbon dioxide evolution resulting from acid 
production in bicarbonate buffer in an atmosphere of 5% carbon dioxide and 95% nitrogen at 
30 °C.^^ All the spectrophotometeric methods involved measurement of the decrease in 
absorbance at 360 nm (e= -4500 M'lcm-i) upon the conversion of kynurenine to anthranilic 
acid at 25 °C. However, different buffers have been employed. The standard assay system 
of Moriguchi et al. consisted of 200 pmol of tris(hydroxymethyl)amino methane (pH 8.0), 
1 pmol of 25-kynurenine sulphate, 0.2 pmol of PLP and enzyme in a final volume of
3.1 ml.^ "^  The assay buffers used by Phillips and Dua contained 0.4 mM 25"-kynurenine in 
0.04 M potassium phosphate (pH 7.8) with 40 pM PLP.^^
1.2.3.2 Substrate Specificity.
A number of kynurenine analogues have been prepared to obtain information on 
kynureninase structure and mechanism. Although the enzyme from Pseudomonas 
fluorescens and Pseudomonas marginalis is identical, different results have been obtained by 
different groups.^’ This could be due to the different methods of detection employed. 
These include measuring the alanine formed by paper chromatography or determining 
anthranilic acid derivatives formed fluorometrically or determining the hydrolysis of the 
substrate spectophotomerically. The results (summarised in table 1.1) show that the 
a-amino group is essential and that only the 25'-enantiomers are reactive. When the aromatic 
ortho-?iïmno group of kynurenine is blocked with a formyl group (23), replaced by a nitro 
group (24) or moved to the para-position (25) the activity disappears. The derivatives in 
which the aromatic amino group is substituted by a hydroxy group (26), or removed (27), 
show some activity with the enzyme, although the rate of reaction is considerably decreased. 
The introduction of a hydroxyl group to the aromatic ring (28) significantly decreases the 
reaction rate but the fluoro compound (29) has high reactivity.
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Relative reactivity (%), kynureninase of
Rat liver^ Pseudomonas
fluorescens^
Pseudomonas
marginalis^
(1) O C02‘
++ 100 100
(23) O GO2
0 14.9
(24) 0  CO2
- 0
(25) 0  Ç0 2 - 
N H2-JV NH3+ 0
(26) 0  CDs’
13.4
(27) 0  CO2
++ 6.0 2.7
(28) 0 CO2
55.0 1.2
(29) 0  Ç0 2W - 91.2
(30) OH ÇO2
65.1
(31) OH ÇO2
O ^ h" . ++
(32) OH CO2*
+
(33) 0  C0 2 '
NH3 + +
Table 1.1
a-Relative reactivities are expressed as relative amounts of alanine formed.^^
b-Relative reactivities were determined by measuring spectrophotometrically the substrate hydrolysed.^ 
c-data from reference.^^
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The occurrence of y-carbonyl group is not essential in substrates because y-hydroxy 
derivatives (30, 31, 32) are also cleaved (see 1.2.3.5 Further Mechanistic Studies). 
Compounds (32) and (33) were also found to be substrates, suggesting that an aryl group is 
not necessarily required (Table 1.1).
The results show that the aromatic amino group at the ortho-position of kynurenine has a 
significant influence on the reactivity. The relative rates of hydrolysis of the analogues may 
be explained, although not quantitatively, by the inductive and resonance effects of 
substituents (ie. NH2 , NO2 , OH etc ) and by only the inductive effect of mgfa-hydroxyls as 
suggested by Hayaishi.^
However, substituents in the aromatic moiety of kynurenine have an insignificant influence 
on the affinity of the enzyme for the substrate. 2-Amino-4-oxo-4-phenyl-butyric acid (27) 
has a relatively low Km value (1.6 x 10"^ M) but is hydrolysed very slowly.^^
1.2.3.3 Stereochemistrv.
The stereochemical course of the reaction with regard to C-3 has been elegantly determined 
(Scheme 1.5) by Floss, Soda and co-workers.^^
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NHa
Tryptophan
Dioxygenase---------------
O2
Formylkynurenine^ 
Formamidase^
N-CHOH
CXl"NH2
Kynureninase
2H2O
CO2H
NH2
i f  "H
i) HNO2
ii) K2Cr2 0 7 /H+
2H ^C 02H  
^ (36)
Scheme 1.5
(25,3/?)-Kynurenine and (25,35')-[3-3H] kynurenine (34) were first prepared from the 
corresponding stereospecifically tritiated tryptophan species (35) by enzymic methods. They 
were then converted into alanine using kynureninase in deuterium oxide. Alanine can be 
converted into acetic acid (36), by diazotisation and dichromate oxidation, for chiral analysis 
of the methyl group by the method of Cornforth,^^ to determine the steric course of the 
replacement of the anthranilyl group by hydrogen. The reaction was found to occur with 
retention of configuration i.e. the proton is added on the same side from which the anthranilyl 
group has depaited.
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1.2.3.4 Proposed mechanism.
Of all the mechanisms proposed the following seems the most reasonable and accounts for 
the above results (Scheme 1.6).^^
H
(37)
Enzyme
until H
H2+B^ H (38)
Enzyme
Oiiiiiii HO
,/^ H
*b02
H)N ^ c :  ' ^
HgrHjB
XEnzyme
h. c/ h
I
OIIIIIII H (2h)
. HgB
Enzyme
O IHO Hp^ B^ H
vtI/' Enzyme
(®H)
PLP-Enzyme
R= \\
X
X= HgO, OH, 
NHs  ^ Enz-Nu’
Scheme 1.6
The PLP binds to the apoenzyme via the e-amino group of an active site lysine residue to 
give a Schiff s base. This is termed the internal aldimine and is common to most other 
pyridoxal phosphate dependent enzymes. Kynurenine then binds to the enzyme and a 
transaldimination reaction talces place, displacing the active site lysine and forming a Schiff s
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base between the PLP and kynurenine (37), the external aldimine. Cleavage of the Ca-H 
bond then generates the ketimine intermediate (38), a resonance-stabilised carbanionic 
species. As suggested by Dunathan,"^  ^orientation of the Ca-H bond perpendicular to the n 
plane of the substrate-pyridoxal phosphate Schiff s base should favour cleavage of this bond 
by maximising orbital overlap between the electrons of the a(Ca-H) bond and the extended 
n system of the cofactor. Attack of an enzymic nucleophile, water molecule or hydroxide ion 
(X) then takes place at the y-carbonyl group of the quinoid intermediate. The p,y-carbon- 
carbon bond is cleaved to give anthranilate and an a-aminoacrylate derivative (39). For the 
above stereoelectronic reasons the Cp,Cy bond should be oriented perpendicular to the plane 
of the PLP 7i-system. However it may lie on the same or the opposite side to the Ca-H 
bond. The stereochemical results show that protonation of the a-aminoacrylate is 
stereospecific and therefore enzyme mediated, and that it occurs with retention. Therefore, 
the departing anthranilyl group and the base delivering a proton must be disposed on the 
same face of the pyridoxal phosphate-substrate complex. The finding of internal proton 
recycling from the a-proton of the substrate kynurenine, not only to the a-position but also 
to the p-position of the product alanine, indicates that proton abstraction / addition at C a and 
protonation at Cp are mediated by the same base. This and the observed retention of 
stereochemistry, support an active site conformation of the pyridoxal phosphate-substrate 
complex in which the a-hydrogen and the anthranilyl group at Cp are syn oriented. It was 
assumed but not proven, that they were both on the si face relative to C4' of the coenzyme, 
as in all other PLP dependent enzymes so fai" examined.^^ The identity of the active site base 
has not been confirmed. ICishore'^  ^ observed alkylation of an active site carboxyl group 
using mechanism based inhibitors of kynureninase, implying that this was involved. 
However the observed partitioning of the tritium between Ca and Cp of alanine also suggests 
that the base mediating these proton transfers is polyprotic such as the e-amino group of a 
lysine residue.
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Although the stereochemistry is Icnown for the reaction, the identity of X in the hydrolysis 
step is unloiown. The hydrolysis could be mediated by a water molecule bound at the active 
site using general base catalysis from the enzyme, or alternatively, by an enzymic 
nucleophile. This is currently one of the main areas of investigation and several putative 
inhibitors have been designed in an attempt to distinguish between the two alternatives (see 
Chapter 2).
1.2.3.5 Further mechanistic studies
Trapping of the a-aminoacrylate intermediate (40) with added aromatic aldehydes was 
obsei’ved by Bild and Morris.^^ The characteristics of the novel reaction product produced 
from benzaldehyde (41) and kynurenine, in the presence of kynureninase and pyridoxal 
phosphate, are consistent with the identity of the compound as 2-amino-4-hydroxy-4- 
phenylbutyiic acid (42). Phillips and Dua demonstrated that the reaction was stereospecific 
and that only the (25,4/?) isomer was formed.^^ The aromatic ring is derived from 
benzaldehyde, as shown by the dependence of the reaction on the presence of benzaldehyde 
and the observation that the substitution of other aromatic aldehydes for benzaldehyde 
produced a predictable variation in the Rf value on thin layer chromatography plates. 
Radioactive labelling demonstrated that the side chain of kynurenine was incorporated into 
the product.
It therefore appears that the a-aminoacrylate intermediate, once formed, can partition in the 
presence of benzaldehyde to form either alanine or 2-amino-4-hydroxy-4-phenylbutyric acid 
(Scheme 1.7). The reaction is specific to aromatic aldehydes, which is presumably a 
consequence of the ability of aromatic electrophiles to bind to the site normally occupied by 
either anthranilic acid or the aromatic portion of kynurenine. The observed product would 
seem to suggest that the a-aminoacrylate intermediate has a sufficiently long lifetime to enable 
the anthranilic acid to debind from the active site, and the benzaldehyde bind and undergo
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reaction. It would seem feasible that 2-amino-4-hydroxy-4-phenylbutyric acid could be 
formed equally as well from alanine or kynurenine. It was, however, determined that the 
reaction proceeded only approximately 1% as rapidly with alanine. This was shown not to 
be due to an inactive enzyme conformation which would have been reconverted into an active 
conformation by the addition of anthranilate or an anthranilate analogue. It was, therefore, 
reasoned that formation of the a-aminoacrylate intermediate (40) from alanine may be 
thermodynamically less favourable than from kynurenine."^^
%
H OH 9 ^ 2 NH? Ph. J
+ PLP-Enz
Scheme 1.7
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1.23.6 Inhibitors of kynureninase.
A number of compounds have been observed to act as mechanism based inhibitors of 
kynureninase. These have all been ^-substituted amino acids, a class of compounds known 
to inhibit PLP dependent enzym esE xam ples include p-chloro-25-alanine and 25'-serine- 
0-sulphate. Interestingly the ortho- amino group, as observed in kynurenine is not necessary 
for activity since 2-amino-4-oxo-4-phenyl-butyric acid is a substrate for the enzyme and (5- 
chloro-alanine and analogues are inhibitors. The most potent, however, was 2^-S-(ortho- 
nitrophenyl)-cysteine (43) presumably as a result of the strong binding interaction between 
the aromatic moiety and the active site.
CO2-
NH3+
"NO2 (43)
The effects of various aromatic compounds on kynureninase activity have also been 
investigated.^^ 0-Aminophenyl compounds having a carbonyl group, especially a formyl 
group are most inhibitoiy. 0-Aminobenzaldehyde, o-aminoacetophenone and benzaldehyde 
inhibit about 80-40% of the activity, while o-nitrobenzaldehyde and anthranilic acid are much 
less inhibitory, and aniline, benzoic acid and acetophenone are not inhibitory at all. The 
inhibition by o-aminobenzaldehyde is non-competitive with the substrate. This could be due 
to o-aminobenzaldehyde binding only to the enzyme aminoacrylate complex and as this does 
not compete with the binding of kynurenine to the enzyme non-competitive inhibition results 
(Scheme 1.8)
-A *E + Ky E.Ky E.A.B E.B E.Ala E + Ala
E = enzyme, Ky = Kynurenine, A = anthranilate, B = aminoacrylate, Ala = alanine.
Scheme 1.8
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Phillips and Dua^^ examined both diastereomers of 2-amino-4-hydroxy-4-phenylbutyric acid 
(30, dihydro-2S-kynurenine) as inhibitors of kynureninase from Pseudomonas fluorescens. 
The {AR,2S) diastereomer was a potent competitive inhibitor with a Ki of 1.4 pM but was 
also a substrate for the enzyme, undergoing a retro-aldol cleavage reaction (Scheme 1.9)  ^ to 
give 2-aminobenzaldehyde (44) and 25-alanine (3). The (45,25) diastereomer was an even 
more potent competitive inhibitor with a Ki of 0.3 pM but did not act as a substrate.
OH COgH
_  . COgHKynui^nmas^ I j l  +
(44) (3)
Scheme 1.9
Both dihydro-25-kynurenines are similar in structure to the tetrahedral intermediate (45) 
formed if the reaction mechanism involves hydrolysis using a bound water molecule. This 
intermediate is a model of the transition state and the potent competitive inhibition exhibited 
by these compounds suggests that they are transition state analogues .^
HO  ^ OH CO2H
It was previously shown for kynureninase that reaction proceeds with retention of 
configuration at This result, along with the demonstration of stereospecific recycling 
of the a-hydrogen of the substrate to the cofactor and / or the p-carbon of the product, 
suggested that reaction took place on one side of a planar coenzyme-substrate complex and 
was catalysed by a single base in the enzyme active site. However, from the study of the 
dihydro-25-kynurenine diastereomers Phillips and Dua^^ proposed that there must be a
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second base present to remove the proton from the alcohol to facilitate the retro aldol cleavage 
(Scheme 1.10).
HBg
COg-
® o
OcCHNH2 
Scheme 1.10
The observed stereospecificity is then due to the fact that the (45',25') diastereomer of 
dihydro-25-kynurenine would have the OH oriented projecting away from the catalytic base 
and is not cleaved since proton abstraction cannot occur.
The majority of PLP dependent enzymes which catalyse  ^replacement reactions and a,13- 
elimination reactions have, like kynureninase, been shown to react with retention of 
configuration e.g. tryptophan synthetase, tyrosine phenol lyase and 25-selenocysteine (3- 
lyase."^ "^
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Kynureninase has been classified in the same group as aspartate p-decarboxylase"^^ and 25- 
selenocysteine p-lyase,^^ both of which have been studied and ai*e described below. These 
three enzymes, which catalyse p-eliminadon reactions, also catalyse transamination reactions, 
although more slowly
Aspartate p-decarboxylase catalyses the decarboxylation of 25-aspartic acid (46) to alanine 
(Scheme 1.11).
COg-
+  H+ —— ^  CO2 + JL-H
(46)
Scheme 1.11
O'Leary, Floss and coworkers studied the stereochemical course of the (3-decarboxylation of 
25-aspartic acid by incubating C-p tritiated 25-aspartic acid with the enzyme in which 
gave samples of 25-alanine containing chiral methyl groups. Determination of the 
stereochemistry of the labelled alanine revealed that p-decarboxylation had occurred 
predominantly with inversion of configuration at C-p of aspartate. This is therefore different 
from all related PLP dependent enzymes that have been studied.^’ They concluded that 
there was one base mediating deprotonation and protonation at C a and optionally protonating 
C-4' on the si face. A second enzymic base at C-p was proposed to cover the C-4' re face 
and be responsible for protonating at C-p of aspartate. Their evidence against a single base 
came from studying the transamination reaction. Incubation of the enzyme with Ca-tritiated 
25-aspartic acid led to 17% incorporation of the label at C-4' of pyridoxamine 5' phosphate 
(PMP), but only 1% appears in 25-alanine. Since protonation at C-p must precede 
protonation at C-4' a single base charged with tritium from C a should deliver more of this 
tritium at C-p than at C4'."^ ^
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However, an alternative possibility exists that transfer of hydrogen from C-a of aspartate to 
C4' of the coenzyme occurs in both the normal p-decarboxylation and abortive 
transamination, before further reaction. p-Decarboxylation would then yield the enamine (47) 
which would be protonated from the C-4' si face of the coenzyme by the enzyme bound base 
to give the ketimine with inversion of configuration. As most of the label present at C-a of 
aspartate would have already been transfered to C-4' of the coenzyme, the remaining label 
associated with the base would not be expected to result in a large enrichment at C-p of the 
ketamine. Solvent exchange must account for the small enrichment observed on the back 
transfer of 4'-H atoms to C-a as otherwise both one and two base mechanisms would predict 
significant incorporation at C-a. Rosenberg and O'Leary proposed this mechanism from 
their results that showed that a- and p- hydrogen / solvent hydrogen exchange are faster than 
the decarboxylation of 25-aspartic acid and that decaiboxylation is not entirely rate limiting."^^
Thus, a-hydrogen abstraction produces a quinoid intermediate (48) which undergoes a 
hydrogen transfer to give the ketimine intermediate (49). Decarboxylation then yields the 
corresponding enamine (47) which leads to the product and PLP as described above (Scheme
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Scheme 1.12
Selenocysteine p-lyase is a unique PLP dependent enzyme that catalyses the p-elimination of 
2S-selenocysteine (50) into 25-alanine (Scheme 1.13). The enzyme is found in mammalian 
tissues and in bacteria. Elemental selenium is released enzymatically from selenocysteine (a 
lyase reaction) and then reduced nonenzymatically to H2 Se with selenocysteine or other 
reductants in the reaction mixture.
CO2 -
HSe^ ^ ' H  + 2RXH
NH3+(50)
CO2' + H2Se
+(RX)2
Scheme 1.13
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The following mechanism has been proposed (Scheme 1.14) where the selenocysteine PLP 
complex (51) is converted into a quinoid intermediate (52) through a-hydrogen abstraction. 
Selenium is released in elemental form from this intermediate and an aminoacrylate 
intermediate (53) is formed.
® o
(51)
CO2-
Alanine + PLP
B+H
O® o ® 0
H+
(54)
Scheme 1.14
The and NMR spectra of alanine produced from selenocysteine in deuterium oxide 
indicated the enzymatic formation of and [p-%2 ] alanines. Therefore, in addition to
the incorporation of one deuterium atom into the p position of alanine after removal of 
elemental selenium one of the two p-hydrogen atoms of selenocysteine is exchanged with a 
solvent deuterium. Since the enzyme catalyses no hydrogen exchange at a  and p positions of 
alanine with a solvent deuterium, [p-% 2 ] alanine is probably formed from selenocysteine 
through the rapid reversible reaction between intermediates (53) and (54). A two-base 
mechanism was proposed for the enzyme reaction where the a-protonation and deprotonation
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is performed by one base and the other base, which is probably in its protonated form in 
order to function catalytically mediates the p-protonation.^^ Evidence for this was provided 
by the fact that when reaction was carried out in the a-hydrogen of selenocysteine was 
fully retained in the product alanine. For kynureninase, experiments were carried out to 
probe for internal transfer of tritium fix>m the a-position of kynurenine to the pmduct alanine. 
These indicated that 40% of the tritium from the a-position of the substrate is transferred to 
the p-position of the product alanine and 60% to the a-position of the product. Indicating 
that proton abstraction /  addition at C a and protonation at Cp are mediated by the same 
base.^^ Thus, a one base mechanism has been proposed for kynureninase and 
selenocysteine p-lyase and aspartate p-decarboxylase probably follows a one base 
mechanism. For kynureninase, a second base has been proposed as a result of studies on 
dihydro-25-kynurenine (See 1.2.3.6 Inhibitors of Kvnureninasel.^ * In the physiological 
reaction, the role of this second base could be removal of a proton from a water molecule to 
assist in attack of the carbonyl group.
.1.2.3.8 Transamination Catalysed bv Kynureninase.
It has also been shown that kynureninase is inactivated by 2S-alanine a reaction product, or 
by 2S-omithine (55). The activity is restored by the addition of PLP. Spectrophotometric 
studies on the inactivation indicate that the addition of 25-alanine or 25-ornithine to the 
holoenzyme leads to loss of peaks at 337 and 430 nm and appearance of a new peak at 325 
nm. Therefore, inactivation is due to formation of the bound PMP (56) from the bound PLP 
by transamination with 25-alanine or 25-omithine. The product from 25-ornithine was 
identified as A'-pyrroline-2-carboxylic acid (57), the dehydrated form of a-keto-y- 
aminovaleric acid (58) (Scheme 1.15). It is thought that the enzyme's activity as a highly 
substrate specific a-aminotransferase is important as a regulator of enzyme activity in vivo, 
by interconversion of the coenzyme from PLP to PMP.^^
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1.2.4 3-Hydroxykynurenmase.
3-Hydroxykynureninase (EC 3.7.1.3) catalyses the hydrolysis of 25-3-hydroxykynurenine to 
3-hydroxyanthranilic acid and 25-alanine. PLP is the required enzyme cofactor. The enzyme 
although catalysing a similar reaction to kynureninase is not inducible by tryptophan and 
functions primarily in the biosynthesis of NAD from tryptophan. Kynureninase is inducible 
by tryptophan and is involved in the catabolism of tryptophan.^^ Two types of kynureninase 
were isolated from Neurospora crassa. One of them was independent of the presence of
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tryptophan in the growth medium. The molecular weight and optimum pH values of both 
enzymes are very similar. However, the constitutive enzyme shows much higher activity and 
affinity for 25-3-hydroxykynurenine than for 25-kynurenine suggesting that the enzyme 
functions as a 3-hydroxykynureninase.^^
1,2.5 Kynurenine 3-hydroxylase
Kynurenine 3-hydroxylase (EC 1.14.13.9) is an external flavoprotein monoxygenase located 
in the outer mitochondrial membrane which incorporates oxygen into kynurenine to give 3- 
hydroxykynurenine. It requires FAD and either NADH or NADPH as co-reductant. The 
purified enzyme is an oligomer containing four moles of FAD per monomeric unit. The 
monomer has only about 10% of the catalytic activity of the dimer. The catalytic cycle has 
been proposed based on available kinetic and spectroscopic data^^ (Scheme 1.16).
The cycle begins with a reduced enzyme / kynurenine complex (59) which reacts with 
molecular oxygen to give the corresponding C(4a)-hydroperoxyflavin intermediate (60). 
Electrophilic attack from the hydroperoxy group to the aromatic ring of kynurenine, followed 
by electron transfer, deprotonation of the cationic substrate (61) and protonation of 
isoalloxazine anionic group leads to (62). This then undergoes dehydration of the 
hydroxyflavin moiety and liberation of 3-hydroxykynurenine. A new molecule of kynurenine 
binds to the enzyme and the catalytic cycle is completed when the enzyme / kynurenine 
complex (63) reacts with NADPH reducing the flavin and liberating NADP+.
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1.2,5.1 Inhibitors of kvnurenine-3-hvdroxvlase.
Kynurenine-3>hydroxylase from Saccharomyces carlsbergensis is inhibited by the a-oxoacids 
of branched chain amino acids. In particular, a-oxo-isocaproate (64), derived from leucine, 
is a competitive inhibitor with respect to both kynurenine (Kj = 4.2 mM) and NÂDPH (K; = 
8.3 m M )P
Pellicciari et have carried out the synthesis of nicotinylalanine (65), o-nitrobenzoyl-
(66), m-nitrobenzoyl-(67), p-nitrobenzoyl-alanine (68), all analogues of kynurenine, and 
reported their evaluation as inhibitors of kynureninase and kynurenine-3-hydioxylase. 
Nicotinylalanine with an IC5 0  of 800 ±120 p,M for kynureninase and 900 ±180  p.M for 
kynurenine-3-hydroxylase, showed similar but weak activities toward both enzymes. Of the 
nitro analogues, m-nitrobenzoylalanine, with an IC5 0  of 100 ± 12 p,M for kynureninase and 
0.9 ±0.1 fxM for kynurenine-3-hydroxylase, proved to be a potent and selective inhibitor for 
the latter enzyme.
O CO2 O CO2
A T
(64) (65) R’
(66) o- R=N02,R’=H ,R "=H
(67) m- R= H, R'= NO2, R"= H
(68) p- R= H, R'= H, R*'= NO2
In order to account for the selectivity observed molecular modelling studies were carried out 
with the three nitro analogues. In m-nitrobenzoylalanine one of the oxygen atoms of the nitro 
group was shown to mimic closely the oxygen atom of molecular oxygen involved in the 
hydrogen bonding network, thus accounting for the potent inhibition observed.
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As a continuation of this work Pellicciari et al. reported an enantioselective synthesis of (2S)- 
m-(nitrobenzoyl)-alanine along with its inhibition of kynureninase and kynurenine 3- 
hydroxylase.^^ 25-m-Nitrobenzoylalanine with an IC5 0  of 0.5 p.M proved to be the active 
constituent of the previously reported racemic mixture.
1.2.6 Kynurenine Aminotransferase.
Kynurenine aminotransferase (KAT, EC 2.6.1.7) catalyses the transamination of kynurenine. 
This reaction is irreversible as the transamination product (69) undergoes cyclisation, 
dehydration and tautomérisation to give kynurenic acid (9), which is a stable aromatic product 
(Scheme 1.17).^^
(1) (69) \
O o
CO-COhH OÇ^COzH
N ^ C O jH
Scheme 1.17
Kynurenic acid is in fact an antagonist at the glycine site of N-methyl-D-aspartate receptors 
and increased levels of kynurenic acid may exert a neuroprotective action in some pathological 
conditions (See 1.3 NEUROLOGICAL IMPORTANCE OF KYNURENINES). 
Since several PLP dependent aminotransferases with broad substrate specificity aie able to 
catalyse this reaction, the identification of the isoenzyme responsible for the biosynthesis of
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cerebral kynurenic acid is of importance for clarifying the role of this metabolic pathway in 
pathophysiology.
The enzyme has been isolated from various sources including yeasts, bacteria and mammals. 
Takeuchi et al. isolated an enzyme from rat liver mitochondria which was found to have 
identical elution patterns on all column chromatographies to a-aminoadipate aminotransferase 
(EC 2.6.1.39).^^ Alberti-Giani et a l and Mosca et a l have found a single enzyme which 
accounts for both KAT and cysteine conjugate |3-lyase (also known as, glutamine 
transaminase K, GTK, EC 2.6.1.64) activities in rat kidney cytosol.^^"^^ Buckberry reports 
a similar enzyme in human kidney.^® Malherbe et a l have isolated an enzyme in rat brain 
which is identical to the soluble form but also carries an additional stretch of thirty two amino 
acids at its NH2 terminus. Several structural features of this sequence resemble those of 
leader peptides for mitochondrial import.^ ^  By using physiological concentrations of the 
substrate kynurenine and by determining the irreversible conversion of [^HJ-kynurenine to 
[^H]-kynurenic acid as a measure of KAT activity, a novel, simple and sensitive assay was 
developed which permitted the detailed characterisation of the enzyme.^^ A single enzyme is 
responsible for kynurenic acid production in the rat brain and is found mainly in 
mitochondria. This is in contrast to the human brain which contains two distinct KAT 
proteins, KAT 1 and KAT II, capable of kynurenic acid biosynthesis.^^ Schwarcz et a l 
have confirmed the characterisation by Baran using [^H]-kynurenine as a substrate.^^ KAT I 
was found to be a dimer consisting of two identical subunits of approximately 60 kDa. 
Kinetic analyses of the pure enzyme revealed an absolute Km of 2.0 mM and 10.0 mM for 
25'-kynurenine and pyruvate respectively. Unlike KAT II activity, which displays a shallow 
pH optimum in the physiological range and does not appear to be inhibited by common amino 
acids, KAT I has a sharp pH optimum at pH 9.5-10 and is potentially blocked by glutamine, 
tryptophan or phenylalanine. This has led to the conclusion that KAT II may be preferentially
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responsible for the production of kynurenic acid under physiological conditions, whereas 
KAT I may become of particular importance in pathological situations.
1.2.6.1 Inhibitors of kynurenine aminotransferase.
Aminooxyacetic acid, a non specific transaminase inhibitor blocked KAT activity, from rat 
brain, with an apparent K% of 5 Amphetamine is a competitive inhibitor of kynurenine
aminotransferase and also kynureninase. It has been suggested that the inhibitory effect was 
due to the formation of a Schiff s base with pyridoxal phosphate, causing a reduction in the 
level of free pyridoxal phosphate, which is a co-factor for both enzymes.^^ Schwarcz et al. 
reported the synthesis of a number of substituted kynurenines, both racemic and enantiomers 
(70) and their testing with a partially purified enzyme from rat brain.^^’
O COgH
R= Cl, Br, cyclohexyl. 
Me, Et, "Pr, 'Pr
The most potent of these was 5 -chloro-kynurenine with most of the activity residing in the 2S 
enantiomer. Kinetic analysis gave a IQ for the 2S enantiomer of 5.4 pM (K m  for kynurenine 
is 28 pM). Reduction or elimination of the keto group or decaiboxylation of the amino acid 
moiety yielded compounds which were completely inactive as enzyme inhibitors. This could 
mean that a H-bond acceptor residue in the enzyme's active site is important. It was also 
shown that chlorination in positions 3 and 4 produced compounds with a relatively low 
inhibitory effect, therefore the existence of a lipophilic pocket in the active site of the enzyme 
able to bind the substituent at the 5-position of kynurenine, is likely to play a role in enzyme 
inhibition.
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1.2.7 3-Hydroxyanthranillc Acid Dioxygenase.
3-Hydroxyanthranilic acid-3,4-dioxygenase (3HAO, EC 1.13.11.6) is a monomeric cytosolic 
protein belonging to the family of intramolecular dioxygenases containing non-haem ferrous 
iron. 3HAO catalyses the cleavage of the benzene ring of 3-hydroxyanthranilic acid (6). The 
product of the reaction is an unstable intermediate, a-amino-p-carboxymuconic acid co­
semialdehyde (71) which can either spontaneously rearrange to quinolinic acid (7) or be 
converted to picolinic acid (72) after decaiboxylation (Scheme 1.18).^  ^ The rate limiting step 
in its spontaneous disappearance is probably isomérisation of the double bond to place the 
carboxyl groups in the cis position. This would be followed by a rapid condensation to form 
the stable pyridine ring. The enzyme that converts the intermediate to picolinic acid is much 
slower in its activity so the bulk of the intermediate goes spontaneously to quinolinic acid.
02/Fe2+
OH
NH;
(6)
3-HAO
(72) a
HOgC NHg (71)
a
Non-enzymatic
COgH
N COgH "N" 'COgH
Scheme 1.18
(7)
The reaction has been followed spectroscopically by Bolonan et al. An absorption maximum 
occured at 360 nm with the simultaneous disappearance of 3-hydroxyanthranilate (absorption 
maximum 315-320 nm). The product was then observed from the appearance of an 
absorption maximum at 268 nm, which indicated that the metabolism of 3- 
hydroxyanthranilate resulted in the formation of an intermediate before quinolinic acid was 
formed.^^ Conversion of the intermediate to quinolinic acid was proposed to be spontaneous
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as theoretical amounts of quinolinic acid were produced from decomposition of the 
intermediate in aqueous or ethanolic solutions after removal of the protein with 83-92% 
ethanol 7^
3HAO is widely distributed in peripheral organs such as liver and kidney and is also present 
in small amounts in the brain where the enzyme is localised in astrocytes7  ^ The enzyme has 
been isolated from rat liver, rat brain and a human enzyme has been cloned The human 
enzyme is a protein with 286 amino acid residues and a molecular mass of approximately 32 
IcDa. The enzyme has a Km for 3-hydroxyanthranilic acid of approximately 2 pM.
1.2.7.1 Inhibitiors of 3-Hvdroxyanthranilic acid Dioxygenase.
Using either liver homogenate or purified 3HAO 4-chloro-3-hydroxyanthianilic acid (73) was 
found to inhibit enzyme activity. Initially it was thought that the inhibition occurred when the
4-chloro-3-hydroxyanthranilic acid was oxidised by the enzyme to produce an electrophilic 
product (74) that can react with an active site nucleophile and irreversibly inhibit 3HAO 
(Scheme 1.19). "^^
COgH
.COgH 02/Fe2+ -^ n z -N u
Enz-Nu
Cl ^  NHg 3_HAO °  ^OH NHg (7 4 )
(73)
H.O
H O ^ C C H ^  CO^H
H O ^N ^C O gH
(75)
Scheme 1.19
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In vitro experiments indicated that this binding resulted in non-competitive inhibition of the 
enzyme. It is difficult to distinguish between competitive and non-competitive enzyme 
inhibition when dealing with dmgs which bind very tightly to the protein and also difficult to 
differentiate between reversible and irreversible inhibitors. Walsh et al. who also tested the 
fluoro- and bromo-derivatives actually detected reversibility after warming the complexes at 
37 °C. This result was confirmed when the physical association between enzyme and 
inhibitors was examined by dialysis.^^
Further examination showed the inhibition was in fact competitive in nature and gave apparent 
Ki values of 190 nM, 6  nM and 4 nM for the fluoro-, chloro- and bromo- derivatives 
respectively. Since all thiee inhibitors aie substrate analogues they may be metabolised in an 
identical manner as 3-hydroxyanthranilic acid itself and yield 6 -hydroxyquinolinic acid (75), 
although this has not been identified.^^
1,2.8 Quînolinate Phosphorlbosyl transferase (QPRTase)
Quinolinate phosphoribosyl transferase (QPRTase, EC 2.4.2.19) is an enzyme of the de novo 
NAD biosynthetic pathway. The enzyme catalyses the reaction between quinolinic acid (7) 
and 5-phosphoribosyl-l-pyrophosphate (76, FRF?) in the presence of Mg^+ to give nicotinic 
acid mononucleotide (77), pyrophosphate (78) and CO2  (Scheme 1.20).^^
" V ° v  9 9 xsI ^ O - P - O - P - c P  
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Although there are at least three different pathways to the production of quinolinic acid in 
various organisms, the formation of nicotinic acid mononucleotide and its subsequent 
conversion to NAD follows the same sequence of biosynthetic steps in all biological systems 
including micro-organisms, plants and animals.
The enzyme has been isolated from several sources including E. coli^^' a soil 
pseudomonad,^^ Alcaligens euîrophm^^ pig kidney®® and pig liver.®  ^ The enzymes have a 
varying number of subunits depending on the source, although the monomer molecular 
weight is 32 to 35 kDa. Although Mn2+ can be used by the enzyme Mg2+ is the preferred 
metal ion. The enzyme is specific for quinolinate and no reaction with nicotinate is detectable.
The chemical mechanism of decarboxylation and phosphoribosyl transfer is unknown. In 
terms of the phosphoribosyl transfer the PRPP and quinolinic acid may both bind 
simultaneously giving a ternary complex and the transfer reaction then talces place in one 
step.^® Alternatively, there could be a two step process where PRPP binds first and reaction 
takes place to eliminate pyrophosphate and leave a reactive phosphoribosyl intermediate at the 
active site. The quinolinic acid then binds and reacts with this intermediate to give the 
mononucleotide (79). From their kinetic studies Bhatia and Calvo have shown that there is an 
ordered binding mechanism where the magnesium ion complex of PRPP binds first followed 
by quinolinate. Based on inhibitor studies Bhatia and Calvo have therefore proposed a two 
step reaction for the enzyme in which quinolinic acid displaces pyrophosphate from PRPP to 
form quinolinic acid mononucleotide (79)J^ This intermediate then undergoes 
decarboxylation to yield a nitrogen y lid intermediate (80) that is protonated to give the final 
product (77) (Scheme 1.21). This type of mechanism has been proposed for orotidine-5'- 
monophosphate.®^ However, on the metabolism of orotic acid the sequence of 
phosphoribosyl transferase and decarboxylation is catalysed by two separate enzymes, 
whereas for quinolinic acid only a single protein, QPRTase, is involved.
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1.2.8.1 Inhibitors of QPRTase.
Phthalic acid (81) was a good inhibitor for QPRTase from a variety of sources. 
Picolinic acid (82) on the other hand is a potent inhibitor of enzymes from some sources^^ but 
a poor inhibitor of enzymes from others.^^ With the enzyme from Alcaligens eutrophus both 
picolinic and phthalic acid showed competitive inhibition. Picolinic acid methyl ester and 
phthalic acid butyl ester did not have much inhibitory effect. These results suggest that the 2- 
carboxyl group of quinolinic acid plays a very important role in the binding of substrate to the 
active site of the enzyme.^^
0
c c
(81)
aN C O 0
(82)
C c"X
X = SH, OH 
(83)
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Y = SH, OH 
(84)
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Kalikin and Calvo tested the activity of some quinolinic acid analogues (83, 84).^ ''^  The 2- 
hydroxy (and 2 -mercapto) pyridines exist mostly in a tautomeric form where the oxygen (or 
sulphur) is present as a carbonyl and the ring is really an unsaturated lactam (or thiolactam). 
All the compounds are inhibitors of the enzyme with the 3-nitro compounds (83) being the 
most potent. The general effect of the nitro substituent at the 3-position of pyridine is to 
increase the amount of hydroxyl or thiol form relative to lactam or thiolactam. Therefore, the 
degree of inhibition can be correlated with the degree of ionisation of the group at C-2, 
implying that a negative charge is an important contributor to tight binding of the enzyme. 
The pH dependence of the inhibition also supports this hypothesis. Kalikin and Calvo 
suggested that the inhibition observed by these pyridines with tautomeric thiolates or 
alcoholates at the 2 -position might be due to the fact that these compounds resemble the 
intermediate y lid that was formed immediately following decarboxylation. However, on the 
substrate the charge is two atoms away from the aromatic ring and the ylid has the charge on 
the ring. The inhibitors have the charge one atom away from the ring so could equally well 
mimic the substrate and not the ylid.
1.3 NEUROLOGICAL IMPORTANCE OF KYNURENINES.
In recent years there has been a resurgence of interest in the kynurenine pathway due to its 
neurological importance. Two metabolites of tryptophan, quinolinic acid (7) and kynurenic 
acid (8 ) have pronounced affects on neuronal activity. Quinolinic acid is a selective agonist 
for the N-methyl-D-aspartate (NMDA) population of receptors. Conversely kynurenic acid is 
a selective antagonist, at low concentrations, at the strychnine-resistant glycine modulatory 
site associated with the NMDA receptor^^ and may serve as the endogenous neuroprotective 
antidote to quinolinic acid.^^ Thus the balance between these two metabolites may be very 
important in maintaining the activity of the NMDA receptor.
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Of the kynurenines, quinolinic acid may be the most relevant to neurodegenerative diseases, 
since the dicarboxylic acid has been implicated in the aetiology of a number of neurologic 
disorders, including Huntington's disease, temporal lobe epilepsy, glutaric aciduria, hepatic 
encephalopathy and coma.^^ Neurotoxicity induced by quinolinic acid occurs preferentially in 
the neocortex, striatum and hippocampus, sites in the brain particularly affected by these 
disorders.
Early studies of the biochemistry of the kynurenines were concerned primarily with 
metabolism in peripheral tissues. Although tryptophan-2,3-dioxygenase activity was reported 
in brain, it was not until 1977^ that the first reports appeared of the definitive presence of any 
products of this pathway in the CNS. Since then, several of the key enzymes of the 
kynurenine pathway, including indoleamine 2,3-dioxygenase, kynureninase, kynurenine 
hydroxylase, kynurenine aminotransferase, 3-hydroxyanthranilic oxygenase and quinolinate 
phosphoribosyltransferase have been demonstrated to occur in brain tissue.^^ Using the 
incorporation of tritium label into various tryptophan metabolites Guidetti et al, provided 
evidence for a functional kynurenine pathway in the normal rat brain and for an increase in 
metabolism in lesioned tissue.®  ^ Using radiolabelled tryptophan it can be seen that 40% of 
the 2iS-kynurenine detected within the CNS is synthesised in that tissue. This implies that 
60% is derived by uptake from plasma kynurenines, synthesised in peripheral t i s s u e s . I t  
has been shown by Schwarcz et al. that 25-kynurenine is readily taken up into brain by the 
large neutral amino acid carrier of the blood brain barrier.^^ The same carrier may also 
mediate the brain uptake of 3-hydroxykynurenine. They also showed that for 3- 
hydroxyanthranilic acid, anthranilic acid, kynurenic acid and quinolinic acid uptake appeared 
to be mediated by passive diffusion. This occurred at a significant rate for anthranilic acid and 
at far lower rates for the other metabolites.
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1.3,1 Quînolmic acid.
Quinolinic acid can cause neurological damage by overstimulation of the NMDA receptor and 
it has been shown to be capable of discriminating between the NMDA receptor subtypes.^^ 
In rat brain this results in a selective pattern of nerve cell death, the neuropathology of which 
is veiy similar to that found in human diseases such as Huntington's disease and temporal 
lobe ep i l ep syT her e f or e  increased endogenous levels of quinolinic acid have been 
proposed to be an important etiological factor in these diseases. Recently, it has been 
demonstrated, using newly developed analytical procedures and labelling s tudies , tha t  
[l^Cô] kynurenic acid is synthesised from 2S-[^^Cs] tryptophan in vivo.^^
It is interesting to note that the maximal enzymatic rate for 3-hydroxyanthranilate oxygenase is 
approximately 100 fold higher than that for QPRTase, although the Michaelis Menten constant 
is about the same. Thus an increased flux of tryptophan into the kynurenine pathway could 
increase levels of quinolinic acid which QPRTase might be unable to remove. The levels of 
tryptophan are precisely regulated, human serum albumin binds tryptophan and its availability 
to cross the blood-brain barrier is determined by the amount of plasma free tryptophan. In 
addition, it is controlled by a specific large neutral amino acid transport system.
An excess of the tryptophan metabolite quinolinic acid in the brain has been hypothetically 
related to the pathogenesis of Huntington's disease.^^* Other recent studies show 
conflicting evidence^^' and it has been suggested that there is a decrease in the amount of 
kynurenic acid rather than an increase in quinolinic acid.^®^ The activity of 
3-hydroxyanthranilate oxygenase has also been observed to be increased in Huntington's 
disease brains as compared to control brains.^^
In epileptic human brain tissue Feldblum et al. showed a reduction of QPRTase activity which 
accounts for the pathological accumulation of quinolinic acid as it is not degraded.
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High levels of quinolinic acid have also been observed in the brains of patients with various 
inflammatory neurological diseases including AIDS,^®  ^lyme disease^ and poliovirus.^®^ Up 
to two thirds of AIDS patients suffer from neurological problems including dysfunction of 
cognition movement and s e n s a t i o n . S o m e  very detailed studies have shown that the 
degree of damage may be correlated with the level of quinolinic acid.^ ®"^  It seems likely that 
there is a general increase in kynurenine pathway activity which accounts for the observed 
increase in 3-hydroxykynurenine and 3-hydroxykynureninase a c t i v i t y . I t  has also been 
postulated that the HIV virus activates macrophage cells of the immune system to 
biosynthesise the quinolinic acid.^ ®^ *
Studies have also shown that infection and immune activation are associated with 
accumulations of quinolinic acid. Heyes et al. examined the cerebrospinal fluid quinolinic 
acid concenti*ations in children with infections of the central nervous system, hydrocephalus, 
tumors or haemorrhage.^®^ Extremely high concentrations of quinolinic acid were found in 
patients with bacterial infections of the central nervous system. These high concentrations are 
attributed to increased metabolism of 25-tryptophan through the kynurenine p a t h w a y . 25- 
Kynurenine levels increased in parallel to the accumulation of quinolinic acid, which is 
consistent with increased activity of indoleamine-2,3-dioxygenase.^®^ Heyes et al. concluded 
that y-interferon is an important mediator between immune stimulation and indoleamine-2,3- 
dioxygenase induction following CNS inflammation.^®^
In the human brain 3-hydroxyanthranilic oxygenase and quinolinic acid 
phosphoribosylü’ansferase (QPRTase) are located in morphologically distinct compartments in 
the brain. In view of this differential localisation, the conclusion seems inescapable that 
quinolinic acid must be synthesised in one population of glial cells and must presumably exit 
those cells to be metabolised by QPRTase in a separate population of QPRTase containing 
glial cells and neurones. This raises the interesting possibility that quinolinic acid must exist in
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the extracellular fluid and under some circumstances may accumulate sufficiently to activate or 
otherwise modify, for example, by potentiation or desensitisation, the NMDA sensitive 
population of glutamate receptors.
The striatum at least does not appear to possess mechanisms either for the rapid removal of 
quinolinic acid or for its metabolic degradation in the extracellular space by significant 
QPRTase or other metabolising enzymes. On the basis of this lack of uptalce and extracellulai* 
metabolism, it therefore seems unlikely that quinolinic acid is a neurotransmitter in the 
classical sense.
Interestingly, quinolinic acid has recently been shown to increase permeability of the blood- 
brain barrier. Intracerebroventricular injections of quinolinic acid increased the penetration of 
magnesium from plasma into brain. It is not clear whether this effect involved activation of 
NMDA receptors, a secondary change of extracellular osmolarity or pH effects.^
1,3.2 Kynurenic acid.
25-Kynurenine can cross the blood-brain barrier as a result of transport by the large neutral 
amino acid c a r r i e r . K y n u r e n i c  acid, on the other hand has been considered essentially 
unable to cross the barrier in normal animals. The latter is important because in many of the 
pathological states in which kynurenines may be implicated (encephalopathies, AIDS-related 
brain damage etc.) there is likely to be a significant weakening of the barrier's integrity. The 
barrier is known to be compromised, for example, in Alzheimer's dementia, raising the 
possibility that enhanced penetration by kynurenic acid may occur in such conditions.
Most of the normal extracellular kynurenic acid in brain is probably of glial origin.^ Since 
release of kynurenic acid into the extracellular medium persisted in the absence of external
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calcium, it is probably the result of diffusional efflux rather than an active exocytotic 
mechanism.^ ^
It has been argued that quinolinic acid and kynurenic acid cannot be of physiological or 
pathological relevance because their normal extracellular concentrations are in the nanomolar 
range, at least three orders of magnitude lower than those required to act at NMDA 
receptors. However one possibility is that both quinolinic acid and kynurenic acid may be 
present in very high concentrations locally at some sites in the brain that cannot be reflected in 
mean extracellular levels. A second possibility is that there may be a subpopulation of NMDA 
receptors that possess a glycine modulatory site with a much higher sensitivity to kynurenic 
acid making them more susceptible to fluctuations of endogenous kynurenic acid levels.^
1.3.3 NMDA Receptors.
The NMDA sensitive population of receptors is involved not only with the process of synaptic 
transmission in many parts of the CNS but also in long term aspects of neuronal activity. 
NMDA receptors are also involved in the plastic processes concerned in the targeting of 
neurones and synapses and their adjustment during development, especially in the visual 
system of vertebrates and invertebrates. They are also involved in the determination of cell 
viability and can activate destructive enzymes such as phospholipases, proteases and protein 
kinases. This may be of importance in explaining some cell death occurring with ageing and 
loss of neurones that occur in dementing disorders such as Alzheimer's disease. It may also 
explain related neurodegenerative disorders such as Huntington's disease and epilepsy as well 
as the widespread neuronal damage that results from cerebral infarctions.^^
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1.4 MODULATION OF THE KYNURENINE PATHWAY.
Further information regarding the regulation of this metabolic pathway is required to fully 
elucidate the neurological roles of the various metabolites. Two main strategies aimed at 
favourably altering the kynurenic and quinolinic acid balance have so far been followed.
The first strategy focused on the development of more selective and potent kynurenic acid 
analogues. Leeson et al. investigated substituents at the 5, 7 and 5 and 7 positions of 
kynurenic acids and evaluated their in vivo antagonist activity at the glycine modulatory site of 
7-Chloro kynurenic acid (85) had the greatest increase in antagonist activity 
over kynurenic acid itself. Moroni et al. showed similar activity with the thiokynurenate 
(8 6 ).^^  ^ Further studies showed that the 3-nitro-3,4-dihydro-2(li7)-quinolone (87)
is the most potent combined glycine / NMDA-AMPA antagonist yet reported, in vivo, and 
may prove to be a useful pharmacological tool.
, j c a
NOg
COgH o r  ^  N "O
Y = OH (85) (87)
Y = SH (86)
The second strategy is aimed either at blocldng quinolinic acid production or at increasing the 
kynurenic acid production by inhibiting key enzymes of the kynurenine pathway. 
Kynurenine loading has been shown to increase kynurenic acid levels and has been shown to 
exert antiepileptic e f fec t s . I nh ib i t i on  of kynureninase should prevent quinolinic acid 
synthesis and accumulation, as should inhibition of kynurenine hydroxylase. 
Nicotinylalanine, an inhibitor of kynureninase and kynurenine hydroxylase, has been shown 
to increase the cerebral kynurenic acid content in rat b r a i n . I t  has also been shown to 
inhibit the accumulation of quinolinic acid, following the administration of bacterial
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endotoxins. Naritsin et al. found that 4-chloro-3-hydroxyanthranilate (73), an inhibitor of 
3-hydroxyanthranilate-3,4-dioxygenase, decreased the accumulation of quinolinic acid in the 
brain following immune activation. This was accompanied by an increase in kynurenic acid 
concentration and a decrease in kynurenine concentration. On the other hand, 6-chloro-25- 
tryptophan decreased the formation of quinolinic acid, but also decreased the formation of 
kynurenine and kynurenic acid.^^ 6-Chloro-25-tryptophan may be an effective pro drug for 
the delivery of 7-chloro-kynurenic acid (see above) as it is a substrate for indoleamine-2,3- 
dioxygenase and the 4-chlorokynurenine produced is a substrate for kynurenine 
aminotransferase. Chiarugi et al. have compared the inhibitory properties of 
m-nitrobenzoylalanine (67) as an inhibitor of kynurenine hydroxylase and 
o-methoxybenzoylalanine (8 8 ) as an inhibitor of kynureninase.
O COgH 
NHg
OMe (8 8 )
It has been shown that inhibiting either of these enzymes results in an increase in kynurenic 
acid in the brain. In addition, kynurenine hydroxylase inhibition resulted in a larger increase 
of kynurenine and kynurenic acid in the brain of rats than kynureninase inhibition. However 
a selective inhibition of kynureninase may result in the accumulation of 3 -hydroxykynurenine 
and there is evidence from studies in cell culture that this is also neur o t ox ic .Th i s  finding 
has not as yet been duplicated in vivo, however, and 3-hydroxykynurenine toxicity seems to 
be related to the generation of free radicals rather than a direct action on excitatory amino acid 
receptors. Thus 3-hydroxykynurenine may play a role in brain pathology without 
functioning as a neuroactive brain metabolite under physiological conditions.
It can thus be seen that there is still a need for further research into the mechanisms of the 
enzymes to enable more active and selective inhibitors to be developed. Such compounds
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may be employed to investigate in greater detail the neurological consequences of inhibiting 
the tryptophan pathway. Eventually, this may then lead to the production of drugs suitable 
for the tieatment of these neurological disorders.
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CHAPTER 2
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2. INVESTIGATION OF HYDROLYSIS REACTION AND DESIGN OF 
INHIBITORS.
As discussed in the introduction t l .2.3.4 Proposed mechanism) one of the major questions 
concerning the chemical mechanism of kynureninase is the mode of the hydrolysis reaction. 
This could be mediated by a water molecule bound at the active site or by an enzymic 
nucleophile. One way to probe this part of the reaction is to use novel inhibitors of 
kynureninase which are designed by making assumptions concerning the mechanism. The 
relative efficiencies of the inhibitors will then provide circumstantial evidence concerning the 
mechanism.
2.1 THE BOUND WATER MEDIATED MECHANISM.
The first possible mechanism involves a water molecule bound at the active site. General 
base catalysis, by an active site amino group, then generates hydroxide ion which attacks at 
the y-carbonyl group of the substrate. This mechanism is given in Scheme 2.1.
NH+
IPLP
HO 
I —H B^Enz '•HB—Enz
(89)
V
4-
COg-
NH^
PLP
(39)
Scheme 2.1
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Such a reaction must proceed via a tetrahedral intermediate (89), which then breaks down to 
give an a-aminoacrylate derivative (39) and anthranilate.
A tetrahedral intermediate is a high energy species on the reaction co-ordinate pathway and as 
a result, it can be used as a model for the transition state structure. Designing a stable 
analogue of this structure provides a useful method for designing inhibitors for the enzyme. 
Indeed if such an inhibitor bound tightly to kynureninase it would be evidence that such a 
bound water mechanism was in operation. There is already some evidence from 
stereochemical studies that implies that a bound water mediated reaction is most likely. Also 
in agreement are the inhibitory properties of the dihydro-25-kynurenines (30). Both 
dihydro-25-kynurenines are similar in structure to this proposed tetrahedral intermediate. As 
this intermediate is a model of the transition state, the potent competitive inhibition observed 
by these compounds suggests that they may also act as transition state analogues.^^
2.2 TRANSITION STATE ANALOGUES.
The concept of transition state mimics has been particularly successful for the design of 
potent enzyme inhibitors for peptidase e n z y m e s . T h e  rationale for this approach is the 
recognition that additional, favourable binding interactions develop between an enzyme and 
the substrate as their complex approaches its transition-state conformation. Such extra 
binding interactions, which are not available in the ground-state complex, assist in lowering 
the energy of activation of the reaction and therefore are an important mechanism for 
enzymatic rate enhancement. Transition-state analogue inhibitors seek to talce advantage of 
these extra binding interactions by incorporating key structural elements of the unstable, 
transition-state structure of the substrate in the stable structure of the inhibitor.
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For the zinc and aspartic peptidases a number of effective strategies have been developed 
based on the ability of phosphorous containing amino acid analogues to mimic the unstable 
tetrahedral intermediates involved in peptide hydrolysis.
For the aspartic peptidases incorporation of a tetrahedral species into an oligopeptide, as a 
mimic of the transition state has led to effective inhibitors. The most potent inhibitors for the 
aspartic peptidases have been analogues of the naturally occurring pepsin inhibitor pepstatin
(90) in which the unusual amino acid statine occupies the Pi and ? i' positions and presents a 
secondary hydroxyl group to the catalytic residues in the enzyme active site. Bartlett and 
Kezer synthesised and evaluated a number of ’phosphastatine' derivatives (91) as pepsin 
i n h i b i t o r s . T h e  25-derivative of Iva-Val-Sta^-Ala-Iaa shows very high affinity and is a 
slow binding inhibitor of the aspartic peptidase pepsin with a of <0.07 nM.
CONH CONH CONH CONH
OH
CONH
ÔH
Iva-V al-V al-2iS-Sta-Ala-25'-Sta (90)
C O N H ^ CONH-^ "CONH-^ CONH
0 ^  ' o h
Iva-Val-2S-Sta'’-Ala-Iaa (91)
Bartlett and Marlowe have also synthesised a series of phosphonamidate peptide derivatives 
(92) as transition state analogues for the zinc peptidase thermolysin. The most potent 
inhibitor, where Y= Leu, had a K% of 9.1 nM.^^^
56
H ^CH2CH(CH3)2
C bz—  HNHgC
A number of HIV-1 (human immunodeficiency virus type-1) proteinase inhibitors have also 
been studied. The HIV-1 proteinase is a member of the family of aspartyl retroviral 
proteinases and plays an essential role in viral replication. One strategy to inhibit the 
proteinase has been replacement of the scissile peptide bond at the substrate cleavage site with 
non-hydrolysable transition state analogue moieties. McLeod et al. synthesised some 
phosphonamidate dipeptide analogues (93, 94) which showed modest potency as inhibitors 
with Ki values of 45 |iM and 52 [lM respectively.^^^
NH
(93)
CF3COHN
CONH2
(94)
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2.2.1 Design of Proposed Transition State Analogue.
Prior to our work McCarthy et al. had devised convenient synthetic access to 2,2-difluoro-2- 
benzoyl-alanine (95)^^^ as a potential new inhibitor of kynureninase. Fluoroketone 
containing peptides are proteolytic enzyme inhibitors. These compounds form stable 
hydrates or hemiketals which are thought to inhibit proteolytic enzymes by mimicking the 
tetrahedral transition state of the amide bond cleavage. On the basis of this precedent, the 
difluoro analogue is an attractive target however, as yet, there are no biological data.
C0 2 "
""•H 
p NH3+
(95)
H2O
CO2- OH. OH I
NH.3+
However it was decided to employ the phosphorous based approach to transition state 
mimics. The target compound was thus the phosphinic acid (96). This has the required 
tetrahedral arrangement of groups, but should be chemically stable. It, like the transition 
state, has two oxygens present and should show similar hydrogen bonding. The P-O bond 
length is midway between the C=0 bond length and the C-O bond length. The transition 
state bonds are thought to be of a similar intermediate length, in which only partial bonding 
has developed between the carbon atom and the incoming water molecule. Therefore the 
phosphinic acid should be a very good mimic. If this compound acts as a transition state 
mimic it should bind very tightly to the active site. This would be an example of competitive 
reversible inhibition.
(96)
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While our work was in progress Phillips and Dua prepared a series of 5-aryl-25-cysteines 
and their coiTesponding ^,5"-Dioxides and evaluated their interaction with kynureninase. 
The most potent of these compounds 5-(2-aminophenyl)-25-cysteine 5,5-dioxide (97) has a 
Ki value of 70 nM. These results suggested that the sulphone group may be generally useful 
in the design of potent inhibitors of enzymes which proceed via hydrated tetrahedral 
intermediates.
COg-
2.3 SYNTHESIS OF TRANSITION STATE ANALOGUES.
The desired phosphorous analogue (96) is an example of a p-substituted alanine. Various 
synthetic routes can be envisaged to the target molecule. The two general routes to p- 
substituted alanines require either a cation (98) or an anion (99) equivalent. A number of 
synthons are available for these fragments, most of which are prepared from the amino acid 
serine (100). As both enantiomeric forms of serine are available in high optical purity, at 
relatively low expense, they are especially attractive chiral starting materials. A number of 
approaches used in the literature aie outlined below.
(98) NHg
HO. ÇO2H 
{'•H
NHg (100)
59
2.3.1 Alanine |3“Cation Equivalents.
2.3.1.1 p-Lactone Methodology.
Arnold, Kalantar and Verderas^^^ have reported the conversion of serine to stereochemically 
pure p-substituted a-amino acids via p-lactones (Scheme 2.2). Pure enantiomers of N~ 
(benzyloxycarbonyl)-serine (A-Cbz-serine, 101a) and iV-(rerr-butoxycarbonyl)-serine 
(N~^Boc serine, 101b) were cyclised without racémisation to give the corresponding N- 
protected a-amino p-lactones (1 0 2 a, 1 0 2 b) in 60 and 12% yield respectively, using modified 
Mitsunobu conditions, (PhgP and dimethyl azodicarboxylate, DM AD).
"'"t: >
(lOla) R=CH2Ph (102a) 60% qqB)
( 1 0 1 b)R=C(Me)3 (1 0 2 b) 72%
Scheme 2.2
Ring opening of the p-lactone with a variety of halogen, oxygen, sulphur, or nitrogen 
nucleophiles then produced pure enantiomers of A-protected p-substituted alanines (103) in 
high yield (Scheme 2.3). Attack occurred exclusively at the p-carbon (Path a, Scheme 2.3). 
The product was obtained in a stereochemically pure form and deprotection was carried out 
by conventional methods. Only relatively hard nucleophiles, like ammonia and methoxide, 
attacked the carbonyl to give acyl oxygen cleavage (Path b. Scheme 2.3) (see Table 2.1).
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Path a
( 102) OR
O
Path b
[f'H
OR
X
N/
(103) OR
O
N/
(103) OR
X'= Hal, O, S, nucleophiles 
Y’= OMe, NH3
Scheme 2.3
P“lactosne 
(102a, 102b)
Nucleophile X (103) Y(103) Config, Yield
(%)
102a MgBr2-Et2 0  
Et20, 22 °C
-Br ' -OH 2S 67
102b PhCH2S“Na+ 
DMF, 22 °C
-SCH2Ph -OH 2R 65
102a NH3 (g)/MeCN 
0°C
-OH -NH2 I S 77
102a NaOMe -OH -OMe 2 R S ^ 88
» Racemised.
Table 2.1
A complimentary p-lactone system that directly provides access to the corresponding free 
amino acid has also been described (Scheme 2.4).^^^
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„ ' * Y °OBu
(1 0 2 b)
HX o - f °  ^
NHa+X-
(104a) X=CF3C0 2  
(104b) X=OTs
Scheme 2.4
Y
CO2*
NHg-*
(105)
Removal of the %utoxycarbonyl protecting group on the amine with acid gave the 
corresponding amine salts (104a, 104b). The tosylate salt was reported to be crystalline, 
stable and amenable to storage. These interesting compounds readily added even very weak 
nucleophiles (such as trifluoroacetic acid, TFA) at the p-carbon, directly forming the free 
amino acids (105). The authors noted that some functionalities, such as azido, introduced 
using the protected p-lactones were labile to the conditions required to remove the nitrogen 
protecting groups. Therefore, the salts allowed the preparation of even relatively labile amino 
acids in a very simple manner. The yields were generally good and the diversity of the 
nucleophiles impressive (Table 2.2). It is also significant that some of the addition reactions 
(for example, with sulphur nucleophiles) could be performed in water neai* pH 5.
Nucleophillc reagent
(Y:)
Conditions Y (105) Yield
(% )
H2NCH2CH2 SH-HCI pH 5.5 -SCH2 CH2NH2 85
LiSH MeCN/THF -SH 8 8
CF3CO2 - TFA -OCOCF3 87
K2 HPO4 18-crown-6, DMF -OPO3H2 87
conc. HCl 30 min -Cl 92
^-Bu4NCN DMF, 10 °C -CN 84
NaNs DMF -N3 96
Table 2.2
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The addition of cuprates to serine p-lactone (Scheme 2.5) was also shown to provide a 
practical and convenient method for introducing carbon functionality at the p-carbon.
yO
COgHH R"M H
OBn OBn
Scheme 2.5
2.3.1.2 Aziridine-2-carboxylic acid derivatives.
Aziridine-2-carboxylic acid derivatives (106) are another class of a-amino acid p-cation 
equivalents. They may be considered simultaneously as a -  or p- amino acid derivatives. 
Most of the syntheses of aziridinecarboxylic acids are non-stereospecific and are generally 
not applicable to A-unsubstituted derivatives. Zwanenburg and co-workers were particularly 
interested in A-unsubstituted examples because they can be incorporated into a peptide chain 
and serve therein as an electrophilic moiety.
Optically active glycidic esters (107) were prepared from ally lie alcohols (108) by the 
Sharpless epoxidation. The glycidic esters were then treated with sodium azide. In the case 
of alkyl substituted glycidic esters this Sn2  type reaction invariably led to a mixture of the 
isomeric azido alcohols (109). The azido alcohols were treated with triphenylphosphine to 
give the corresponding 1,3,2-oxazaphospholidines (110), which could be isolated when 
reaction was carried out in ether. Theimal elimination of tiiphenylphosphine oxide was then 
effected by Kiigelrohr distillation to yield the aziridinecarboxylic esters in moderate yields. 
When however, the Staudinger reaction was performed in DMF or acetonitrile, stirring at 
room temperature followed by heating at 80 °C for a few hours afforded the aziridines (106) 
in good yields without isolation of the inteimediate oxazaphospholidines (Scheme 2.6).
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(108)
Sharpless
epoxidation
R O
i) a) (COCl)2, DMSO 
b) NaC102, NaH2P0 4
ii) CH2N2
N3 COglVIe
R
Phg
5  « (107)
COaMe
V
NaNg, NH4CI, 
MeOH
R.
HO R R
N3
COgMe (109)
PPh,
V
R
y - f
Phg
COgM©
(110)
VA
(106)
Scheme 2.6
Applications of these optically active aziridinecarboxylic acid derivatives include the 
preparation of tryptophan derivatives and nucleophilic ring opening. The possibility of 
preparing optically pure tryptophan derivatives (111) from various substituted indoles and 
{2Ry or (2S)-2-aziridinecarboxylates has been examined (Scheme 2.7, Table 2.3). Sato et 
ai found that zinc triflate was the only Lewis acid capable of bringing about this reaction in 
moderate yields.
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R" H
COzR'
Zn (OTf)2, CHCI3, 78 °C
COpR'
NHR"
Scheme 2.7
NH (111)
(%)
Cbz
Boc
44Bn
Me
5-Me CbzBn
Cbz4-OMe
6 -Cl
Bn
CbzBn
CbzBn
Table 2.3
Indole derivatives containing electron releasing groups, for example 5-methyl and 4- 
methoxy, reacted under these conditions to afford the desired tryptophan products. 
Although, indoles with an election withdrawing substituent, for example 6 -chloro and 4- 
nitro, gave rise to little if any of the expected tryptophan products. Thus the chemistry 
described offers a useful method for gaining access to optically pure tryptophan derivatives 
only in certain instances.
Other nucleophiles have also been employed, for example, ring opening of 3-aryl aziridine 
ester (1 1 2 ) with thiophenol in the presence of one equivalent of boron trifluoride etherate 
affords the 3-phenylthio amino ester (113) in 67% yield as a single diastereomer (Scheme 
2.8).^33
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PhSH, BF3.Et20, 
CH2CI2
( 112) COglVIe
Ph 
PhS
NHg
C0 2 M© 
(113)
Scheme 2.8
2.3.1.3 Serine sulphamidates.
Baldwin and co-workers used the serine sulphamidate as a substitute for aziridinecaiboxylate 
in substitutions with a variety of nucleophiles including cyanide, pyrazole and malonate (See 
Table 2.4). They hypothesised that a cyclic sulphamidate derived from serine might 
simultaneously activate the p-position to nucleophilic attack and partially protect the amino 
group and thus provide a useful 'p-alanyl cation' synthon for the synthesis of a-amino acids.
NHBn i) tBuMc2SiCl, imidazole, 
DMF
OH
'COgH
(114)
y
o NBu
ii) CCl3(=NH)O^Bu
BF3.Et20, CH2C I2: 
cyclohexane (2 : 1)
SOCI2, EtsN, toluene, 0  °C
J
COgBu
NaI0 4 , RUCI3.H2O (cat.), 
MeCN: H2 0 (l: 1)
?
Nu-
/  \  ------O NBu\ _ /
(116) COg^ Bu
SO?
NBn
Nu
*COg‘Bu
Scheme 2.9
NHBn
A\ COgBu 
OTBDMS
"BU4N+F-, 
THF, 0 °C
V
NHBn (115)
‘COgtBu
OH
H3
‘COg'Bu
Nu
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The sulphamidate was synthesised from A^-benzyl serine (114). The acid was protected as 
the Ibutyl ester (115), using ^butyl trichloroacetimidate in the prescence of a catalytic amount 
of boron trifluoride e t h e r a t e . F o r m a t i o n  of the cyclic sulphamidate (116) was then 
achieved by reaction with thionyl chloride and oxidation was carried out using sodium 
periodate with catalytic ruthenium (Scheme 2.9).^^^
N ucleophile Reaction conditions Yield (%)
H2O 2 M HCl: dioxane (1; 1), 14 h, 0-20 °C 63
N3" NaNg, acetone: water (1: 1), 12 h, 20 °C 93
SCN- NH4 SCN, DMF, 12 h, 20 °C 91
pyrazole pyrazole, DMF, 11 h, 60 °C 55
CN" NaCN, DMF, 12 h, 20 °C 82
Table 2.4
Although the protected amino acids were prepared in good to excellent yields, the authors did 
not provide any details of the deprotection and isolation of the free amino acid.
2.3.2 ASaniîie p“Anion Equivalents.
The polai’ity of the serine side chain can be reversed from electrophilic to nucleophilic by the 
preparation of p-iodoalanine (117) and the derived organozinc reagent (118) as reported by 
Jackson et The latter is prepared by treatment of protected iodoalanine with activated
zinc. 138
X COgBn 
NHBoc
X=I(117)'
X= Znl(118)' Zn/Cu
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This organozinc reagent (119) can undergo carbonylative cross coupling with functionalised 
aryl iodides (120) using palladium catalysis to give protected 4-aryl-4-oxo a-amino acids 
(121) (Scheme 2.10, Table 2.5). In fact, 25'-lcynurenine has been successfully prepared 
using this method.
CO, [Pd(PPh3)4]
X
(119)
CO2M6
COoMe
NHBoc
Scheme 2.10
Aryl iodide Yield (%)
lodobenzene 60
1-Napthyl Iodide 54
4-Iodoanisole 58
4-Iodotoluene 59
2 -Iodoanaline 52
Table 2.5
2.3.4 Conclusions.
It was decided to employ the p-lactone methodology for the synthesis of the phosphinic 
acid using phenyl dimethylphosphonite as the nucleophile. Direct access to the free amino 
acid via the p-lactone salt ^^Ms unnecessaiy as the methyl ester should be formed on reaction 
with the nucleophile in an Arbusov type reaction (Scheme 2.11). Therefore, a final 
hydrolysis step is inevitable.
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Phs  “C y ”
M eO ''/ ' mMeO /  OMe N q
(102a) OCHaPh OCHgPh
Ph-
MeO 
OMe N o
YH OCHgPh
Scheme 2.11
A similar reaction has been carried out by Smith et al. using trimethyl phosphite as the 
nucleophile (Scheme 2.12).^^^ This provided more evidence for the viability of this route.
<Vo
HN *'^  ii) propylene ©Q NHgV - 0 ‘Bu II oxide, EtOH, ©
If o  50 °CO
Scheme 2.12
2.4 SYNTHESIS OF THE PHOSPHINIC ACID ANALOGUE.
Serine was first protected as the A-Benzyloxycarbonyl (Cbz) derivative. Reaction was 
carried out under aqueous conditions using potassium bicarbonate and benzylchloroformate 
(Scheme 2.13). The product was isolated after acidification of the reaction solution and
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extraction into ether in 77% yield. The identity of the product was confirmed by NMR
spectroscopy which showed the methylene protons of the Cbz group at 5.05 ppm.
R
PhC H jO -C -C I
H zO /N aH œ , (77%)
NHa NH
(1(K)) 0 ^ \ r o(1 0 1 a)
Scheme 2.13
Serine p-lactone (102a) was then prepared by cyclisation of iV-Cbz serine (101a) under 
modified Mitsunobu conditions. Triphenylphosphine and diethyl azodicarboxylate were 
dissolved in THF and cooled to -78 °C (Scheme 2.14).
)  COgH O — ^
PhjP/DEAD  %"H (3 9 %)
NH NH
O /  T H F / -78-C Q /
(1 0 1 a)
Scheme 2.14
The scale of this reaction was limited as the solution had a tendency to solidify as the iV-Cbz 
serine solution was being added. This problem was minimised by periodical shaking of the 
reaction mixture. The product was purified by column chromatography (silica, ethyl acetate: 
petroleum ether; 45: 55). Solubility problems necessitated preabsorption of the product onto 
silica to obtain optimum results. The lactone and the hydrazine ran very close together on 
silica under these conditions, with triphenylphosphine oxide running close to the solvent
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front and unreacted Cbz serine close to the baseline. The hydrazine was readily visualised by 
staining with potassium permanganate, while the other compounds were visualised using 
bromocrescol green. The product and hydrazine were thus easily separated from these other 
components. A second column was then carried out with a larger excess of silica to give 
white needles of the pure product which were observed to directly precipitate out of solution 
in the column fractions. The optimised yield of pure p-lactone was 39%.
The p-lactone was then ring opened with a suitable phosphorous nucleophile. iV-Cbz-serine 
p-lactone (102a) was heated in excess phenyl dimethylphosphonite at 40 °C. The 
phosphonite was employed both as the solvent and the nucleophile. After distillation the 
product (122) was obtained in 85% yield. The methyl ester obtained as a result of the 
Arbusov reaction was observed in the iR  NMR spectrum at 3.55 ppm. The phosphinate 
ester was observed at 3.75 ppm as a doublet due to coupling with the phosphorous, with a 
value of /pH 11 Hz. Partial purification was carried out using column chromatography 
(silica, dichloromethane: IPA, 95: 5) and the product used without further purification. 
Although attempts were made to purify the product further these were unsuccessful due to 
decomposition of the product. The main impurity was discovered to be the diester (123).
— y ^ ^ y — Ij^OMe
OMe (123)
It was therefore decided to carry the material through and leave further purification until the 
end of the synthesis. Deprotection was achieved by heating at reflux in 6 M HCl. Isolation 
of the free amino acid was carried out by heating with ethanol and propylene oxide to 
neutralise the hydrochloride salt^^^ (Scheme 2.15). Further purification was initially 
attempted by ion exchange chromatography (on IR 120 (H)) although only a very small 
amount of pure material was recovered in 13% yield. Preparative tic (cellulose, IPA: NH3 :
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H 2 O; 36: 6 : 10) gave two ninhydrin positive broad bands which were extracted with 
(methanol: water; 1: 1). The product band (Rf 0,3-0.5) was identified by NMR 
spectroscopy. Although the white crystals produced in 87% yield appeared to be pure by 
NMR spectroscopy, microanalysis revealed that recrystallisation was required and this was 
attempted from ethanol /  water. At this stage the quantity was too small for repeated 
recrystallisation and therefore an alternative to preparative tic was sought.
COgMe
èbz
PhP(QMe)2  
40 °C
(122)
6 N HCl, Reflux 
24 hrs
O CO2I D I, ii) Propylene Oxide
Scheme 2.15
An alternative strategy involved removal of the protecting groups consecutively rather than 
simultaneously. In the synthesis of kynurenine^^® (see 4.3.2.1 Synthesis of Kvnureninel 
the protecting groups were removed consecutively allowing purification of each individual 
intermediate, eliminating impurities in stages rather than in one attempt. Thus lithium 
hydroxide could be used to hydrolyse the methyl ester, TMS-iodide or hydrogenation to 
remove the N-Chz group and finally cleavage of the phosphinate ester with TMS-iodide. In 
this way access to a new compound (124) should also be available (Scheme 2.16).
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p 
IOMe
ÇOgMe
u n i
(122)
Ph
O
i) LiOH
(124)
i) LiOH
ü)2eqTM S-I
Scheme 2.16
The (2S)-methyl iV-Cbz-2-amino-3-(0-methyl phenylphosphino)-propanoate was dissolved 
in (THF: water; 1: 1), lithium hydroxide monohydrate added and the solution warmed at 70 
°C. After reaction the solution was poured into 1 M HCl and extracted with ethyl acetate. ^H 
NMR spectroscopy showed that both the carboxylate methyl ester (3.55 ppm) and the 
phosphinate methyl ester (3.75 ppm) had been removed. However, slow addition of the 
lithium hydroxide gave a mixture where the desired product was obtained in addition to the 
compound with both esters removed. This mixture was difficult to separate by column 
chromatography so it was deprotected in this form.
An alternative procedure for neutralisation of the amino acid hydrochloride was employed 
using propylene oxide and isopropanol, as in the synthesis of kynurenine, to replace the use 
of propylene oxide and ethanol. This method did not requiie any heating so it was hoped that 
these milder conditions would aid in the isolation of a pure free amino acid. This was tried 
on the product from the partial deprotection using lithium hydroxide and was found to give a 
solid product. At this stage it was not clear if the use of propylene oxide and isopropanol
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was sufficient to produce a solid product, or if this was helped by the partial deprotection 
using lithium hydroxide. To clarify this point it was necessary to deprotect the phosphorous 
compound using acid and then isolate the amino acid using propylene oxide and isopropanol. 
For a comparison partial deprotection using lithium hydroxide and then isolation of the amino 
acid using this method was necessary. These two alternatives could then be evaluated. A 
racemic version of the protected phosphorous compound (125) was prepared on a large scale 
to help to predict the viability of this procedure.
Thus, 2-acetamidoacrylic acid (126) was dissolved in excess phenyl dimethylphosphonite 
and heated to 70 °C for seventy two hours (Scheme 2.17).
70 °C. 72 hours uOH
Me
Ph—
OMe HN
<125) m/
6MHC1 
IPA, propylene
oxideVO CO2H
^27)
OH NH2 25)
racemicScheme 2.17
Excess phenyl dimethylphosphonite was removed by Kiigelrohr distillation. Washing with 
5% sodium bicarbonate and extraction into ethyl acetate removed any residual phenyl 
dimethylphosphonite still remaining. This protected compound showed four stereoisomers 
in the iR NMR which can be seen from the four singlets present due to the hydrogens of the 
methyl group of the N-acetyl at 1.44, 1.51, 1.68 and 1.72 ppm. Deprotection was carried 
out without further purification, by dissolving in 6  M HCl and refluxing for twelve hours. 
The solution was concentrated at reduced pressure and talcen up in isopropanol containing a
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small amount of 2R5'-dithiothreitol. This was then neutralised with propylene oxide and a 
white solid precipitated out of solution. Diethyl ether was added and more white solid 
precipitated out of solution. This was filtered under nitrogen and recrystallised from acetone 
/ water to give the pure amino acid in 54% yield. The spectral data were identical to those 
obtained for the product from the p-lactone route.
As a result of this experiment, the same method was then applied to the chiral protected 
phosphorous compound and this also resulted in a microanalytically pure sample.
Preliminary investigation of the inhibition of kynureninase, isolated from Pseudomonas 
fluorescens^, by the phosphinic acid showed poor inhibition. (Full details are reported in 
Section 2.6.1 Phosphinic acid). A possible reason for this poor inhibition was sought. 
The pKa of the phosphinic acid is very low (ca. 3 to 3.5)^^  ^and so at the pH of the assays it 
will be negatively charged. This negative charge may produce destabilising interactions with 
groups at the active site of the enzyme. There is precedent for this phenomenon in work on 
aspartyl proteases where studies of related phosphinic acid analogues showed that the 
inhibitory proficiency of the compounds increased with decreasing pH, from which it was 
concluded that the proteinase has a preference for the uncharged form of the phosphinic 
acid.^^^ It is believed that these effects result from repulsive interactions that develop 
between an active site aspartate carboxylate and the negatively charged phosphonamidate as it 
ionises with increasing pH.^^^
2.5 SYNTHESIS OF METHYL PHOSPHINATE ANALOGUE.
It was hypothesised above that the negative charged phosphinate group may produce 
destabilising interactions with groups at the active site of the enzyme. In order to test this 
hypothesis it was decided to prepare the methyl phosphinate analogue. Examination of the
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inhibitory properties of the methyl phosphinate should then allow the importance of the 
negative charge to be assessed.
O -
O CO2 H 
OMe (124)
As the dimethyl ester (122) had been previously prepared via the p-lactone route, further 
attempts were made to selectively hydrolyse the carboxylate ester using lithium hydroxide 
(Scheme 2.18). Previous attempts had involved heating the mixture at 70 °C and so milder 
conditions were employed. Treatment with one equivalent of lithium hydroxide in a 1: 1 
mixture of THF and water at 0 °C gave a product that appeared to be correct as mass 
spectrometry showed a pealc at 379 and ^H NMR spectroscopy showed a doublet due to the 
phosphinate ester at 3.75 ppm ( / I I  Hz, PH). However, the compound proved to be 
difficult to isolate and purify.
O (122) ^  (128)
Scheme 2.18
An alternative route to the product was devised, using a different protecting group strategy. 
This would furnish a compound amenable to purification by column chromatography. A 
final deprotection step using hydrogenation could then be employed to give the final product.
OMe
O (129)
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The proposed route involved reaction of N-Cbz 2-bromoalanine benzyl ester (130) with 
phenyl dimethylphosphonite. This protected intermediate (129) could then be hydiogenated 
to give the methyl phosphinate analogue (Scheme 2.19).
V _ /  j^ ..=.^ 0CH2Ph
 ^ (130) '  (129)
O CO2H
OMe 
Scheme 2.19
Starting with iV-Cbz serine benzyl ester (131), the alcohol was converted to the bromide 
using carbontetrabromide and triphenylphosphine in toluene (Scheme 2.20).^"^  ^ The 
triphenyl phosphine oxide by-product was removed by filtration through celite and column 
chromatography (ethyl acetate: 2: 8 ) gave a white crystalline solid in 75% yield. Mass 
spectrometry confirmed the identity of the product and the optical rotation was identical to the 
literature value.
HO C02CH2Ph Br C02CH2Ph (75%)W ...H  CBr4,Ph3P W ,\  ^ 0 CH2Ph Na-dry toluene \  ^ 0 Ch2Ph
Scheme 2.20
Reaction of N-Cbz 2-bromoalanine benzyl ester (130) with phenyl dimethylphosphonite was 
then attempted (See Scheme 2.19). Reaction at reflux at 120 °C in toluene for seventy two 
hours gave no product on distillation. The number of equivalents of phenyl 
dimethylphosphonite was increased from 2.2 to five. The compounds were also heated
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P -O M e
Me (132)
without toluene in a 1: 1 ratio as a melt, however, still no reaction was seen. Along with 
starting material the only compounds isolated were (132) and (123). It therefore, seemed 
necessary to explore some other alternative routes.
O
P-OMe 
OMe (123)
An alternative reagent to dimethyl phenylphosphonite was methyl phenylphosphinate (133). 
This was prepared according to the method of DeBriun '^ '^  ^ (See Scheme 2.21). Thus, a 
solution of methanol and pyridine in toluene was added dropwise over one and a half hours 
to a stined, cooled solution of dichlorophenylphosphine (134) in toluene. The pyridinium 
hydrochloride, formed within one hour, was vacuum filtered from solution, and water was 
added dropwise to the filtrate. The organic layer was extracted with saturated sodium 
bicarbonate and water and then the aqueous phase was back extracted twice with 
dichloromethane. The combined organic phases were dried and concentrated and distillation 
gave 43% of the pure product. This reaction was found to be most successful when carried 
out on as large a scale a possible. The NMR spectmm clearly showed the proton attached 
to the phosphorus at 7.55 ppm. This was a doublet due to coupling with phosphorus, giving 
J  565 Hz which is in good agreement with the literature value ( /  560 Hz, PH).^"^
o ~
(134)
MeOH 
pyridine
MeO*^  \
(133)
43%
Scheme 2.21
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Methyl phenylphosphinate was then reacted with N-Cbz-2-bromo-alanine benzyl ester (130) 
in a procedure based on the method of P a rs o n s ,w h o  was interested in 3-substituted-2- 
phosphomethyl acrylates, (135) and (136), both as inhibitors and synthetic intermediates. 
The syntheses of these compounds were described using this easily obtainable phosphorous 
nucleophile (See Scheme 2.22).
1) NaOMe/MeOH, 
0°C
2) P(0)(0Me)2 , 0 O Q
(133)
Na+
.OMe
MeO
OMe
C0 2 Me
3) CH3CHO, 25 °C
MeO C0 2 Me
2 (Z) (135) 
42%
MeO
Scheme 2,22
C0 2 Me
2(E) (136) 
38%
For our purposes, methanolic sodium methoxide (2 M) was initially used as the base. This 
proved to be unsuccessful even in alternative solvents such as THF and DMF. A variety of 
different bases were also employed such as sodium hydride and "butyl lithium. "Butyl 
lithium was found to be the most promising and some product was formed in the reaction. 
Thus "butyl lithium was added dropwise to methyl phenylphosphinate (133) in THF at 
-78 °C under nitrogen (See Scheme 2.23).
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/P (133)
MeO H 
"BuLi
THF, -78 °C 
Br COaCHgPh
THF, V-
-40 °C ^..^O C H zPh
^ O (130)
/ — \  O COzCHgPh
OMe [ï|-^-j>j-^0^^2Ph
O (129)
11%
Scheme 2.23
After stirring for thirty minutes the bromo compound (130), which had previously been dried 
under vacuum, was added at -40 °C in THF. A tic examination (silica, ethyl acetate) of the 
reaction showed seven spots and mass spectrometry was carried out on each of these to 
identify the desired product. Separation was then achieved by column chromatography using 
a gradient solvent system (silica, initially ethyl acetate: petroleum ether, 1:1, then 3: 1, then 
pure ethyl acetate) giving pure product (129) but in only 4% yield. Incomplete reaction 
between methyl phenylphosphinate and the "butyl lithium was thought to be the reason, 
leaving excess base to react with the bromo compound. The alkene product can be seen in 
the ^H NMR spectrum and is characterised by two singlets at 6 = 5.85 ppm and 6.28 ppm, 
the geminal coupling is very small and is not observed in the spectrum. In an attempt to 
alleviate this problem, the reaction mixture was allowed to warm to room temperature after 
the addition of "butyl lithium and stirred for thirty minutes before being cooled to -40 °C. A 
lower temperature of -50 resulted in the isolation of less product. As a strong base is 
employed in this reaction a low temperature was desirable to reduce the possibility of
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racémisation. In addition a few crystals of 2,2-dipyridyl were added which gave the solution 
a red colour if excess "butyl lithium was added. These improvements however, only 
increased the yield to 11%. Nevertheless hydrogenation could be carried out to allow 
isolation of the desired product in 38% yield. Due to the fact that this reaction gave such a 
crude mixture of products further alternatives were investigated in the hope that these may 
give purer products.
The first of these was the reaction of the phosphinate with serine p-lactone (102a) (See 
Scheme 2.24), this was carried out in a similar manner as with the bromo compound, 
however, no product was isolated.
p f  (133) 
MeO H
THF
"BuLi
THF, -78 °C
H
S (1 0 2 a)
 ---- , O COaCHjPh
OMe M-^OCH^Ph 
O (129)
Scheme 2.24
Attention was then returned to the selective hydrolysis of the carboxylate ester. One 
approach to obtaining such selectivity is to use enzymic methods. For example, pig liver 
esterase is a serine type of esterase that catalyses the stereoselective hydrolysis of a wide
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variety of esters. It is relatively cheap and does not require the use of cofactors. In 
particular pig liver esterase has been widely used in the enantioselective hydrolysis of 
symmetrical diesters. Most of these transformations, such as the example by Lukas^ "^  ^were 
carried out in aqueous solution (Scheme 2.25). Thus hydrolysis of mcso-tetrahydrophthalic 
anhydride (137) was carried out using pig liver esterase in pH 7 buffer at ambient 
temperature and resulted in almost exclusive hydrolysis of the (IR)-ester group to afford the 
enantiomerically pure (15,2/?)-monoester (138). The optical purity of the monoester was 
analysed by conversion to the lactone and analysis by chiral GC. This compound has been 
widely used as an important chiral synthon in the preparation of some complex natural 
products. o:ffiC0 2 MôCO2M6 PLE94%, pH 7.0,> 98% ee l| I ,«6%C0 2 M6C^0 2 H (138)
(137)
1. (COCl)2 , CHCI3
2. NaBH4,EtOH
3. H+, heat
Oo O
Scheme 2.25
The (25)-iV“(benzyloxycarbonyl)-2-aminO“3-(0-methyl phenyl phosphino)-propanoate (122) 
was poorly soluble in aqueous solution, however it was noted that Ohno et al. had used 10% 
acetone to solubilise their starting material. A similar solvent system was therefore 
employed for our substrate (See Scheme 2.26).
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. - s m s -
OMe phosphate buffer, pH 8  \ = /  ô ^ e  |^"'^O G H 2Ph
O (122) acetone (1 2 8 ) o
Scheme 2.26
Pig liver esterase was added to a solution of the diester (122) in 10% acetone and 0.1 M 
potassium phosphate buffer (pH 8 ). Initially incubation was carried out at 25 °C but no 
product was observed by mass spectrometry of aliquots removed from the reaction mixture. 
The temperature was thus increased to 33 °C and the amount of esterase increased. After 
twelve hours some reaction was observed. This was further increased to an optimum 
temperature of 38 °C and approximately five units of pig liver esterase per milligram of 
compound. Incubation was continued until ^H NMR spectroscopy showed reaction to be 
complete, with the disappearance of the methyl ester at 3.55 ppm and the phosphinate ester 
remaining at 3.70 ppm. Mass spectrometry also confirmed that one of the methyl groups had 
been selectively removed. The reaction mixture was acidified and the product extracted. 
Chromatography was not successful so the compound was deprotected in this form. 
Deprotection was achieved by hydrogenation at atmospheric pressure in methanol using a 
palladium catalyst (Scheme 2.27). The product (124) was obtained in 67% yield after 
recrystallisation from acetone / water. The product was observed to be a mixture of 
diastereomers in a 2: 1 ratio by NMR spectroscopy, the 31p NMR spectrum showed two 
peaks and the clearest indication in the NMR was due to two doublets of the p-carbon at 
29.63 and 31.61 ppm (/pc 100 Hz).
0 “
O COjMe H2 /Pd,M eOH O _  COjH
I I / N ( . . . . h  ^
OMe \ = /  Q^g NH2
o  (122) (124)
Scheme 2.27
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2.6 INVESTIGATION OF THE INTERACTION OF THE PUTATIVE 
INHIBITORS WITH KYNURENINASE.
Kinetic studies were carried out to examine the interaction of the two phosphorus based 
transition state analogues, the phosphinic acid (96) and methyl phosphinate (124), with 
kynureninase. The enzyme was partially purified from Pseudomonas fluorescens (see 
Chapter 5). The kinetic studies were carried out under the same conditions as employed for 
the assay of kynureninase activity. Incubation was carried out at 25 °C and the assay buffer 
contained 0.4 mM kynurenine, 40 |J,M PLP in 0.04 M potassium phosphate at pH 7.0. The 
reaction was followed by UV spectophotometry by measuring the rate of decrease in 
absorbance at 360 nm due to conversion of kynurenine to anthranilic acid (see Experimental).
Using commercial kynurenine, obtained from Sigma as the sulphate salt, the Idnetic data for 
the substrate were determined. Km and Vmax data were determined by non linear regression 
using the ENZFITTER^^^ programme. In order to determine the inhibitory properties of the 
phosphinic acid analogues the kinetic parameters were re-determined in the prescence of 
varying concentrations of the inhibitors. The effect on the Idnetics then gave a measure of the 
strength and type of inhibition.
For kynurenine the values used were the average values obtained i.e. Km = 25.5 ± 0.6 (xM, 
in excellent agreement with Palfreyman et al. (Km = 25 and Vmax = (1.07 ± 0 .0 1 ) x
10’  ^mol dm-3 min i (corrected for one unit of enzyme activity). (The full data are in the 
Appendix).
2.6.1 Phosphinic Acid (96).
The data obtained for the inhibition of kynureninase by the phosphinic acid analogue are 
given in tables 2.6, 2.7, 2.8 and shown graphically in graph 2.1. Each rate was determined
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two or three times until the values were consistent (± 3%) and the average values (±1% from 
regression analyses) are shown.
KS mM Phosphinic Acid
[Substrate] (mM) l/[Substrate] 
(xl04 mol’l dm3)
Rate
(min-l)
1/Rate(nun)
0 . 1 0 1 . 0 3.77 0.265
0 . 2 0 0.50 4.17 0.240
0.30 0.333 4.29 (X233
0.45 0 . 2 2 2 4.56 0.219
0.50 0 . 2 0 4.60 0.217
Table 2.6
1 mM Phosphinic Acid
[Substrate] (mM) l/[Substrate] Rate 1/Rate
(xl04 mol’l dm3) (min-1) (nun)
0 . 1 0 1 . 0 3.70 0.270
0 . 2 0 0.50 4.12 0.243
0.30 0.333 4.25 0.235
0.45 0 . 2 2 2 4.53 0 . 2 2 1
0.50 0 . 2 0 4.61 0.217
Table 2.7
2 mM Phosphinic Acid
[Substrate] (mM) l/[Substrate] 
(xl04 mol'^ dm3)
Rate
(min-l)
1/Rate(nun)
0 . 2 0 0.50 4.04 0.248
0.45 0 . 2 2 2 4.41 0.227
0.50 0 . 2 0 4.49 0.223
Table 2.8
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0.29
0.27
0.25
0.23
0.21
0.19
0.17
0.15
1 -0.5 0 0.5 1
Concentrations 
□ 0 mM 
<®>0,5 mM 
o  1.0 mM 
A 2.0 mM
1/[S] (10** mor
Graph 2.1 : Lineweaver-Burk plot for kynureninase catalysed reaction of Icynurènine in the 
presence of varying concentrations of phosphinic acid.
For the phosphinic acid it can be seen that V/K varies while Vmax is constant which implies 
that the phosphinic acid is a competitive inhibitor. Competitive inhibition occurs when the 
inhibitor competes with the substrate to bind at the active site, therefore, the enzyme can bind 
substrate or inhibitor but not both. The substrate is thereby prevented from binding to the 
same active site. A competitive inhibitor diminishes the rate of catalysis by reducing the 
proportion of enzyme molecules bound to a substrate.
In order to show the type of inhibition it is often preferable to display it using the 
Lineweaver-Burk plot.
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Y = ^max
[S] +K m
therefore,
_LV KMVmax max [S]
A plot of 1/V versus 1/[S], called a Lineweaver-Burk plot, yields a straight line whose 
intercept with the x axis is -1/K m  and the intercept with the y axis is 1/Vmax and the gradient 
is equal to KM/Vmax-
■1/Km
Gradient = Km/V
max
max
1/[S]
Lineweaver-Burk plot
In competitive inhibition, the intercept of the plot 1/V  versus 1/[S] is the same in the 
prescence and absence of inhibitor, although the slope is different. This reflects the fact that 
Vmax is not altered by a competitive inhibitor. The hallmark of competitive inhibition is that it 
can be overcome by a sufficiently high concentration of substrate. At a sufficiently high 
concentration, virtually all the active sites are filled with substrate, and the enzyme is fully
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operative. The increase in the slope of the 1/V versus 1/[S] plot indicates the strength of 
binding of the competitive inhibitor.
Michaelis and Menten proposed a simple model to account for the kinetic characteristics of 
single substrate reactions.
kcatE + S ES  ^  ProductsKm
The catalytic reaction is divided into two processes. The enzyme and the substrate first 
combine to give an enzyme substrate complex, ES. This step is assumed to be rapid and 
reversible with no chemical changes taking place; the enzyme and the substrate are held 
together by physical forces. The chemical processes then occur in a second step with a first 
order rate constant, It^ at (the turnover number). For competitive inhibition an additional 
equilibrium must be considered.
kcatE + S ■ ~4 ^  ES ----------- ^  Products
K
Kmh' I
The modified equation is:
V = Vmax [S][S] 4-KM (1 + [I]/K i)
Therefore,
Km is apparently increased by a factor of (1+[I]/Ki).
This is denoted Kapp and this equation can be used to determine the value of Kp
Kapp -  Km ( l +  )
i e T< -  [I]I.e. ivapp — Kt 4- K M
Thus a plot of Kapp versus [I] gives a graph whose gradient is equal to K^/Ki.
Kapp is in fact, the value determined in the presence of varying concentrations of the 
inhibitor.
The data and plot for Kapp versus [I] for the kynureninase catalysed reaction of kynurenine in 
the presence of varying concentrations of the phosphinic acid analogue are shown in table 2.9 
and graph 2.2 respectively. Thus from the gradient of this graph we can determine Ki as Km 
is already known. Linear regression analyses was employed to determine the best straight 
line and errors were obtained from the regression analyses.
Inhibitor Inhibitor
concentration
(mM)
Vmax"* (X 10-3)
(mo! dm-3 min-i)
l^app (P-M)®
No inhibitor OmM 1.07 + 0.01 25.5 ± 0.6
Phosphinic acid 0.5 mM 1.07 ± 0.02 28.6 ± 0.4
Phosphinic acid 1.0 mM 1.07 ± 0.02 31.6 ±0.5
Phosphinic acid 2.0 mM 1.07 ±0.01 37.7 ± 0.4
®Vmax and Kapp were obtained from fitting the data to the Michaelis-Menten equation by non linear 
regression using the ENZFITTER ^programme.
Table 2.9
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<No
PVmM
gi’aph 2.2: Plot of Kapp versus [I] for the Kynureninase Catalysed Reaction of Kynurenine 
in the Presence of Varying Concentrations of Phosphinic Acid Analogue.
From the graph,
The Ki for the phosphinic acid analogue = 4.19 ± 0.1 mM
2.6.2 Methyl Phosphlnate (124).
The data obtained for the inhibition of kynureninase by the methyl phosphinate analogue is 
given in tables 2.10, 2.11, 2.12, 2.13 and shown graphically in graph 2.3. Each rate was 
determined two or three times until the values were consistent (± 3%) and the average values 
(± 1 .2 % from regression analyses) are shown.
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[Substrate] (mM) l/[Substrate] Rate 1/Rate
(xl04 mol‘l dm3) (min“l) (min)
0 . 1 0 1 . 0 2.79 0.358
0 . 2 0 0.50 3.77 0.265
0.30 (X333 4.25 (X235
0.45 0 . 2 2 2 4.44 0.225
0.50 0 . 2 0 4.59 0.218
Table 2.10
0.5 mM Methyl Pliosphinate
[Substrate] (mM) l/[Substrate] 
(xl04 mol'l dm3)
Rate
(min-1)
1/Rate(min)
0 . 1 0 1 . 0 3.50 0.286
0 . 2 0 0.50 4.14 0.242
0.30 0.333 4.29 0.233
0.45 0 . 2 2 2 4.46 0.224
0.50 0 . 2 0 4.57 0.219
Table 2.11
1 mM Methyl Phosphinate
[Substrate] (mM) l/[Substrate] Rate 1/Rate
(xl04 mol'l dm3) (min-1) (min)
0 . 1 0 1 . 0 3.15 0.317
0 . 2 0 0.50 3.98 0.251
0.30 0.333 4.25 0.235
0.45 0 . 2 2 2 4.43 0.226
0.50 0 . 2 0 4.50 0 . 2 2 2
Table 2.12
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2 mM Methyl Phosphinate
Substrate] (mM) i/Substrate] Rate 1/Rate
(xl04 mol"^  dm3) (min-1) (min)
0.10 1.0 2.86 0.350
0.20 0.50 3.69 0.271
0.30 0.333 4.10 0.244
().45 0 .222 4.41 0.227
1 0.50 0.20 4.48 0.223
0.4
0.35 -
.3  0.3
S 0 35-
0.2 -
0.15
Table 2.13
Methyl Phosphmate 
ConcemtratioMO
□ 0 mM 
€>0.5 mM 
o  1.0 mM 
A 2.0 mM
1/[S1 (lo f mor* dm^
Graph 2.3: Lineweaver-Burk plot for Kynureninase Catalysed Reaction of Kynurenine in 
the Presence of Varying Concentrations of Methyl Phosphinate.
For the methyl phosphinate it can be seen that K m  varies while V m a x  is constant which 
implies that the methyl phoshinate may also be a competitive inhibitor.
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The data and plot for Kapp versus [I] for the kynureninase catalysed reaction of kynurenine in 
the presence of varying concentrations of the methyl phosphinate analogue are shown in table 
2.14 and graph 2.4 respectively. Thus from the gradient of this graph we can determine Ki as 
Km is already known. Linear regression analyses was employed to determine the best 
straight line and errors were obtained from the regression analyses.
Inhibitor Inhibitor
concentration
(mM)
Vmax" (X 10-^) 
(moi dm^
S^app (M-^)"
No inhibitor OmM 1.07 ± 0.01 25.5 ± 0.6
Methyl phosphinate 0.5 mM 1.09 ± 0.01 39.0 ± 0.3
Methyl phosphinate 1.0 mM 1 . 1 2  ± 0 . 0 2 57.6 ± 0.4
Methyl phosphinate 2.0 mM 1.16 ±0.03 83.1 ±0 .9
®nd Kapp were obtained from fitting the data to the Michaelis-Menten equation by non linear 
regression using the ENZFITTER^^^ programme.
Table 2.14
8 0 “
60 -
c
I
o cs «N
[X]/mM
graph 2.4: Plot of Kapp versus [I] for the Kynureninase Catalysed Reaction of Kynurenine 
in the Presence of Varying Concentrations of Methyl Phosphinate Analogue.
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From the graph,
The Ki for the methyl phosphinate analogue = 0.88 ± 0.05 mM
This implied that the methyl ester improved binding relative to the free acid, by almost five 
fold.
2.6.3 Discussion of Enzyme Results.
It can therefore be seen that preparation of the phosphinate ester does improve the inhibitory 
properties, presumably by removing the negative charge and hence its interaction with the 
active site, as discussed earlier. Phosphinic acid inhibitors of pepsin are amongst the most 
potent reported. However, initial attempts to get similar results with HIV-1 proteinase 
were disappointing. This is possibly due to the anionic nature of the phosphinate at the assay 
pH of 6.0 (pKa 3-3.5). The assay pH of pepsin was 3.5 thus, more protonated phosphinate 
should be present which could account for greater inhibition as there is precedent for the 
repulsion of negatively charged species away from a negative aspartate. This theory is 
backed up by an experiment with the HIV-1 proteinase and its interaction with the phosphinic 
acid isostere of the dipeptide Cbz-Phe-Phe (139). This was found to be a moderately potent 
inhibitor of HIV-1 proteinase with a K% of 26 pM at pH 6.5 and 1 pM at pH 4.5. The 
inhibition increases at lower pH possibly due to the presence of the more protonated 
phosphinate.
Q O OH (139)
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A potent phosphinic acid inhibitor, SB 204144 (140), has been reported by Abdel-Meguid 
and co-workers which had a Kj of 2.8 nM at pH 6.0. Their pH analysis failed to 
unambiguously answer the question of whether the inhibitor would be more potent at lower 
pH, however, crystallographic results indicated the presence of a protonated phosphinate.
OH S! H CbZ“ Val“ N. ^ N = V al“ -Cbz
:  o n T
(109) p ^ /  ph (140)
Gani et al. have synthesised stereochemically defined and epimeric phosphonamidate methyl 
ester containing peptide analogues (141, and related stmctures) of the HIV-1 proteinase.
Me o
(141)
CONHg
^^O M e>.H HN
0  r
H \
0
They reasoned that the lack of potency of phosphonamidate inhibitors for the HIV-1 
proteinase stems from their negatively ionised nature at the pH optimum for the enzyme 
which results in repulsive interactions between the inhibitor and the negatively charged active 
site carboxylate group. This problem of ionisation is not inherent in the phosphonamidate 
methyl ester analogues and consequently these neutral compounds have proved to be better 
inhibitors with IC5 0  values from 1-100 p,M. However, Gani et and McLeod et al}^^ 
noticed only small differences in the potencies of the phosponamidates and the coiTesponding 
methyl esters as inhibitors for HIV-1 proteinase.
95
It is interesting that neither of our phosphorus compounds are as potent inhibitors of 
kynureninase as the sulphone transition state analogue, 5- (2-aminophenyl)-L-cysteine 5,5- 
dioxide (97), prepared by Phillips and Dua, which had a Kj of 70 The reduced
binding may in part result from the absence of the ortho-smino group. The Kj for racemic 
desaminokynurenine under our conditions was 23.2 + 3.1 fXM (see Chapter 3) and the rate of 
turnover was approximately twenty times less than that of kynurenine, implying that the kcat 
is reduced twenty times. As noted by Bartlett and Marlowe the inhibition constant Ki for a 
transition state analogue should be related to the KM/^cat value of the corresponding 
substrate. Thus it might be predicted that the ortho-smino substituted analogue of the 
methyl phosphinate would have a Kj of approximately 44 pM, still about six hundred times 
greater than that of the sulphone. Interestingly, with the 5,5-dioxide an ortho-amino group 
gave a fifty five times increase in the observed Ki value. The Ki for 5-(2-aminophenyl)- 
25-cysteine 5,5-dioxide (142) was 0.07 pM whereas the Kj for 5-(phenyl)-25-cysteine 5,5- 
dioxide (142) was 3.9 pM.
One reason for the poor binding is that the methyl ester may be too large for the active site. 
However, as there is no crystal structure of kynureninase at present it is difficult to be sure of 
this. Whether the poor binding of the phosphinic acid transition state analogues has any 
implications for the proposed general base catalysed mechanism of kynureninase is as yet 
unclear. This mechanism will also be discussed in relation to the results of the solvent 
isotope effect studies (see Chapter 4).
O Ç^2‘
O NHa<
(142)
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2.7 THE ENZYMIC NUCLEOPHILE MEDIATED REACTION.
As mentioned previously the hydrolysis of kynurenine could also be mediated by an enzymic 
nucleophile (Scheme 2.28). In this case the ketimine intermediate (38) is attacked by an 
enzymic nucleophile at the y-carbonyl group. Cleavage of the p,y-carbon-carbon bond then 
talces place, thus giving an a-aminoacrylate derivative p9) and a covalent intermediate (143). 
Reaction of this with water gives anthranilate (2) and regenerates the enzymic nucleophile.
EnZ“X (143)
Scheme 2.28
m .
O
^ 0 -
NH3+
+ (2)
Enz-X'
One method to probe for the nucleophile mediated mechanism is to design inhibitors to 
alkylate the putative active site nucleophile. Examples of these would be the fluoro, chloro 
and bromo derivatives (144) and the epoxide (145). These compounds should form the 
Schiff s bases with the coenzyme but when attacked by the nucleophile they will become 
covalently attached to the enzyme. This is an example of irreversible inhibition (Scheme 
2.29). If the inhibitors do indeed become irreversibly attached to the protein they could then 
be prepared in a radioactively labelled form. Covalent attachment to the protein and digestion 
of the inactive enzyme should then produce a number of labelled peptides. Purification and 
analysis of the peptides would then allow identification of amino acid residues at the active 
site. This would be the first structural information regaining the active site of kynureninase.
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Enz-X
(144) Y =F,C l,B r
Enz-X'
INACTIVEENZYME
o  9^2 f O  ÇO2
Enz-X' 
Scheme 2.29
Enz-X
INACTIVEENZYME
Synthetic studies towards the preparation of the epoxide analogue (145) were undertaken.
2 .7 .1  Design o f  Proposed Epoxide Analogue.
A possible synthetic route to the epoxide (145) is given in Scheme 2.30.
COO-R' COO-R'
PhCH2-PPh3 + Br
NH-R NH-R
Deprotection
Potential Suicide Inhibitor
R 'C O gH O
Deprotection
COO-R'I  C O Ü -
Ph NH-R
H
Ph (1 4 5 ) NHg
Affinity Label
Scheme 2.30
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The key intermediate is the alkene (146). The alkene could be prepared by using Wittig 
chemistry with the serine aldehyde (147) and the ylid derived from the 
alkyltriphenylphosphonium salt. The allcene (148) is itself a potential suicide inhibitor of 
kynureninase. Reaction of the alkene with meta-chloroperbenzoic acid should then give 
the epoxide (149). Theoretically it should be possible to carry out the deprotection before 
or after this epoxidation step.
There are many examples of allcene inhibitors of PLP dependent enzymes, such as vinyl 
glycine (150) an inhibitor of aspartate aminotransferase.^^'^ Aspartate amino transferase 
catalyses the amino transfer from glutamate (151) to oxaloacetic acid (152) to give a- 
ketoglutaric acid (153) and aspartate (154) (Scheme 2.31).
02 H
+NHa
(151)
O2C
(153) O
PLP
o
(152)
(154) 
Scheme 2.31
H
+NH3
(150)
The vinyl glycine PLP complex (155) fits in the same orientation as the glutamate PLP 
complex and after a-hydrogen abstraction gives the quinoid intermediate (156). 
Protonation then occurs at the double bond, instead of at C-4' as in the normal enzyme 
catalysed reaction. This results in the formation of a Michael acceptor (157) which 
undergoes conjugate addition producing inactivated enzyme. Either protonation at the a- 
C or at C-4' furnishes a product which is irreversibly attached to the enzyme (Scheme 
2.32).
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(156)
1^
(157)
INACTIVATED ENZYME 
protonate at a-C protonate at C-4'
^COo
" v V '
COp-
o
+ PMP
COg-
NHg+ PLP
Scheme 2.32
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Therefore, the first target on the route to the epoxide analogue is a chiral serine aldehyde 
synthon. Literature syntheses of some routes to suitable compounds are outlined below.
O COO-R*
/
NH-R (147)
2.7.1.1 V-r9-FluorenvlmethvloxycarbonylVl l^)-l-amino-2-hvdroxyethyl-4-methyl-2,6,7- 
trioxabicyclo 12.2.21 octane fFmoc-5'-Serine Ortho ester).
Blaskovich and Lajoie^^^ prepared a base stable cyclic-ortho ester (158) serine aldehyde 
equivalent. The reason for the ortho-esier protecting group can be explained as follows. If 
the protecting group was, for example, a methyl ester, this would mean that the a-proton 
would be quite acidic due to the electron withdrawing effects of both protecting groups. This 
would mean that the a-centie would racemise under Wittig conditions, that is, in the presence 
of base the stereochemistry would be lost. In contrast, with the less electron withdrawing 
ortho-ester as protecting group, the a-proton is much less acidic and thus should alleviate the 
problem. Thus the amine group was protected as the N^-9-fluorenyl-methoxycarbonyl 
(Fmoc) (159) derivative. The oxetane ester (160) was prepared from Fmoc-25'-serine and 3- 
methyl-3-(hydroxymethyl)-oxetane using dicyclohexylcarbodiimide (DCC), and 
dimethylaminopyridine (DMAP) to effect the coupling. The oxetane ester was then converted 
to the ortho-ester (161) using boron trifluoride etherate and oxidation under Swern conditions 
gave the aldehyde (158) (Scheme 2.33).
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HO.
R— N
DCC, DMAP,
(159)
HO.
(160)
1. DMSO, (COCl)2
2. DIPEA
R = Fmoc =
OCO- 
Scheme 2.33
HO,
LL'"HR - N
(161)
The ortho-QSiQT has been reacted with Grignaid reagents and used in a Reformatsky reaction, 
as shown below. Thus Grignard addition with MeMgBr at room temperature resulted in 
protected 25-threonine in 77% yield. Similarly reaction with PhMgBr at room temperature 
provided protected 25-phenylserine in 85% yield (Scheme 2.34, Table 2.15). The resulting 
(3-hydroxy intermediates were deprotected with piperidine. After evaporation the free amino 
derivative was reacted with aqueous trifluoroacetic acid (TFA) to give the dihydroxyester. 
Finally hydrolysis with CS2CO3 gave the free amino acid (162).
Fmoc—N
R2MgX
H 1) piperidine
2R ^ 0 H 2) TFA H
3) CS2CO3
Fmoc—N JL'H
H2N ' ^COgH 
(162)
Scheme 2.34
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R Yield (162, %) 2S,3R : 2S,3S e.e. (%)
Me 77 84: 16 98
Ph 85 83: 17 98
Table 2.15
Reformatsky reaction of the aldehyde with the organozinc compound derived from %utyl 
bromoacetate gave a p-hydroxyglutamic acid derivative (163) in 73% yield as a 92: 8  mixture 
of (25,3^: 2S,3S) diastereomers. Deprotection with trimethylsilyl iodide removed all the 
protecting groups to give (25,3^)-p-hydroxyglutamic acid (164) in good yield with >98% 
e.e. (Scheme 2.35).
BrCHjCOj'Bu
Fmoc-
BU^ OgC |-j
Zn Fmoc—N
OH 1)TMSI HO2C H
u 2) NaOH = . OHn ^
H
(163) 
Scheme 2.35
(164)
2.7.1.2 The Garner Aldehyde.
The most popular serine aldehyde equivalent is the Garner aldehyde. The acetonides (165) 
were introduced by Garner in 1984 and aie noted for their synthetic versatility. They have 
been prepared with various nitrogen protecting groups (165 a to d).^^^
o
(139)
a)R: C0 2 ^Bu
b)R: COzCHzPh
c)R: CO2CH3
d)R: CHsPh
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It should be noted that with this synthon, the carboxylic acid of serine becomes the aldehyde. 
On deprotection, what was originally the alcohol becomes the carboxylic acid of the new 
amino acid derivative and so as a result 2 R-serine is eventually converted to the 25-amino 
acid derivative.
The synthesis begins with protection of the amino group of serine (100) with ài-îert~ 
butyldicarbonate and formation of the ester using iodomethane and potassium caibonate in 
DMF. The oxazolidine (166) was then prepaied by reaction with 2,2-dimethoxypropane and 
a catalytic amount of p-toluenesulphonic acid monohydrate. Reduction of the ester with 
diisobutylaluminium hydride (DIBAL) gave the desired ester. The product (165 a) was 
obtained in good yield and was determined to be 95% enantiomerically pure (Scheme 2.36).
(100) NHg NHBoc
DMP 
cat. TsOH
^ C H O  y-,4^C 02M e
^  \  Boo
(165a) 
Boc =
(70-89% )
Boc
(166)
MeO. OMe
^  D M P= X
Scheme 2.36
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Alternative syntheses of this intermediate have been developed, for example Branquet et a l 
overcame the limitation of using diazomethane by using the Mitsunobu reaction (Scheme
2.37).^58
HO COaH P P h 3 ,E tg ,M ep H ^
NHBoc
DEAD 
Scheme 2.37
COgMe 
7I..H
NHBoc
McICillop and co-workers carried out the estérification of serine by reaction with methanol 
and acetyl chloride. The ester was then converted into the carbamate (167) by using 
di-fer^-butyldicarbonate in THE and triethylamine. Formation of the oxazolidine (166) was 
achieved by the use of 2,2-dimethoxypropane in acetone at room temperature with boron 
trifluoride etherate as the catalyst. The ester was then reduced with DIBAL following 
Garner's procedure (165a) (Scheme 2.38).^^^
NH3+
COs' l.MeOH, AcCl
2. (Boc)20, EtgN 
THF
^  HO
CHO DIBAL
Toluene
C02Me (167)
NHBoc (90%)
DMP, Acetone 
BF3.0Et2
CO2MG
O'
(165a) (70%)
X '  w  (91% ) 
(166)
Scheme 2.38
The Garner aldehyde has been used in the synthesis of AT-Boc halides (168), which are 
required for the synthesis of naturally occurring antibiotics. Wittig olefination using 
potassium bis(trimethylsilyl)amide (KHDMS) was carried out. Hydrolysis of the acetonide 
(169) using Amberlyst 120H resin then gave vinyl glycinol. Mesylation of the alcohol
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followed by displacement using lithium iodide or lithium bromide in THF with 
ultrasonication gave the desired A-Boc halides (168) (Scheme 2.39).^^^
r— Amber l yst
(93%)  ^  ^ (69%)
(169) MsCl, EtsN,
CH2CI2
NBoc
(98%)
U X ,  THF 
 ^ NBOC ((( 40 °C
x : %
NBoc
Scheme 2.39
The Garner Aldehyde has also been used in the stereoselective synthesis of monocyclic 
p-lactams. This can be achieved by cycloaddition between benzyloxyacetyl chloride and the 
imine derived from N,0-diprotected 25-serinal (170).^^^» The product was isolated in 
85% as a single diastereomer which could be converted into the formyl derivative (171). 
This was achieved by simultaneous N,0 deprotection of both aminolcetal and Boc groups to 
afford the (3-lactam in 70% yield. The amino alcohol was then cleaved by treatment with a 
slight excess of lead tetraacetate at room temperature in benzene to give the foimyl derivative 
in almost quantitative yield (Scheme 2.40).^^^
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PhHaC' s  + NEt). CH2CI2
COCI ilj -78°C tor.t_ PhCHgO^
''Pmp 
(170)
(85%)
Pmp
3 M HCl-MeOH 
70
P h C H , 0 _ ^ C H 0 ^ g ^  P h C H a O J J  " 
(171) O ^ '^ - p m p  ^ Pmp
Pmp = p-methoxyphenyl
Scheme 2.40
2.7.1.3 The Strecker Synthesis.
Another possibility is to investigate the racemic synthesis of the (3,Y-unsaturated amino acid
(172). This would provide a good comparison with the stereospecific alkene (148), 
synthesised via the chiral serine aldehyde derivative, when these compounds are incubated 
with the enzyme. A method has been devised by G re e n le e w h ic h  utilises a Strecker 
reaction.
R2 R3 
r^«^C=C-CHO
(173)
R-NH2
4A mol. sieves 
CH2CI2
R2 R3 
C = C - C H = N H R - #  
(172) CO2H
R2 R3 (174) 
R^  — C = C - C = N — R
TMSCN
CH2CI2
u
19%  ^  6MHÇ1 R^— c = C - C H = N - R
exch an ge  reflux I
CN (175)
Scheme 2.41
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Treatment of a,p-unsaturated aldehydes (173) with primary amines in the presence of 
molecular sieves afforded the corresponding imine (174). These were then subjected to the 
action of trimethylsilyl cyanide, which, by 1,2-addition, produced p,y-unsaturated 
aminonitriles (175). Direct treatment with aqueous HCl (6M) provided, after ion-exchange 
chromatography, the (3,y-unsaturated amino acids in moderate yields (Scheme 2.41).
When 4,4'-dimethoxybenzhydrylamine (176) was used as the amine component the 
dimethoxybenzhydryl group was cleaved under acidic hydrolysis which allowed isolation of 
the free amino acid (see table 2.16).
A ldehyde Amine Product Yield
H3CQ— ^ ^ CHNHa
CO2H
48
PhCH2NH2 3H-NHCH2Ph
CO2H
43
CHa
H3CO — ^  CHNH2
CH3
A^  CH-NH2 1CO2H
44
H3CO -—^  CHNH2 ^  CH“ NH2 1C0 2 H
15
Table 2.16
2.8 ATTEMPTED SYNTHESIS OF SERINE ALDEHYDE EQUIVALENT.
The orf/îo-ester as described by Blaskovich and Lajoie was chosen as the most suitable 
synthon for our purposes. In this case, however, Cbz was used to protect the amino group 
instead of Fmoc (177). As the Fmoc group is removed under basic conditions (Scheme 
2.42) and a base would also be required for the Wittig reaction, this protecting group is 
unsuitable for this route.
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Scheme 2.42
The first step in the synthesis (Scheme 2.43) involved the preparation of Cbz-serine (101a) 
from serine (100) as described in section 2.4 (SYNTHESIS OF THE PHOSPHINIC 
ANALOGUE) and was carried out in 11% yield. This was then added to a stirred solution 
of DCC, DMAP and oxetane alcohol (178) at 0 °C under nitrogen. As a different protecting 
group for the nitrogen, was used, Cbz instead of Fmoc, the starting material was not as 
soluble in dichloromethane. After the reaction was complete the solution was reduced in 
volume and dicyclohexylurea, the biproduct of the reaction, removed by filtration. The 
product was purified by column chi'omatography (silica, ethyl acetate: petroleum ether; 2: 1). 
Recrystallisation was carried out using ethyl acetate which helped remove the remaining 
dicyclohexylurea giving the product in 57% yield. The identity of iV-Cbz serine oxetane ester 
(179) was confirmed by NMR and this could be achieved by comparing the product with 
oxetane alcohol. In oxetane alcohol the methylene group next to the alcohol is seen at ô = 
3.45 ppm as a singlet and the ring methylene protons as two doublets at Ô = 4.20 and 4.35 
ppm (7 6 Hz, CH). In the product the singlet disappears and the six methylene protons can 
be seen as a multiplet at Ô = 4.50 ppm. The methyl protons are also shifted from Ô = 1.10 
ppm in the alcohol to ô = 1.30 ppm in the product.
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OH ÇO2 H
'«.-H
(101a)NH-
(178)
, 0 OH
(179)
DCC/DMAP NH-Cbz
BF3.Et20 (0.027 eq.) 
DCM
i)DMSO/(COCl)2
ii) DIPEA
NH-Cbz
OH
NH-Cbz
Scheme 2.43
The next step was the preparation of the ortho-QSlQv using boron trifluoride etherate. 
However, the formation of the ortho-^st&x proved to be problematic. Blaskovich and 
Lajoie stated that in order to isolate high yields of the orfAo-ester, it was essential to 
maintain the concentration of boron trifluoride at less than 0.1 equivalent. The boron 
trifluoride was therefore added as a dilute solution in dichloromethane. However, the 
stability of this solution was under some doubt. A fresh stock of solution was prepared 
using freshly distilled boron trifluoride before each addition. Unfortunately, this did not 
improve the reaction. It was thought that an extended reaction time was also detremental 
as there seemed to be an equihbrium between the product and the starting material. This 
was investigated by reducing the reaction time but, this did not improve the yield of the 
product. As isolation of the ortho- ester was proving to be extremely difficult, it seemed 
reasonable to investigate whether the Cbz protecting group was causing any problem.
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Therefore the literature method was repeated using the Fmoc protecting group on the 
nitrogen. Unfortunately, the formation of the ortho-Qsi&t proved to be as much of a problem, 
and was low yielding and difficult to purify.
At this stage other aspects of the project were thought to be more fruitful and work was 
discontinued. However, it was thought that the alternative route using the Garner 
aldehyde^would be worth pursuing.
2.8.1 Synthesis of Serine Aldehyde Equivalent.
Indeed further work in the group has resulted in the synthesis of the aldehyde in 26% 
overall yield using the McKillop route.
/X y C O g  1 . MeOH, AcCl /V  .COgMe (167)
I T  2. (Boc)20,Et3NrNH3+ THF NHBoo (48%)
DMP, Acetone 
Bp3.0Et2
CHOO i _ DIBAL
(69%)
(165a) (77%) (166)
Scheme 2.44
Serine was refluxed with acetyl chloride in methanol to give methyl serinate hydrochloride 
with a yield of 82% and this was then used without further purification to produce the 
protected methyl ester using di-fgrf-butyldicarbonate in THF / triethylamine in 59% yield. 
The formation of the oxazolidine methyl ester was carried out by the use of 2,2- 
dimethoxypropane with boron trifluoride etherate as catalyst, distillation under reduced 
pressure gave the product in 69% yield. The aldehyde was then formed by reducing the ester
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with DIBAL and distillation under reduced pressure gave the product in 11% yield 
(Scheme 2.44).
The alkene (181) was produced in good yield after optimisation of the reaction 
conditions, using Wittig chemistry, as a 3: 1 mixture of E and Z isomers which could be 
separated using column chromatography.
PhCHzPPhBr 
«BuLi, THF
(181) N 
(94%) B o c
b,c, d
b, c, d
a) mCPBA, DCM; b) Amberlite IR-120, MeOH/HiO;
c) Cr0 3 -H2S0 4 , Acetone/H20,0 °C - RT; d) HCl, EtOAc, RT
Scheme 2.45
The epoxidation of the fully protected alkene was investigated and preliminaiy results 
indicated that mera-chloroperbenzoic acid was effective. The deprotection and oxidation 
steps now need to be optimised (Scheme 2.45). The deprotection conditions are very 
likely to cleave the epoxide. Therefore, it may be better to deprotect the alkene by
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hydrolysis of the aminoketal group, oxidise the alcohol to the acid and then epoxidise the 
double bond. Finally, removal of the Boc protecting group should give the epoxide 
target. Full deprotection and epoxidation of the free vinyl amino acid is also a 
possibility.
When the epoxide has been obtained its interaction with kynureninase will be examined 
Idnetically in order to investigate the mechanism of hydrolysis in the enzyme catalysed 
reaction. The synthesis will obviously give a mixture of diastereomers of the epoxide. If 
inhibition is observed, then further information about the structure of the active site may 
be obtained by examining the relative inhibitory activities of the separated diastereomers. 
However, separation and / or stereospecific synthesis is probably only worthwhile if 
inhibition is observed with the mixture.
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CHAPTER 3
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3
It was decided to prepare a number of kynurenine analogues and examine their activity with 
kynureninase in order to obtain information on the specificity of the enzyme and the 
important interactions at the active site. The compounds identified were the cyclohexyl (182) 
and naphthyl (183) amino acid derivatives as well as desaminokynurenine (27).
O COgH O COgH
I  T NHs r T NHs
(27) (182)
3.1 L IT E R A T U R E  SYNTHESES OF R A C EM IC  K Y N U REN IN E 
ANALOGUES.
In the literature, essentially the same basic method has been employed for the synthesis of all 
racemic kynurenines. This involves the addition of diethyl acetamidomalonate to an 
appropriate a-haloacetophenone derivative (184), followed by decarboxylative hydrolysis
NHAc
O u '^ ^ C O g E t  O NHAc
„ J l ^ x  —
<l«4)
X = Hal HCl
O NHg
D' ^  \ -COgH 
H
Scheme 3.1
Pellicciari et al. synthesised ortho, meta and para nitrobenzoyl alanines (66, 67 and 68 
respectively).^^  Condensation of the nitrophenylacyl bromide (185) with
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I
(Scheme 3.1). !
diethyl acetamidomalonate was carried out in DMF at room temperature using sodium 
hydride to give the anion (Scheme 3.2).
O NHAc
R' (185)
Br
NaH, DMF
NHAc
^CO aEt 
C O g E t
R  =  N 0 2 : R  = H ; R " = H
R = H;R* = N 0 2 ; R " = H  
R = H ; R ’ =H;R '*  = N 0 2
Scheme 3.2
Hydrolysis was then achieved with 6M HCl followed by neutralisation with sodium 
hydrogen carbonate to give the product as a free base.
Varasi et al. prepared a number of kynurenine analogues which were substituted on the 3-, 
4-, 5- and 6- positions of the benzene ring.^^ The syntheses began with the corresponding 
substituted alanines (186) which were converted to a-chloroacetophenones (187) under 
Houben-Hoesch conditions according to the procedure of Sugasawa.^^® The anion of 
diethylacetamidomalonate was prepared using sodium ethoxide in ethanol at 45 °C for one 
hour. After cooling a solution of the a-chloroacetophenone in ethanol was then added 
drop wise under nitrogen. The product was then refluxed in 37% HCl to afford the amino 
acid. Mono- or dimethylation of the aromatic amino group was achieved by treatment of 
foimaldehyde /  sodium cyanoborohydride or iodomethane /  potassium carbonate before the 
hydrolytic step (Scheme 3.3).
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(186)
BCU.A1CU
ClCHzCN
37% HCl
O
COpCHoCI
NHAc
Na © ^cO aE t 
COaEt
NHAc
COgEt
COgEt
i) CHgO, NaBHsCN
ii) 37% HCl
COgH
NHCHg 
Scheme 3.3
i)CH 3l,K 2C0 3
ii) 37% HCl
NHc
A%^N(CH3)2
6-Chlorokynurenine (188) was prepared from the corresponding 6-chloro-2~nitro-a- 
bromoacetophenone (189). Condensation with diethyl acetamidomalonate was followed by 
Fe /  AcOH reduction of the nitro group and hydrolysis (Scheme 3.4).^^
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6T' Br2NO2
Cl O NHAc
Fe/AcOH
37% HCl
01 O NH2 
(188)
Scheme 3.4
C00H2Br
(189)
NO2
NHAc
K+ TCOgEt
COgEt
01 O NHAc
Similar syntheses have also been carried out by Varasi^^^ et al. starting from the substituted 
a-bromoacetophenone (190) and Schwarcz^^ et al. have prepared kynurenine derivatives 
starting from 4-substituted aniline.
O
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3.2 SYNTHESIS OF KYNURENINE ANALOGUES.
The method of Pellicciari was adopted and modified for the various analogues as described 
below.
3.2.1 Preparation of 2-amino-4-oxo-4-t)henvl-butvric acid (desaminokynurenine. 271 
Diethyl acetamidomalonate in redistilled DMF was added to sodium hydride at 0 °C under a 
nitrogen atmosphere. Stirring was continued for three hours, a solution of the 
a-bromoacetophenone (191) in redistilled DMF was added and the resulting mixture stirred 
overnight. After extraction the residue was triturated with diethyl ether: dichloromethane, 3:1 
to give pure diethyl (phenacyl) acetamidomalonate (192) in 51% yield. Mass spectrometry 
confirmed the disappearance of bromine and the melting point (118-122 °C) agreed well with 
the literature value (118-119 Deprotection was then accomplished by refluxing in 6 M
HCl. Upon cooling, the organic impurities were removed by washing with ethyl acetate. 
Trituration with acetone and neutralisation with 5% sodium hydrogen carbonate afforded the 
free base (27) as a solid. Recrystallisation from acetone /  water yielded the microanalytically 
pure product in 56% yield (Scheme 3.5).
(191)
C02Et
H -J
NHAc
NaH
DMF
O COaEt 
11 J^N H A c
COgEt
(192) (51%) 
6MHC1
COgH 
(27) (56%)
Scheme 3.5
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The identity of the product was confirmed by mass spectrometry and the melting point (189- 
191 decomposes 200 °C) agreed well with the literature value (190-200 °C, with 
decomposition).
3.2.2 Bromination of methvi ketones.
For the preparation of the cyclohexyl and naphthyl analogues the corresponding bromo ketone 
was required. Bromination of 2-acetyl naphthalene (193) was initially attempted using the 
method of Vogel^^® (Scheme 3.6). Thus, 2-acetyl naphthalene was dissolved in glacial acetic 
acid and bromine was added dropwise very slowly over thirty minutes. After stirring for two 
hours the flask was cooled in an ice salt bath and the precipitated product filtered and washed 
with a little cold glacial acetic acid, followed by a small volume of water. Recrystallisation 
was then carried out from ethanol giving the product in only 36% yield. A small amount of 
the dibromo product was seen which could be identified by the appearance of the remaining 
a-proton at 6.10 ppm. In the desired product the methylene protons were observed at 4.60 
ppm. As this reaction was low yielding an alternative was sought.
CHa Br2
(193) AcOH (36%)
Scheme 3.6
Reaction using bromine in methanol, was then attempted as it is reported that dibromination is 
very slow in methanol. Indeed, the crude reaction products appeared to contain only traces of 
dibromoketones. Cyclohexyl methyl ketone (194) had also previously been brominated using 
this method.
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3.2.3 Preparation of 2-amino-4-oxo-4-cvclohexvl-butvric acid (cyclohexyl amino acid 
derivative. 1821.
The first step was preparation of bromo-methyl cyclohexyl ketone (195). Thus, bromine was 
added slowly to cyclohexyl methyl ketone (194) in redistilled methanol. The reaction mixture 
was maintained at 5-6 °C during the reaction and was warmed to room temperature once the 
red colour had disappeared. After extraction the product was purified by distillation and gave 
a colourless liquid in 85% yield. NMR spectroscopy showed the appearance of the 
methylene protons which gave a signal at 3.9 ppm. There was a peak at 2.40 ppm in the %  
NMR spectrum which could correspond to the protons that would be shifted with bromination 
occurring at I'C on the ring, however this only appeared to be approximately 4% of the 
product.
In the second step, diethylacetamidomalonate in redistilled DMF was added to sodium hydride
at 0 °C under a nitrogen atmosphere. Stirring was continued for three hours after which a
solution of the bromo-methyl cyclohexyl ketone in redistilled DMF was added and the
resulting mixture stirred overnight. After extraction the residue was triturated with diethyl
ether: dichloromethane, 3:1 to give pure diethyl (cyclohexane carbonyl) acetamidomalonate
(196) in 84% yield. Mass spectrometry and NMR confirmed the structure of the product.
Finally deprotection was accomplished by refluxing in 6 M HCl (Scheme 3.7).
O O
CH3 rjV 95)
(194) COgEt
NaH
DMF
(74%) O
EtOgC’ NHAc
Q ÇOgEt
NHAc
(196)
NHs ^ 6 M H C 1  r  y  ^  NcOsEt
Scheme 3.7
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upon cooling the impurities were removed by washing with ethyl acetate and then trituration 
with acetone afforded the free base after neutralisation with 5% sodium hydrogen carbonate. 
This was recrystallised twice from acetone /  water to give microanalytically pure product 
(182) in 74% yield.
3.2.4 Preparation of 2-amino-4-oxo-4-nanhthovl-butvric acid (naohthvl amino acid 
derivative. 183).
A similar method was used for the preparation of the naphthyl amino acid derivative (183), 
the first step being bromination of 2-acetyl naphthalene (193) (See Scheme 3.8). The 2-acetyl 
naphthalene precipitated out of solution when the reaction mixture was cooled, although it 
was seen to redissolve as the reaction proceeded, some starting material was also isolated. By 
increasing the amount of methanol the precipitation of the starting material was prevented and 
the reaction went smoothly to completion. Recrystallisation from ethyl acetate gave the pure 
product (197) in 91% yield. iR NMR spectroscopy showed the appearance of the methylene 
protons which gave a signal at 4.6 ppm. A iR-l^c COSY spectrum allowed the identification 
of all the carbon signals (Pages 123 and 124).
(197)
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Number Signal In Signal In Assignment In
spectrum (ppm) spectrum (ppm) spectrum^
3 ’ 124.1 8.05 h
6' 127.0 7.59 g
7' 127.9 7.92 e
5' 128.8 7.95 d
8' 129.0 7.65 f
4' 129.6 8.00 c
1' 130.9 8.52 a
^  Spectrum shown on page 123 .
Table 3.1
The a-bromoketone was then reacted with diethyl acetamidomalonate as before to give diethyl 
(2-naphthoyl) acetamidomalomnate (198) which was purified by column chromatography 
(silica, ethyl acetate: hexane; 45: 55) to give a pale yellow solid in 8 6 % yield. Mass 
spectrometry and NMR spectroscopy confirmed the structure of the product. Deprotection 
was carried out by refluxing in 6  M HCl. The impurities were removed by washing with 
ether as ethyl acetate was found to be too polar and trituration with acetone afforded the 
hydrochloride salt which was neutralised with 5% sodium hydrogen carbonate to give the free 
base. This was recrystallised from methanol to give microanalytically pure product in 65% 
yield (Scheme 3.8).
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(193) y (197) NaH /
D M F / C0 2 Et
/ " i L ,^  EtOaC 'NHAc
6MHC1
ÇOgEt
NHAc (86%) 
COgEt
(183)
Scheme 3.8
(65% )
3.3 TESTING OF ANALOGUES AS INHIBITORS OF KYNURENINASE. 
Once the three kynurenine analogues had been successfully prepared, Idnetic studies were 
carried out to examine their interaction with kynureninase. Initially work was focused on 
their action as inhibitors of the enzyme catalysed reaction. Thus the kinetic parameters for 
kynurenine (Km and V^ax) were determined in the presence of fixed concentrations of each 
analogue. The kinetic parameters of kynurenine without putative inhibitor were the average 
values calculated (Km = 25.5 ± 0.6 |XM and Vmax = (1.07 ± 0.01) x 10-3 mol dm-3 min-i, 
see experimental). The same experimental conditions were employed as for the normal assay 
of enzyme activity. Incubation was carried out at 25 °C and the assay buffer contained
0.4 mM kynurenine, 40 jxM PLP in 0.04 M potassium phosphate at pH 7.0. The reaction 
was followed by UV spectophotometry by measuring the rate of decrease in absorbance at 
360 nm due to conversion of kynurenine to anthranilic acid (see Experimental for full
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details). The analogues had limited solubility and sonication was often required to aid 
dissolution.
It was found that all three analogues acted as inhibitors of kynureninase to various degrees.
3.3.1. 2-amino-4-oxo-4-cvclohexvl-butvric acid (cvclohexvl amino acid derivative. 182). 
The data obtained for the inhibition of kynureninase by the cyclohexyl amino acid is given in 
tables 3.2, 3.3, 3.4 and shown graphically in graph 3.1 using a Lineweaver-Burk plot. Each 
rate was determined two or three times until the values were consistent (± 3%) and the 
average values ( ± 1.7% from regression analyses) are shown. For the cyclohexyl amino 
acid Km varies and Vmax is constant which is possibly due to competitive inhibition.
0.05 mM Cyclohexyl Amino Acid
[J^ubstrate] (mM) l/[Substrate] 
(xl()^ mol'l dm^)
Rate
(min‘1)
1/Rate(min)
0 . 1 0 1 . 0 3.72 0.269
0 . 2 0 0.50 4.02 0.249
0.30 0.333 4.24 0.236
0.45 0 . 2 2 2 4.40 0.227
0.50 0 . 2 0 4.49 0.223
Table 3.2
0.1 mM Cyclohexyl Ammo Acid
[Substrate] (mM) l/[Substrate] 
(xl04 mol'i dm3)
Rate
(min-l)
1/Rate(min)
0 . 1 0 1 . 0 3.65 0.274
0 . 2 0 0.50 3.96 0.253
0.30 0.333 4.15 0.241
0.45 0 . 2 2 2 4.39 0.228
0.50 0 . 2 0 4.44 0.225
Table 3.3 
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[Substrate] (mM) l/[Substrate] 
(xlO^ mol'l dm^)
Rate 1 1/Rate 
(min-l) 1 (min)
0 . 1 0 1 . 0 3.58 1 0.279
0 . 2 0 0.50 3.89 0.257
0.30 0.333 4.13 0.242
0.45 0 . 2 2 2 4.38 1 0.228
0.50 0 . 2 0 4.42 1 0.226
Table 3.4
0.29
0.27
0.25
0.23
0.21
0.19
0.17
0.15
1 -0.5 0.50 1
Cyclohesyl Amino AcM 
Concentrations 
□  0 mM 
00.05 mM 
00.1 mM 
A0.15 mM
1/[S] (10^ mol * dm^)
Graph 3.1 : Lineweaver-Burk Plot for Kynureninase Catalysed Reaction of Kynurenine in 
the Presence of Varying Concentrations of Cyclohexyl Amino Acid.
The data and plot for Kapp versus [I] for the kynureninase catalysed reaction of Icynurenine in 
the presence of varying concentrations of cyclohexyl amino acid are shown in table 3 . 5  and 
graph 3.2 respectively. Thus from the gradient of this graph we can determine Kj as Km is
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already known. Linear regression analyses was employed to determine the best straight line
and errors were obtained from the regression analyses.
Inhibitor Inhib itor
concentration
(mM)
Vmax» (x 10-3)
(mol dm’3 mÎE’i)
^app (p^M)
No inhibitor 0 1 1.07 ± 0.01 25.5 ± 0.6
Cyclohexyl Amino 
Acid
0.05 1.04 ± 0.02 26.9 ± 3.6
Cyclohexyl Amino 
Acid
0 . 1 1.03 ± 0.02 29.0 ± 4.9
Cyclohexyl Amino 
Acid
0 . 2 1.03 ± 0.02 31.8 + 5.4
^Vmax and Kapp were obtained from fitting the data to the Michaelis-Menten equation by non linear 
regression using the ENZFITTER^^^ programme.
Table 3.5
a
32
30
28
26
24
od
cs
d
V-)<s
[I] (mM)
graph 3.2: Plot of Kapp versus [I] for the Kynureninase Catalysed Reaction of Kynurenine 
in the Presence of Varying Concentrations of Cyclohexyl Amino Acid.
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From the graph,
The Ki for the cyclohexyl amino acid derivative = 844 ± 47 |iM
3.3.2. 2-aminO"4-oxo-4-naDhthovl-butvric acid (naohthvl amino acid derivative. 1831 
The data obtained for the inhibition of kynureninase by the naphthyl amino acid is given in 
tables 3.6, 3.7, 3.8 and shown graphically in graph 3.3. Each rate was detei*mined two or 
three times until the values were consistent (± 3%) and the average values (± 1.1% from 
regression analyses) are shown. For the naphthyl amino acid Km varies and Vmax is 
constant which is possibly due to competitive inhibition.
®.0S mM Naphthyl Amino Acid
[Substrate] (mM) l/[Substrate] 
(xl04 mol'i dm^)
Rate
(min'i)
1/Rate(min)
0 . 1 0 1 . 0 3.82 0.262
0 . 2 0 0.50 4.27 0.234
0.30 0.333 4.36 0.229
0.45 0 . 2 2 2 4.67 0.214
0.50 0 . 2 0 4.70 0.213
Table 3.6
0.1 mM Naphthyl Amino Acid
[Substrate] (mM) l/[Substrate] Rate 1/Rate
(xlO^ mol"l dm^) (min-l) (min)
0 . 1 0 1 . 0 3.56 0.281
0 . 2 0 0.50 4.04 0.248
0.30 0.333 4.26 0.235
0.45 0 . 2 2 2 4.52 0 . 2 2 1
0.50 0 . 2 0 4.56 0,219
Table 3.7
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[Substrate] (mM) l/[Substrate] Rate 1/Rate
(xlO^ mol’l dm^) (min-l) (min)
0 . 1 0 1 . 0 3.36 0.298
0 . 2 0 0.50 3.88 0.258
0.30 0.333 4.09 0.244
0.45 0 . 2 2 2 4.38 0.228
0.50 0 . 2 0 4.42 0.226
Table 3.8
0.29
0.27
Naphthyl Amino Acid 
Concentrations
□  0 mM 
<#>0.05 mM 
00.1 mM 
A 0.15 mM
0.25 /Oy
'e' 1.23
1.21
1.19
1.17
1.15
1 -0.5 0 0.5 1
1/[S] (10^  moi  ^dm^ )
Graph 3.3: Lineweaver-Burk Plot for Kynureninase Catalysed Reaction of Kynurenine in the 
Presence of Varying Concentrations of Naphthyl Amino Acid.
The data and plot for Kapp versus [I] for the kynureninase catalysed reaction of kynurenine in 
the presence of varying concentrations of the naphthyl amino acid are shown in table 3 .9  and 
graph 3.4 respectively. Thus from the gradient of this graph we can determine Ki as Km is
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already known. Linear regression analyses was employed to determine the best straight line
and errors were obtained from the regression analyses.
IgiliBbltor Inhib itor
concentration
(mM)
Vma%" (K 1 0 -^) 
(mol dm-3
®^ app (M-M)
No inhibitor 0 1.07 + 0.01 25.5 ± 0.6
Naphthyl Amino 
Acid
0.05 1 . 1 0  ± 0 . 0 2 30.2 + 4.4
Naphthyl Amino 
Acid
0 . 1 1.08 ± 0 . 0 2
_
38.1 ± 3.5
Naphthyl Amino 
Add
0.15 1.06 ± 0 . 0 2 43.4 ± 3.6
^Vmax and Kapp were obtained from fitting the data to the Michaelis-Menten equation by non linear 
regression using the ENZFTTTER^^^ programme.
Table 3.9
45
40
30
>nod
ts
do o
[I](mM)
Graph 3.4: Plot of Kapp versus [I] for the Kynureninase Catalysed Reaction of Kynurenine 
in the Presence of Varying Concentrations of Naphthyl Amino Acid.
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From the graph,
The Ki of the naphthyl amino add derivative = 207 ± 16 jiM
3.3.3. 2-amino-4-oxo-4-Dhenvl-butvric acid (desaminokvnurenine. 21).
The data obtained for the inhibition of kynureninase by the desaminokynurenine is given in 
tables 3.10, 3.11, 3.12 and shown graphically in graph 3.5. Each rate was determined two 
or three times until the values were consistent (± 5%) and the average values (± 4.6% from 
regression analyses) are shown.
O.OS mM DesawiinokyHmreiiiiie
[Substrate] (mM) l/[Substrate] Rate 1/Rate
(xlO^ mol'l dm^) (min'l) (min)
0 . 1 0 1 . 0 0.891 1 . 1 2
0 . 2 0 0.50 0.983 1 . 0 2
0.30 0.333 1.30 0.769
0.45 0 . 2 2 2 1.35 0.741
0.50 0 . 2 0 1.47 0.680
Table 3.10
0.2 mM PesamlgBokyiTHLireiiiine
[Substrate] (mM) l/[Substiate] 
(xlO^ mol-i dm3)
Rate
(min'i)
1/Rate(min)
0 , 1 0 1 . 0 0.380 2.63
0 . 2 0 0.50 0.681 1.47
0.30 0.333 0.908 1 . 1 0
0.45 0 . 2 2 2 0.947 1.06
0.50 0 . 2 0 0.992 1 .0 1
Table 3.11
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0.3 mM DesaiminoEcynuremiie
[Substrate] (mM) l/[Substrate] 
(xlO^ mol'l dm^)
Rate
(min'l)
1/Rate
(min)
0 . 1 0 1 . 0 0.187 5.35
0 . 2 0 0.50 0.360 2.78
0.30 0.333 0.441 2.27
0.45 0 . 2 2 2 0.526 1.90
0.50 0 . 2 0 0.561 1.78
Table 3.12
6 . 5
5 . 5  -
4 . 5
g  3 . 5  - -1a 2 . 5  - -
0 . 5
- 0 . 5
1 - 0 . 5 0 0 . 5 1
Besaminokyiiui^nÎEie
Concentrations
□  0  m M  
# 0 . 0 5  m M  
O 0 . 2 m M  
A  0 . 3  m M
1/[S1 (10** mor^ dm^)
Graph 3.5: Lineweaver-Burk Plot for Kynureninase Catalysed Reaction of Kynurenine in the 
Presence of Varying Concentrations of Desaminokynurenine.
The Km and V^ax for the kynureninase catalysed reaction of kynurenine in the presence of 
varying concentrations of desaminokynurenine are shown in table 3.13.
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Inhibitor Inhibitor i 
concentration 
(mM)
Vmax»(x 10' )^ 
(mol dm^ m in-l)
^app (fxM)
No inhibitor 0 1.07 ± 0.01 25.5 ± 0.6
Desaminokynurenine 0.05 0.39 ± 0.04 113 ±38
Desaminokynurenine 0 . 2 0.34 ± 0.04 252 ±78
Desaminokynurenine 0 . 2 2  ± 0 . 0 2 371 ± 62
®Vmax and Kapp were obtained from fitting the data to the Michaelis-Menten equation by non linear 
regression using the ENZFITTER^^^ programme.
Table 3.13
Data for inhibition by desaminokynurenine does not show a simple competitive pattern. Both 
Kapp and Vmax vary. However, Kapp does show a linear relationship with inhibitor 
concentration which gives a value of Ki as 23.2 ± 3.1 |iM (Graph 3.6).
400
3 0 0 -
200 “
a
100
o oo o
Graph 3.6: Plot of Kapp versus [I] for the Kynureninase Catalysed Reaction of Kynurenine 
in the Presence of Varying Concentrations of Desaminokynurenine.
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On the other hand, the variation of Vmax with inhibitor concentration is not linear (Graph 
3.7).
1.25
à•o 0.75 -
"oB
0.5 —S
X 0.25
o mdo
[I] (mM)
Graph 3.7: Plot of Vmax versus [I] for the Kynureninase Catalysed Reaction of Kynurenine 
in the Presence of Vaiying Concentrations of Desaminokynurenine.
An IC5 0  value of 17.6 jiM can be estimated, however, which is similar to the Ki calculated. 
Both of these values are similar to the Km determined for desaminokynurenine (see 2.5.1 
Studv of Reaction of Desaminolcynurenine by UV Spectrophotometry!.
This mixed inhibition may be a consequence of the activity of desaminokynurenine as a 
substrate for the normal kynureninase catalysed reaction or possibly as a substrate for 
transaldimination.
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The Kl values obtained are summarised below:
KYNURENINE
ANALOGUE
23.2 + 3.1LUOJ
844 ± 47amino acid derivative
207 ± 16amino acid derivative
The Ki values above are for the racemic mixtures of the amino acid. However, as previous 
work has shown that the 2R isomer is not a substrate or inh ib ito r,it might be implied that in 
this case only the IS  enantiomers are binding. The Ki values for the 2S enantiomers would 
be half those experimentally determined, i.e.
Desaminokynurenine 
Cyclohexyl amino acid derivative 
Naphthyl amino acid derivative
Kj = 11.6 + 3.1 iiM 
Ki = 422 + 47 jxM 
Ki = 103 ± 16 jiiM
3.5 EXAMINATION OF SUBSTRATE ACTIVITY OF ANALOGUES.
In order to determine whether the analogues could act as substrates they were incubated with 
kynureninase and the reactions monitored by tic.
3.5.1 Reactions Monitored bv tic.
Using cellulose as the stationary phase and a mixture of IPA, conc. NH3 and water (36: 6 : 
10) as eluant it was possible to separate desaminokynurenine (Rf 0.63, brown when 
visualised with ninhydrin), alanine (Rf 0.33, purple when visualised with ninhydrin) and 
PLP (baseline, lilac when visualised with ninhydrin). Desaminokynurenine at 0.8 mM 
concentration (1ml) was incubated with (120 (Xl, 0.6 units) enzyme at 25 °C in buffer
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containing 0.4 mM kynurenine, 40 (XM PLP in 0.04 M potassium phosphate, pH 7.0. After 
eighteen hours tic examination, on visualisation with ninhydrin, showed 25-alanine in the 
enzyme mixture which implied that desaminokynurenine was a substrate for the enzyme. 
Under these same conditions it was possible to separate the cyclohexyl amino acid (Rf 0.71, 
brown when visualised with ninhydrin), the naphthyl amino acid (Rf 0.68, brown when 
visualised with ninhydrin), alanine (Rf 0.41, purple when visualised with ninhydrin) and 
PLP (baseline, lilac when visualised with ninhydrin). Using the same procedure no reaction 
was observed on incubation of the cyclohexyl and naphthyl derivative with kynureninase. 
However, if the amount of enzyme was doubled then tic, on visualisation with ninhydrin, the 
naphthyl amino acid mixture showed the presence of some alanine. This implied that the 
naphthyl amino acid was a substrate for the enzyme. Even with another equivalent of enzyme 
no reaction was seen for the cyclohexyl amino acid under these conditions.
3.5.2 Studv of Reaction of Desaminokvnurenine (27) bv UV Spectophotometrv.
As desaminokynurenine seemed to be the most active substrate its reaction was further 
investigated by UV spectophotometry. This should allow the kinetic parameters to be 
determined.
The UV spectrum of desaminokynurenine (1 ml, 0.4 mM, 25 °C in buffer containing 0.4 mM 
kynurenine, 40 (xM PLP in 0.04 M potassium phosphate, pH 7.0.) was first determined. An 
aliquot of kynureninase (30 |xl, 0.15 units) was then added and the spectrum recorded again at 
five minute intervals. When these were superimposed it was possible to see a decrease in 
absorbance at 278 nm.
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4 .000
3.000
2.000
1.000
0.000
250 350300 400
UV Spectra of desaminokynurenine from 200-400 nm.
3.000
2.500
2.000
260 280 300
UV spectra of desaminokynurenine-showing decrease in absorbance at 278 nm. Spectra
recorded at 5 minute intervals.
The UV spectrum of benzoic acid (0.4 mM) the product of the reaction, was recorded under 
identical conditions to ensure that there was no interference at this wavelength due to product 
formation. This was confirmed to be the case. However, the reaction was found to be very 
slow compared to that of the natural substrate. The decrease in absorbance was very small, 
even at high substrate concentrations. It was therefore decided that this wavelength (278 nm) 
was unsuitable for kinetic studies. Further examination of the spectral changes revealed an 
alternative wavelength (330 nm) which was more suitable.
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I 500
1.000
0 500
340300 320
UV spectra of desaminokynurenine-showing increase in absorbance at 330 nm.
The absorbance at this wavelength was seen to increase as reaction took place and was 
probably due to the formation of benzoic acid. This was confirmed by an increase in 
absorbance at this wavelength with increasing concentrations of benzoic acid. The increase in 
absorbance was monitored with time and the initial rates gave a linear increase in absorbance. 
The assays could therefore be carried out at this wavelength and were recorded overnight. 
The rates are shown (See table 3.14).
Substrate concentration (mM) Rate X 10 (AA m ln 'l)
7 3.33
8 3.47
9 4.12
10 4.23
Table 3.14
Non linear regression analysis gave the values of Vmax and Km- Vmax was 15.2 x 10"3 min-l 
and Km was 25.5 (iM. The value of Vmax can be used to determine the rate of reaction for 
desaminokynurenine, if we divide this value by the extinction coefficient for benzoic acid. 
This was determined in 0.04 M potassium phosphate buffer to be 2883 M"  ^cm‘^
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Therefore, rate for desaminokynurenine = 15.2 X 10’^2883
= 5.27 X 10 mol dm"^ m in 'l.
This can be compared with kynurenine,
which has a rate of 1.07 x 10"  ^ mol dm'^ min”f.
Thus desaminokynurenine is hydrolysed twenty times slower than kynurenine implying that 
the orf/zo-amino group is important for substrate activity. This is in good agreement with 
Tanizawa and Soda who determined the reactivity of desaminokynurenine to be 6% that of 
kynurenine, i.e. sixteen times slower, by measuring the relative amounts of 25-alanine 
formed.^^
The Km determined from this experiment was 25.5 jxM in good agreement with the Kj 
determined for desaminokynurenine of 23.2 )liM as described earlier, providing further 
evidence for the validity of this result.
3.6 CONCLUSIONS.
It can thus be seen that the cyclohexyl and naphthyl analogues were competitive inhibitors of 
the enzyme kynureninase to varying extents and desaminokynurenine showed mixed 
inhibition. The relative Ki values determined were Ki = 11.6 ± 3.1 jaM (for 
desaminokynurenine), Ki = 422 ± 47 |XM (for the cyclohexyl amino acid derivative) and Ki = 
103 ± 16 |iM (for the naphthyl amino acid derivative) implying that the cyclohexyl derivative 
binds very poorly to the enzyme. Similarly, the naphthyl amino acid has a poor interaction 
with the enzyme, however, desaminokynurenine has a Kj of a similar magnitude to the 
natural substrate. It was shown by tic that both the naphthyl amino acid and 
desaminokynurenine are substrates of the enzyme. Rough Icinetic data was determined for
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desaminokynurenine by UV spectophotometry and the rate of reaction was found to be 
twenty times slower than that of kynurenine.
These results reveal some information about binding interactions at the active site of 
kynureninase. The ortho-m)ino group is important and when this is absent the binding is 
reduced by twenty times. The cyclohexyl amino acid shows exceptionally poor binding to 
the enzyme suggesting that interactions with the aromatic ring are important. Hydrogen 
bonding interactions between amide groups and aromatic rings have been proposed as 
important factors in determining the three-dimensional stmcture and recognition properties of 
proteins. Structural evidence for interactions in which the ît-electrons of an aromatic ring act 
as a H-bond acceptor comes from crystal structures of small molecules and proteins. This 
would imply that the active site is not just a simple hydrophobic pocket or if it is, the 
cyclohexyl ring may be too large. The naphthyl amino acid shows poor binding compared to 
desaminokynurenine and this indicates that this molecule is probably too large for the active 
site.
Soda and Tanizawa reported that the orfAo-amino group was indispensable in substrates. 
Compounds in which the amino group was blocked with a formyl group (23), replaced by a 
nitro (24) or moved to a para position (25) aie not reactive as substrates.
U UU2M
^^*^NHCHO
(23)
The Ki values were determined for various compounds using bacterial kynureninase from 
Pseudomonas fluorescens, iV’-formyl-25-kynurenine (23) was 2.2 mM showing very weak
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activity towards the enzyme and 25-3-hydroxykynurenine (4) was 200 jxM displaying weak 
activity. The Km of kynurenine in these experiments was 35
ICishore reported the Ki for 25'-S-(ortho-nitrophenyl)-cysteine (43) to be 0.1 mM, thus, also 
showing weak activity towards the enzyme."^^
U 1 ° H  C O ,H
(4) (43)
Soda and Tanizawa also reported that derivatives in which the aromatic amino group was 
replaced by a hydroxyl group (26) or removed (27) are susceptible to the enzyme, however, 
their reactivity was found to be considerably decreased.^^ The relative reactivities reported to 
be 13.4% and 6%, respectively, were determined by measuring spectophotomerically the 
substrate hydrolysed.
(26)
Pellicciari et al. ^^have carried out the synthesis of nicotinylalanine (65), o-nitrobenzoyl-
(66), m-nitrobenzoyl-(67), p-nitrobenzoyl-alanine (68), all analogues of kynurenine, and 
reported their evaluation as inhibitors of kynureninase.
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(65)
(6 6 ) o- R= NO2, R’= H, R"= H
(67) m- R= H, R'= NO2, R"= H
(6 8 ) p- R= H, R'= H, R"= NO2
Nicotinylalanine (65) with an IC5 0  of 800 ± 1 2 0  |jiM for kynureninase showed weak activity 
towards the enzyme. Of the nitro analogues m-nitrobenzoylalanine (67) and o- 
nitrobenzoylalanine (6 6 ) showed similar, but moderate activity with IC5 0  values of 
100 ± 1 2  |iiM and p-nitrobenzoylalanine (6 8 ) showed weak activity with an IC5 0  values of 
9(M)± 12
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CHAPTER 4
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4. STUDIES ON SYNTHESIS OF a-DEUTERIATED KYNURENINE AND 
MEASUREMENT OF ISOTOPE EFFECTS.
4.1 (2S).[2-2H] KYNURENINE.
Specifically deuteriated kynurenine derivatives are required for kinetic isotope effect studies 
on the enzyme catalysed reaction. For example, a-deuteriated kynuienine (199) would allow 
measurement of the a-deuterium kinetic isotope effect for the Ca-H bond cleavage.
O ÇO2H 
NH2
(199)
4.2 LITERATURE SYNTHESES OF KYNURENINE
The original literature synthesis of kynurenine involved the ozonolysis of A^-acetyl 
tryptophan (200) in glacial acetic acid (Scheme 4.1). Oxidative cleavage of the indole double 
bond readily takes place giving AT-formyl, N-acetyl kynurenine (201). Acidic hydrolysis of 
the A'-foimyl and A-acetyl groups was then carried out in 20-50% yield to provide 
kynurenine.
>1»,
(200)
O AcOH
(201)
Scheme 4.1
This method is not vei*y clean and gives poor yields, as has been found in our laboratory. 
However, several modifications have since appealed in the literatui'e. Palfreyman et aL, in
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their synthesis of 4,6-disubstituted kynurenines from 4,6-disubstituted tryptophans, used 
tryptophan protected with the iV-benzyloxycarbonyi group (iV-Cbz) instead of 7V-acetyl. 
They also used the ethyl ester (202) rather than the free carboxylic acid. The reaction was 
carried out in methanol at -78 °C and quenched with dimethylsulphide (Scheme 4.2). The 
yield for ozonolysis of the 4 ,6-dichloro compound was reported to be 96%, an improvement 
on the ozonolysis of iV-acetyl tryptophan. The three deprotection steps were carried out in 
76% overall yield.
COaEt
(202)
Ph 1) 03/M e0H-78 “C 
—    -----------------2) Me2S
Scheme 4.2
Ranganathan, used a similar diprotected tryptophan derivative, but in this case the oxidative 
cleavage was carried out using 4-%utyl iodylbenzene in refluxing chlorobenzene, instead of 
ozone (Scheme 4.3). The protected kynurenine was produced in 70% yield.
COgMe COgMe
4-^utyl Iodylbenzene
| ^ . ^ P h  PhCl, Reflux 
O
Scheme 4.3
However, it is necessary to prepare the 4-%utyl iodylbenzene (203), which is potentially 
explosive. This can be carried out in three steps from 4-%utyl benzene (204) (Scheme 4.4).
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I2 .H I0 3 ,
/ /  AcOH, H2Q'
(204)
dry CI2 ,
\ = /
(71%) aq. NaOCl, 
AcOH
V
o
(85%) (203)
Scheme 4.4
Synthesis of kynurenine can also be achieved by building up the molecule from an amino 
acid synthon and a suitable aromatic side chain. For example, Salituro and McDonald 
coupled (25)-iV-Cbz-5-oxO“4-oxazolidineacctyl chloride (205) with Boc-2- 
(trimethylstannyl) aniline (206) using palladium (0) catalysis (Scheme 4.5).
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Thus, ortho-hûimûon of iV-^  Boc aniline (207) and quenching with trimethylstannyl chloride 
gave N-^ Boc-2-(trimethylstannyl) aniline (205) in 54% y i e l d . T h e  coupling was then 
carried out in toluene at 70 °C using 0.5 mol% of the chloroform adduct of 
tris(dibenzylideneacetone) dipalladium(0) ([Pd2 (DBA)3 ].CHCl3 )^ ®^ as catalyst precursor, 
giving the product in 79% yield. Complete deprotection was achieved in one step with 30% 
hydrobromic acid in acetic acid at room temperature for fifteen to twenty minutes followed by 
addition of diethyl ether which precipitated the bis(dihydrobromide) salt (208). The free 
amino acid was then isolated using propylene oxide and isopropanol in 38% overall yield.
The (25)-iVCbz-5“Oxo-4-oxazolidineacetyl chloride (205) was prepared from the 
corresponding acid by use of an excess of thionyl chloride in toluene. The acid was prepared 
according to the method of Itoh from N-Cbz (25)-aspartic acid, paraformaldehyde, acetic 
anhydride and thionyl chloride which were heated at 100 °C for foui* hours (Scheme 4.6).^^^
Cbz
O CO2H "  _ I? 9
O Q Cbz
N
_  c «Mi ^ 'Mi■ n ^  o
hM  (80%)
CH3C0 2 H
Scheme 4.6
A similar method was employed by Varasi et al. for the synthesis of 
25-5-chlorokynurenine.^^ Pelliciari et al.^^ and Natalini et used the same strategy for 
the stereospecific synthesis of (25)-nicotinylalanine and (25)-m-nitrobenzoyl alanine, 
respectively, although the catalyst employed was dichlorobis(triphenylphosphine) 
palladium(ll) ([PdCl2(PPh3)2]).
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Jackson et employed a similar palladium (0) catalysed reaction of a serine derived 
organozinc reagent with 2-iodoaniline (209). This coupling was achieved at room 
temperature in THF under a caibon monoxide atmosphere using (tetrakis) triphenylphosphine 
palladium (0) [Pd (PPh3 )4 ] as catalyst, giving N -^à c  kynurenine methyl ester (210) in 52% 
yield. Removal of the protecting groups, according to the procedure of Salituro and 
McDonald,^^^ was achieved by treatment with 30% hydrogen bromide in acetic acid to give 
the corresponding bis(hydrobromide) salt (211) which was then converted to the free amino 
acid using propylene oxide in 90% overall yield (Scheme 4.7).
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An interesting alternative strategy for the synthesis of kynurenine is to employ biocatalysis. 
Thus, Bild et al. synthesised labelled ZS'-kynurenine from labelled tryptophan using 
crude extracts of tryptophan-adapted cells of Pseudomonas marginalis.^^^ The synthesis 
was based on the selective, rapid inactivation of kynureninase by 3-chloro-25-alanine, a 
potent suicide inhibitor. Therefore, the crude cell extracts were first incubated with 3-chloro- 
25-alanine, before labelled 25'-tryptophan was added. The reaction was then monitored 
spectroscopically by observing the increase in absorption at 360 nm due to kynurenine
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formation. After sixty minutes of incubation under these conditions, approximately 89% 
conversion, the reaction was quenched by the addition of 2 M HCl and the product isolated 
by ion-exchange chromatography. The overall yield of labelled kynurenine (specific 
activity 35.2 p,Ci mmok^) was 76% of theoretical.
4.3 SYNTHESIS OF (2S).[2-2H] KYNURENINE.
Two potential routes were investigated for the synthesis of (25)-[2-2H] kynurenine (199). 
The first involved the acétylation and racémisation of kynurenine in deuterium oxide and 
resolution of the product. The second involved a similar procedure, using tryptophan, which 
is considerably less expensive, followed by conversion of the deuteriated tryptophan to 
kynurenine.
4.3.1 Direct Synthesis from (2RS)-Kynurenine.
A common procedure for the incorporation of deuterium into the a-position of amino acids is 
to carry out an acétylation /  racémisation reaction in deuterium oxide. The mechanism for 
this reaction involves the acétylation of both the acid and amino functionality of the amino 
acid using acetic anhydride. This is carried out in sodium deuteroxide and deuterium oxide,
i.e. under basic conditions. The acetylated intermediate forms an azalactone (212) with the 
elimination of acetic acid. The a-hydrogen is now highly acidic due to the combined electron 
withdrawing effects of the carbonyl and the imine and therefore, there is rapid exchange with 
a solvent deuterium. Basic hydrolysis then affords the racemic a-deuteriated product which 
retains the iV-acetyl group (Scheme 4.8).
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The required (25)-amino acid can then be obtained using an acylase which specifically 
hydrolyses the 25-enantiomer.^^^’ It is then possible to separate the two chemically 
different compounds. This general method has been used for a number of amino acids. 
However, kynurenine, unlike many other amino acids has two amino groups. It was, 
therefore, unclear how the aromatic amino group would affect the process.
(2/?5)-Kynurenine, as its free base, was reacted with acetic anhydride in sodium deuteroxide 
and deuterium oxide. Spectral data implied that the compound had been diacetylated (213). 
The mass spectrum gave a molecular ion at 292, while the NMR spectrum showed the 
aromatic iV'-acetyl protons at S = 2.0 ppm and the other iV-acetyl protons at 6 = 1.8 ppm
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(from comparisons with the NMR spectrum of iV-acetyl tryptophan from Sigma). Extraction 
was initially attempted using ethyl acetate, however the yields were poor and the material 
difficult to handle. When this was changed to dichloromethane a crystalline solid was 
produced in 98% yield.
Selective hydrolysis was then attempted using acylase from Aspergillus meleus, Acylase 
enzymes isolated from Aspergillus meleus were reported to be much more effective in the 
hydrolysis of iV-acetyl aromatic amino acids than the pig liver acylase normally used.^^^ 
Incubation was carried out for eighteen hours at 38 °C in aqueous solution, which was 
brought to pH 7.5 with concentrated ammonia. Examination by tic (cellulose; IPA: conc. aq 
NH3 : H2O, 36: 6 : 10) gave no indication of the progress of the reaction, therefore, NMR 
spectroscopy was used to deteimine when reaction was complete by examination of the acetyl 
region for the disappearance of the N-acetyl protons at ô = 1.8 ppm. The product was 
purified by ion exchange chromatography (DOWEX 1) and obtained in 63% yield. NMR of 
the purified product showed the aromatic iV-acetyl protons at Ô = 2.0 ppm implying that this 
group was still present. Therefore, the acylase was specific for the removal of the acetyl 
group from the a-amino group.
Deprotection was initially attempted by refluxing in a mixture of dioxan and water with 0.5 M 
HCl.^^^ This method required extensive periods of reflux and resulted in decomposition of 
the product. The acetyl kynurenine (214) was then dissolved in 2 M HCl and the solution 
was refluxed for one hour to remove the acetyl group. The free amino acid was initially 
isolated using propylene oxide and ethanol at reflux, however, this method did not result in 
pure material. Subsequently, the use of propylene oxide and isopropanol resulted in a solid 
product which became an oil on filtration. Lyophilisation was then carried out to obtain a 
pure solid product (scheme 4.9). This was found to be the correct product by NMR
153
GOgH 
H 
NHa 
(1)
o
NHa
NaOD/ACiO/^HzO
COaH
HN (98%)
HN
ACYLASE
Aspergillus
meleus
COaH 
NHa
(63%) y ^ °  (214)
H3C
NH NH
i)2M H C l
ii) IPA / Piopylene oxide
Scheme 4.9
154
The only disadvantage of this procedure is the high cost of kynurenine, 50% of which is by 
necessity lost during the reaction. Note that the yields quoted were corrected for a maximum 
yield of 50%.
4.3.2 Proposed SymÉisesIs via T ryptophan.
The alternative synthesis of a-deuteriated kynurenine involved initial preparation of 
a-deuteriated (25)-tryptophan, by a similar method to that for kynurenine and then 
conversion of this through to a-deuteriated kynurenine. Before this procedure could be 
implemented it was necessary to examine the synthesis of unlabelled kynurenine and optimise 
the reaction conditions.
4.3.2.1 Svnthesis of Kvnurenine.
It was proposed to synthesise kynurenine from tryptophan by the method of Palfreyman, 
as outlined in Scheme 4.10. However, this is reported in a Patent and there are few 
experimental details.
Firstly, tryptophan ethyl ester was prepared by refluxing tryptophan (5) in redistilled ethanol 
and thionyl chloride. The product was then recrystallised from ethanol and obtained in 72% 
yield. NMR analysis showed the ester at Ô = 1.10 and 4.10 ppm and the melting point of the 
product (226-227 °C) was in good agreement with the literature value (225-226 The
amino group was protected as the Cbz derivative (202) by treatment of tryptophan ethyl ester 
(215) with a slight excess of benzylchloroformate and sodium carbonate. This reaction was 
particularly successful due to the fact that 25'-tryptophan ethyl ester was soluble in water 
whereas the product, iV-Cbz tryptophan ethyl ester, was not. Therefore by carrying out this 
reaction in water, the pure product precipitated out of solution and could be filtered off. The 
concentration was important to obtain a crystalline product because if the solution was too 
concentrated the product precipitated as an oil. NMR spectroscopy showed this to be the 
correct product and that no further product remained in the filtrate. The characteristic peak
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for the CH?Ph of the Cbz group was observed at 8  = 5.05 ppm and the melting point (84 °C) 
was very similar to the literature value (84-85 iV~Cbz tryptophan ethyl ester was then
converted to kynurenine in its protected form (216) by ozonolysis. The protected tryptophan 
was dissolved in redistilled methanol and ozone was bubbled through the solution at -78 °C. 
The reaction was quenched with dimethylsulphide to give the desired product which was 
purified by column chromatography and recrystallised from ethyl acetate in 28% yield. The 
ester protons could be seen at S = 1.10 and 4.10 ppm, the CH^Ph of the Cbz group at 8  =
5.05 ppm and the formyl group at 8  = 8.50 ppm. This reaction was fairly low yielding. 
However, it was observed that some N-Cbz kynurenine ethyl ester was also isolated which 
could be used in the remaining deprotection steps. This implies that the formyl group may be 
hydrolysing on the column. Attempts were made to improve the yield of the ozonolysis by 
quenching the reaction using tiimethyl phosphite, however this gave the purified product in a 
poorer yield of 15%.
The next stage was removal of the protecting groups and this was carried out sequentially. 
The formyl group was removed by stirring the protected kynurenine in 4M HCl and dioxan 
in methanol which gave the product in 8 6 % yield. The disappearance of the pealc at 8 = 8.50 
ppm confirmed the loss of the formyl group. The product and starting material were difficult 
to distinguish by tic (silica; petroleum ether: ethyl acetate, 2 : 1 ) so the reaction was monitored 
by NMR spectroscopy. The N-Cbz kynurenine ethyl ester (217) was then dissolved in a 1: 1 
mixture of THF and water and warmed to 70 “C for four hours giving N~Chz kynurenine 
(218) in 8 8 % yield. To ensure complete reaction the iV-Cbz kynurenine ethyl ester was 
initially dissolved in THF and the lithium hydroxide dissolved in water. The disappearance 
of the pealcs at Ô = 1.10 and 4.10 ppm confirmed the loss of the ethyl gioup. Finally the 
amino group was deprotected by hydrogenation over palladium on charcoal to afford the 
product in 70% yield. This was found to be a much cleaner method than the TMS-iodide 
initially tried. Iodine precipitated out of solution when the product was dissolved in water.
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(2iS)- Tryptophan (5) was reacted with sodium deuteroxide and acetic anhydride in deuterium 
oxide (Scheme 4.11) under similar conditions to those employed for kynurenine. This time 
however, the product precipitated out of solution and after refrigeration was filtered and 
washed with cold water. The residue was suspended in 0.2 M HCl, cooled, filtered and 
washed until free of chlorides, then d r i e d .T h e  deuteriated iV-acetyl tryptophan (219) was 
obtained in 75% yield. Selective hydrolysis was then carried out using the acylase from 
Aspergillus meleus, again as for kynurenine. The solubility of the iV-acetyl tryptophan was 
much poorer than the diacetylated kynurenine and as it dissolved the pH decreased. 
However, this was countered by periodically adding concentrated aqueous ammonia. Gentle 
heating also helped the dissolution. Incubation was carried out for several days until NMR 
showed the reaction to be complete. Centrifugation proved to be helpful to remove the 
acylase. The product was then purified by ion exchange chromatography (DOWEX 1) to 
give a microanalytically pure product (2 2 0 ) which precipitated out of solution once collected. 
This was obtained in 97% yield. This material was analysed by chiral hplc and shown to 
have an enantiomeric excess of 99%.
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Figure 4.1: HPLC analysis of (2S)-[2-^H]-Tryptophan. Conditions, Crownpak CR (+) (150 mm 
X 4 mm id, 5|rm) using 2.5% methanol in aqueous HCIO4 at pH 2 (premixed) at 1 ml min ‘ and 50 °C.
a) Commercial RS-tryptophan (Sigma Chemical Co. Ltd.)
b) (2S)-[2-2H]-Tryptophan. Ratio of peak areas gives ee at 99%.
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The synthesis of (2iS)-[2-^H]-kynurenine was then carried out using the procedure outlined 
in Section 4.3.2.1. As before, the carboxylic acid and the amino groups were protected as 
the ethyl ester and iV-Cbz derivatives, respectively, in 60% overall yield. Ozonolysis was 
then performed in methanol solution at -78 °C for one hour to give the protected iV’-formyl 
25-[2-2H]-kynurenine (223) in 33% isolated yield. Removal of the three protecting groups 
was carried out sequentially. The TV'-formyl group was removed by stirring at room 
temperature in 4 M HCl and dioxan in methanol in 98% yield. The ethyl ester was 
hydrolysed using lithium hydroxide in a 1: 1 mixture of THF and water on warming to 70 °C 
for four hours. The product was obtained in 45% yield. Finally the amino group was 
deprotected by hydrogenation over palladium on charcoal. Isolation of the free amino acid 
was achieved using isopropanol and propylene oxide (Scheme 4.12). The material was 
identical in all respects to that obtained from the first method, with an enantiomeric excess of
5004
Time-»
TooTime-» 1.00
Figure 4.2: HPLC analysis of (2iS)-[2-^H]-Kynurenine. Conditions, Crownpalc CR (+) (150 mm 
X 4 mm id, 5pm) using 2.5% methanol in aqueous HCIO4 at pH 2 (premixed) at 1 ml min and 50
a) Commercial /?5-Kynurenine (Sigma Chemical Co. Ltd.)
b) (2S)-[2-^H]-Kynurenine. Ratio of peak areas gives ee at 97.4%.
160
Ç0 2 H
(223)
H (220)
EtOH, SOC12 ----------------
Reflux
ii) MezS
(33%)
MeOH/HCl/Dioxan
NH2 
(224)
C02Et O ittW^H Ji
(98%)
P h  LiOH
THFiHiO
(1:1)
C02Et
> NH2
: (72% )
(221)
PhCH20C0Cl 
NaiCOs, H2O
OO2EX ^
.hhW^H II
^  O’^ ^ P h
(82% ) (222)
ÇO2H O
(95%)
" "Ph 
(225)
i) H2 , Pd-C 
MeOH
ii) JPA/propylene oxide
ÇO2H
" ^ (4 5 % )
Scheme 4.12
161
Both of these routes are complementary and give material of comparable purity and 
enantiomeric excess. The direct synthesis from racemic kynurenine is the shorter route, 
giving an overall yield of 8 %, however, the starting material is expensive. Although, the 
synthesis of kynurenine from tryptophan is longer, it begins from the much cheaper amino 
acid tryptophan. The overall yield is 8 % from 25-[2-%]-tryptophan, but 6 % from 2S~ 
tryptophan. The second route offers the additional advantage that it produces a protected 
compound from which the three protecting groups can be removed selectively.
The a-deuteriated kynurenine prepared using the second route was used to measure the 
primary deuterium isotope effects for the kynureninase catalysed reaction The solvent 
isotope effect was also determined.
ISOTOPE EFFECTS.
Changes in the reaction rate which are brought about by isotopic substitution, i.e. 
substitution of a heavy atom for a lighter one, are known as kinetic isotope effects and carry 
mechanistic information. The most obvious piece of infonnation that can be provided by 
isotope effects is the identity of the rate limiting step for a reaction. It is also possible to 
distinguish stepwise reactions from concerted reactions and for stepwise reactions the order 
of the steps and the nature of the intermediates can often be determined. The following types 
of isotope effect are distinguished;
a) primary, in which the bond to the isotopic atom is broken in the rate 
determining step.
b) secondary, in which the bond to the isotopic atom(s) remains intact 
throughout the reaction.
c) solvent isotope effects, which result from isotopic differences in the 
medium.
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A kinetic isotope effect is the ratio of the reaction rates for molecules containing the light and 
the heavy atoms i.e. kn/ko. Using the nomenclatuie originally developed by Northrop such 
an isotope effect is then written as When the value of an isotope effect is greater than
one it is known as a normal isotope effect, but when it is less than one, it is an inverse 
isotope effect.
Kinetic isotope effects can be determined for enzyme catalysed reactions on the fundamental 
kinetic parameters Vmax (V) and VmaxA^ M (V/K), the apparent first order rate constant for the 
reaction at low substrate concentration. Using the Northop nomenclature they are written as 
Dy and ^ V/K respectively. Thus V and V/K are separately measured for botli the labelled and 
unlabelled substrate and comparison of the results will directly provide the isotope effects on 
V and V/IC.1S®
4.4.1 The Observed Isotope Effect.
An enzyme catalysed reaction usually consists of a large number of separate reaction steps of 
similar energy, the rate of only one of which is affected by isotopic substitution. Therefore, 
it is rare for the isotopically sensitive step to be cleanly rate limiting. For example, the 
binding and debinding of substrate(s) and product(s), further chemical steps and possibly 
conformational changes in the protein may all be paitially rate limiting. It is possible, 
however, to derive an equation to express the obsei*ved isotope effect on either V/K or V.
Di. . „ . Di
'(V /K ) =D/W/Tr\ _ + Cf + Cr1 + Cf + Cr
D(V) = + Cyf + Cr
1 + Cyf + Cj.
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Where, is the intrinsic isotope effect on the isotopically sensitive step in the forward 
direction. The intrinsic isotope effect is the isotope effect that would be observed if the 
isotopically sensitive step was completely rate limiting. ^Keq is the equilibrium isotope effect 
for the overall reaction. The constants Cf and Cr are known as the reaction commitments, in 
the forward and reverse directions respectively. A commitment is a ratio of the rate constant 
for the isotopically sensitive step to a net rate constant that refers to the release of a par ticular 
species from the enzyme. The term Cyf in the equation for is in fact not a commitment but 
a special constant found only in this equation. This is the sum of the ratios of the net 
constant for the isotopically sensitive step to all net rate constants in the forward dir ection 
multiplied by a precatalytic proportion factor.
For example, for a general enzyme catalysed reaction with a single substrate (A) and two 
products (P and Q) (Scheme 4.13). If the isotopically sensitive steps are kg and kg. Then C f ,  
Cr and Cvf are as shown.
ki kg kg k? ko kii
E + A EA EA* EPQ* E P Q ----- ^>E Q ----- E
1(4 1(6 '  kg
Scheme 4.13
Cf — (kg  /  k ^ ) [1 +  (kg /1^2)] 
Cr ~ (kg / ky) [1 + (kg / kg)]
Cvf - (I4.(k4/kg))
'  1 rn r, ksi 1 1 ’-----h 14----- + -- + -----ks kg kfi
An interesting comparison can be seen from ^(V/K) and ^(V). ^(V/K) compares steps near 
the isotopically sensitive one, however, for ^(V), which contains the parameter Cyf, a wider 
range of steps in the enzyme catalysed reaction are considered.
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The precatalytic proportion factor is l/[l+(k4 4-lc3)]. This is the proportion at equilibrium of 
complexes prior to the isotopically sensitive step that are reversibly connected and available to 
undergo the isotopically sensitive step. The net rate constants that are being compared with 
kg are kg, k-yCl+kg/kg), k^ and k n  and if any of these are smaller than kg, then Cyf will be 
large and the values of will approach one.
In general terms, it can be seen from the above equations that the observed isotope effect for 
an enzyme catalysed reaction will vary depending on the values of the forward and reverse 
commitments. Thus, slow release of the substrate, i.e. when Cf is large, commits the reaction 
to take place and suppresses the isotope effect, so that ^(V/K) will approach one. Slow 
product release or slow steps after the isotopically sensitive step but prior to product release 
i.e. Cr is large, brings the chemical step to equilibrium so that ^(V/IC) will approach *^ Keq. 
Only when both Cf and Cr are small will the observed isotope effect approach the intrinsic 
isotope effect, % .
The isotope effect on V is different, in that slow steps following release of the first product 
suppress the observed isotope effect. In the example, if k n  is small then the value of Cyf will 
be increased and as a result Dy will approach one. There is no corresponding effect on 
Dy/K.
Vibrational energy will usually change during the course of a reaction or between reactant and 
transition state, since some bonds are in the course of being broken or made and their 
associated frequencies will be effected. Isotopic substitution should, therefore, effect 
reaction rates. The potential functions for C-H and C-D bond stretching are essentially 
identical but the distribution of vibrational energy levels in each bond differs. Those of the 
C-D bond lie at a lower energy than those of the C-H bond for a given value of V because the
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vibrational frequency of D is lower due to its greater mass. The ground vibrational state is 
defined by V=0, this is known as the zero point energy (vibrational energy remaining even at 
0 K) and lies lower for the C-D bond (Graph 4.1). It is clear, then, that more energy is 
expended in breaking a C-D bond than a C-H bond since it was originally at the lower 
potential. In general, the dissociation energy of a bond to a heavy isotope is greater than that 
to a light isotope of the same element and is associated with a slower rate. Therefore, the 
thermal dissociation of a C-H bond should proceed faster than that of a C-D bond under 
similar conditions since the activation energies are simply the bond dissociation energies.
A
Î1
.
0
V=0
zero-point energy
V
graph 4.1: Potential Energy Curves for C-H and C-D Bonds
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4.4.2.1 Determination of the Primary Isotope Effect for 2-^Hl -kvnmenine.
The purity of (2S)-[2-^H]-kynurenine was confirmed by agreement of the extinction 
coefficients which were determined for both kynurenine and a-deuteriated kynurenine 
(average values are shown below.) NMR showed that there was 13% hydrogen in the 
a-position of the compound.
a-Deiilteriated
kyoureniine
4497 M"' cm"' 
(lit. 4500 M '^cm'b'
4516 M"' cm
Kinetic measurements using (2S)-[2-^H]-kynurenine were cairied out under identical 
conditions to those used for determination of the Km and Vmax for kynurenine. Thus the rate 
was determined at increasing concentrations of (25)-[2-2H]-kynurenine. Each rate was 
detennined two or three times until the values were consistent and the average value is 
quoted. Incubation was carried out at 25 °C and the assay buffer contained 0.4 mM 
kynurenine, 40 p,M PLP in 0.04 M potassium phosphate at pH 7.0. The reaction was 
followed by UY spectophotometry by measuring the rate of decrease in absorbance at 
360 nm due to conversion of kynurenine to anthranilic acid (see Experimental for full 
details). The kinetic parameters of kynurenine without (25)-[2-^H]-kynurenine were the 
average values calculated (K m  = 25.5 ± 0.6 )liM  and Vmax = 4.78 ± 0.06 min"i, see 
experimental).
The averaged results are shown in table 4.1 and the Michealis-Menten and Lineweaver-Burk 
plots are shown in graph 4.2.
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1 [Substrate] (mM) Rate (m:n 1)
1 0.10 2.5 i
0.15 2.97
0.20 3.45
0.25 3.660.30 5.79
1 0.35 3.89
Î 0,40 3.99
1 0.45 4.08
1 0.50 4.13
Table 4.1
3.40
10^ -1
3.803.20
2,60
Graph 4.2
The Km and Vmax values obtained are shown below along with the corresponding values for 
Icynurenine and from these results and ^(V/K)were calculated.
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K ynurenine a^Deuterlated kynurenine
Vmax (1.07 ± 0.01) X 10-3 
mol dm-3 min-i
(1.09 ± 0.02) X 10-3 . 
mol dm-3 min’i
Km 25.5 |j,M±0.6lLiM 93.6 (J,M± 5.3
\ = 0 . 9 8 ,  =3.6
As an isotope effect is observed this implies that a-H  cleavage is at least partially rate 
limiting. These results aie interesting when we compare them to those obtained by Miles and 
McPhie who studied the a-H  abstraction in the reaction catalysed by the p2 subunit of 
tryptophan synthase.
4A2.2 The Primary Isotope Effect for Trvptophan Svnthase 82 Subunit.
The enzyme tryptophan synthase is a multienzyme complex with an a2p2 subunit structure. 
The a-subunit catalyses the cleavage of 3-indole-2i?-glycerol 3' phosphate to 2R- 
glyceraldehyde-3-phosphate and indole. The p-subunit catalyses the condensation of indole 
with 25-serine to form tryptophan. The p-subunit also catalyses the dehydration of serine to 
pyruvate in the absence of indole. Both of these reactions involves an a-p-elimination and 
the intermediate formation of an aminoacrylate derivative with PLP.
The reaction of the tryptophan synthase p2 complex with 25-serine involves formation of an 
enzyme substrate Schiffs base (226), abstraction of the a-proton of 25-serine produces a 
quinoid intermediate (227) and the loss of hydroxide ion forms the aminoacrylate 
intermediate (228). Indole then adds to the product to give tryptophan as the product or, in 
the absence of indole, hydrolysis occurs to give pyruvate and ammonia (229) as the products 
(Scheme 4.14).
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Miles and McPhie studied the rate of proton abstraction for the conversion of 25-serine to 
pyruvate and ammonia. Substitution of deuterium for the a-hydiogen had no effect on the 
Km but increased the Vmax four fold. They reasoned that this kinetic isotope effect indicated 
that cleavage of the a-CH bond of 25-serine is the rate determining step in the formation of 
pyruvate under these conditions.
4.4.2.3 Comparison of Primary Isotope Effects.
The results found for the tryptophan synthase p2 complex were V = 4.0 and ^(V/K) = 4.0. 
However, for kynureninase values of ^V = 0.98 and °(V/K) = 3,6 have been determined. 
As has been discussed the values of ^ V and ^(V/K) can be very different. The rate limiting 
step for V/K is simply the one with the highest bairier on the free energy profile for the
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reaction. When this step comes before or after the isotope sensitive step, then Cf or Cr is large 
and the size of the isotope effect is reduced. The rate limiting step for V, however, may not 
necessarily be the same. It may be limited by steps that follow the first irreversible one or 
steps that precede the addition of the variable substrate.
In both cases, ^V/K is quite large implying that Cf and Cr are not very big, from the equation:
> / K )  =
1 + Cf + Cf
For kynureninase, however, is approximately equal to one implying that Cyf is large from 
the equation:
== + Cyf + ^Keq Cr
1 + Cvf + Cf
This suggests that a-hydrogen abstraction is only partially rate limiting as the effect on is
suppressed by the commitments and a later slower step.
Cf = (kg /  IC4) [1 + (kg /  IC2 )]
Cf = (kg /  ky) [14- (kg /  kg)]
Cyf - k.(l + (k4 /kg)) ky A 9 y ko k 11
This also suggests that one of the later steps in the reaction is more rate limiting as the value 
of Cyf talces into account the rate of these steps, for example, k n  in the general example. In 
the kynureninase catalysed reaction this may correspond to protonation of the aminoacrylate 
derivative, product debinding etc. In contrast, the effect on is not suppressed for 
tryptophan synthase as the a-hydrogen abstraction step is cleanly rate limiting and there are 
no other slower steps following it.
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In order to compare the results with literature observations, further examples of primary 
isotope effects will be discussed later, along with the results for the solvent isotope effect 
studies. The solvent isotope effect for kynurenine was, therefore, measured as a further 
mechanistic probe.
4.4.3 TIte Solvent; Isotope Effect.
With most isotope effect measurements only a single site in the substr ate is substituted with 
the heavy atom and only one reaction step is sensitive to this change. However, solvent 
kinetic isotope effects are much more global in nature. When an enzyme catalysed reaction is 
carried out in 2 H2 O rather than H2 O all the acidic hydrogens in both the enzyme and the 
substrate will be exchanged for deuterium. The consequences of so many substitutions, 
possibly hundreds of atoms, may cause problems in the interpretation of the observed isotope 
effect. Nevertheless, solvent isotope effects have been used extensively in the 
investigation of enzyme catalysed reactions.^^ "^^ "^^
A solvent effect will be observed whenever a reaction involves changes in the bonding of any 
water molecule or exchangeable hydrogen. The effect is primary if the hydrogen is 
ti'ansferred during reaction. The magnitude of the obseived primar y solvent isotope effect is 
greatest when the hydrogen is in flight between water (or an exchangeable position) and a 
carbon atom. If hydrogen is transferred between two atoms such as oxygen or nitrogen 
smaller isotope effects are observed depending on the transition state structure.
4.4.4 Determination of Solvent Isotope Effect for ICynnirenine.
4.4.4.1 Preparation of Buffers.
In order to obtain accurate results all the labile hydrogens must be exchanged for deuterium in 
all the buffers. To achieve this the buffer solutions were lyophilised from 2 H2 O two or three 
times. This did not effect the concentrations or stability of PLP or other buffer constituents.
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as a comparable assay with normal buffer gave the same result. During the preparation of the 
buffers the % 2 0  solutions were not exposed to atmospheric moisture to avoid re-exchange. 
Measurement of the pH (pD) of the solution was carried out using a normal glass pH 
electrode. The electrode was soaked in a small amount of % 2 0  prior to measuring the pD of 
a % 2 0  buffer solution. To determine pD for buffers in % 2 0  an allowance was made for the 
isotope effect on the electrode response. Thus, 
pD = meter reading + 0.4^ ^®
A stock solution of NaO^H was prepared for the pD adjustment of the buffers employed. 
This was prepared by adding sodium, which had been washed in ethanol, petroleum ether 
and ^ H2 0 , to a small amount of % 2 0  This was stored under nitrogen until required.
4.4.4.2 Effects of ^ HoO on Enzyme Structure.
The effect of 2 H2 O on the structure and stability of proteins has been an area of much 
concern in the interpretation of solvent isotope effects. Incomplete exchange of all the acidic 
enzyme protons in 2 H 2 O has been proposed as a source of error in isotope effect 
measurements.^^® Control experiments were therefore carried out to investigate this 
possibility. Stock solutions of enzyme were prepared in equivalently buffered H2 O and 
2H2O and then the isotope effect measured using each stock solution.
4.4.4.3 Preparation of kynureninase in iH^O
One method of obtaining the enzyme in 2H2O involves lyophilising the partially purified 
protein from % 2 0  two or three times so that all the labile hydrogens will be exchanged for 
deuterium. However, when this was carried out using kynureninase the enzyme activity was 
found to be decreased by about forty percent after only one lyophilisation. The protein also 
appeared to be less stable and began to precipitate out of solution during the assay.
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A less harsh method involved the addition of % 2 0  whilst carrying out the ultrafiltration step 
in the purification. Several portions of % 2 0  were added to ensure that all the labile 
hydrogens were exchanged for deuterium. The ultrafiltration apparatus was cooled with cold 
water as opposed to ice due to the higher melting temperature of % 2 0  compared with H2O. 
The enzyme once obtained was used immediately although a portion was also stored in the 
freezer (-78 °C) overnight. The enzyme isolated and purified had been split into two batches. 
Half of it was in H2 O based buffer and the other half in 2 H2O based buffer. The enzyme 
activity of the two portions was compared and it was found that negligible activity was lost in 
the % 2 0  solution compared to the normal buffer solution.
M A A  Mmmmmeiit_cf&3lvenUsm#eJGf3W
The kinetic parameters for kynurenine were then determined in the ^H2 0  buffer solution. 
Thus the rate was determined at increasing concentrations of kynurenine. Each rate was 
determined two or three times until the values were consistent and the average value is 
quoted. Incubation was carried out at 25 °C and the assay buffer contained 0.4 mM 
kynurenine, 40 jiM PLP in 0.04 M potassium phosphate at pH 7.0. The reaction was 
followed by UV spectophotometry by measuring the rate of decrease in absorbance at 
360 nm due to conversion of kynurenine to anthranilic acid (see Experimental for full 
details). Assays were carried out using both stock solutions of kynureninase in H2 O and in 
2 H2 O. In each case, an aliquot of enzyme solution (30|li1) was added to the assay buffer
(1ml) to commence reaction. An example is shown in table 4.2 and graph 4.3 and the full 
results are found in the Appendix.
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[Kynurenine] (mM) Rate (min-^)
0 . 1 0 0.873
0.15 0.920
0.25 0.989
0.30 1 .0 1
1 0.50 1.04
Table 4.2
1.04
1.02
1.00
0.98
0.96
1.140.94
1.10
0.92 1.06
V  1.02
0.98
0.88 0.40
Graph 4.3
A summary of the results obtained are shown below.
Vmax (mol dm’3 min’ )^ Km  (m-M)
(0.24 ± 0.01) X 10-3 a 27.0 ± 0.946 a
(0.24 ± 0.02) X 10-3 b 26.2 ± 1.72 b
(0.24 ± 0.007) X 10-3 b 26.2 ± 0.667 b
® Enzyme in H2O, b enzyme in 2H2O.
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The average Km and Vmax values obtained are shown (table 4.3) along with the 
corresponding values for Icynurenine and from these results and ^(V/K) were calculated.
ICynureiiln© am H2 O Kynurenine in 1
Vmax (1.07 ± 0.01) X 10-3 
mol dm-3 min“^
(0.24 ± 0.01) X 10-3 
mol dm-3 min"^
Km 25.5 \iM ± 0.6 |iM 26.5 |IM ± 0.8 |liM
Table 4.3
Dv  = 4.4, T O )  =4.6
From the results it can be seen that changing the solvent from H2O to % 2 0  has no effect on 
the Km but decreases the V m ax four fold. The kinetic par ameters are identical whether or not 
the kynureninase is pre-incubated in 2H2O. This implies that exchange is faster than reaction 
with kynurenine. The values were also found to be consistent during the enzyme assays 
implying that there are no slowly exchanging sites on the enzyme which can affect the isotope 
effect.
The results can be compared with literature values for similar enzymes. For example, Faleev 
et al. have studied the isotope effects of tyrosine phenol lyase with suitable substrates.
4.4.4.5 Isotope Effects for Tvrosine Phenol Lyase.
Tyrosine phenol lyase has a broad substrate specificity and catalyses the a,(3-elimination of 
25-tyrosine and its ring substituted analogues to give phenols and ammonium pyruvate. The 
generally accepted mechanism of catalysis by tyrosine phenol lyase includes three principle
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chemical transformations of the substrate. The first being abstraction of the a-proton in the 
external aldimine (a), the second being tautomérisation of the aromatic moiety to convert it 
into a good leaving group (b) and finally p-elimination of the leaving group (c) (Scheme 
4.15). The relative significance of these three stages has been elucidated for the reaction with 
2S-tyiosine and 3-fluoro-2S-tyrosine and their deuteriated equivalents.
COgH
COgH
B+H
COgH
Scheme 4.15
For the a-hydrogen abstraction it was found that was 2.9 for tyiosine and was 3.4 for 
3-fluoro-tyrosine which decreased to 2.0 in % 2 0 .
A reaction mechanism was suggested where the tautomérisation stage contributes 
significantly to the total free energy barrier although the highest maximum on the free energy
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profile corresponds to the subsequent p-elimination stage. The a-ldnetic isotope effects may 
seem to be too high to be compatible with this concept. However, if the a-proton abstraction
is an equilibriated stage the kinetic isotope effect reflects the isotope effect on the steady state
concentration of the quinoid intermediate [EX] which is given b y   ------ .k . + k , + k ,
From:
K  kfES EX — P
kr
where:
ka = Rate of isotope sensitive a-proton abstraction 
kr = Rate of reprotonation 
kf = Rate of subsequent steps
The considerable values of obsei’ved a-kinetic isotope effects mean that the following 
conditions are satisfied:
(i) ka is considerably less than Iq + kf
and (ii) kr is not sensitive to a  deutenation of the substrate.
This is possible when the degree of internal return of the abstracted proton is negligible due 
to fast exchange with the solvent. In this case the decrease in the a-kinetic isotope effect on 
going from water to % 2 0  may be a result of a decrease in the kr value, which partially 
compensates the a-kinetic isotope effect on 1%.
Changing the solvent from water to % 2 0  should mainly influence the rate of tautomérisation 
of the phenolic ring into a cyclohexadienone ring. This process consists of protonation of the 
Cl atom of the ring by a general acid catalyst and deprotonation of the phenolic hydroxy 
group by the other base. The protons of both the group performing protonation and the 
phenolic hydroxy groups are exchangable with the solvent; consequently the process should 
be slowed down in 2 H2 O.
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For the solvent isotope effect in % 20,
= 1.66 for tyrosine and =1.7 for 3-fluoro-tyrosine.
The values of solvent and a-kinetic isotope effect are practically the same for tyrosine and 3- 
fluoro-tyrosine. Based on this result and the low absolute solvent kinetic isotope effect it 
may be assumed that the tautomérisation stage is at equilibrium.
4.4.4.6 Isotope Effects for Aspartate Aminotransferase.
Aspartate aminotransferase is another PLP dependent enzyme whose kinetic isotope effects 
have been studied. Aspartate aminotransferase catalyses the reversible exchange of the a- 
amino group between 25'-aspartate (154) and a-ketoglutarate (153) (Scheme 4.16). The 
amino gi’oup of aspartate is transferred to an active site PLP with the subsequent release of 
oxaloacetate (152) and this is followed by the transfer of the amine to a-ketoglutarate to give 
25'-glutamate (151).
.  ÇOg- o  O COg-
(154) (153) (152) (151)
Scheme 4.16
a-Hydrogen abstraction takes place to form a ketimine intermediate (230) which then 
undergoes protonation at C4'. The general base then accepts a water proton to facilitate the 
nucleophilic attack by water and then aids in collapse of the resultant carbinolamine (231) to 
the PMP enzyme. The PMP (56) and a-ketoglutarate (153) then foim a complex which is 
deprotonated at C4' to give the quinoid intermediate (232). Protonation then occurs at the a- 
position and on release from the PLP 25-glutamate (151) is formed and the holoenzyme 
regenerated (Scheme 4.17).
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■ O aC ^ ^C O a- -O aC '^C O ^-
0 \  (153)
ÏH ^ N  ^  ^
¥
N ^ 'VN(2 3 2 ) H
Scheme 4.17
The a-kinetic isotope effects have been determined for aspartate and glutamate. 
For aspartate, = 1.4 and ^(V/K) = 1.7, 
for glutamate, Dy = 1.5 and ^(V/K) = 2.0.
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D(V/K) reflects the rate limitation on the first half reaction and is a function of both half 
reactions. As a result of the effects on (V/K) in both reaction directions, the abstraction of 
the a-proton is at least partially rate determining. In addition, the lower value of 
compared to ^(V/K) suggests that the second half reaction also limits at saturating reactant 
concentrations.
The solvent isotope effects have also been determined for aspartate and were found to be:
Dy= 2.21 andD(V/K)= 1.71
The obseiwed solvent isotope effects suggest that a step in the aspartate amino tr ansferase 
reaction has a proton in flight in the transition state. The larger value of the solvent effect 
compared to the substrate effect suggests that this step is more rate limiting than a-hydrogen 
abstraction.
4.4.4.7 Isotope Effects for HIV-1 Proteinase.
The chemical mechanism of HIV-1 proteinase is another example which involves a water 
molecule. For HIV-1 proteinase, each ninety nine amino acid subunit of the C-2 symmetric 
homodimer contributes a glycine rich loop that constitutes in part the substrate binding site of 
the enzyme and one of two active site aspartyl residues. The active-site aspartyl residues 
exist on opposite sides of the C-2 axis of symmetry present in the homodimeric protein. It is 
believed that the active-site aspartyl groups assume opposite roles in general acid-general 
base catalysis, in which deprotonation of the lytic water is performed by the unprotonated 
aspartyl residue and protonation of the scissile carbonyl oxygen is achieved by the protonated 
aspartyl residue. A proposed chemical mechanism for this is shown in scheme 4.18.
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Scheme 4.18
The solvent isotope effect was detennined for two substrates (233, 234) over a range of pH.
Boo “ Ser ^  Ala-Ala
A c” S er“Gln“Asn
ÔH Val“ Val“ OMe 
(234)(233)
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The value of ^ (V/K) was 1.0 and pH independent while decreased from 2.2-3.2 to 1.5- 
1.7 as the pH was decreased. This was consistent with a change in rate limiting step from a 
chemical one at high pH to product release or enzyme isomérisation being partially rate 
limiting at low pH.^^^
4.4.4.8  Comparisons of Isotope Effects.
The putative mechanism of kynureninase is shown in Scheme 4.19.
For aspartate aminotransferase, the values of the solvent isotope effect were the same for 
and ^(V/K), i.e. 2.21 and ^(V/K)= 1.71. For kynureninase this was also found to be 
the case where, ^V= 4.4 and ^ (V/K)= 4.6. This result was interpreted as a proton in flight in 
the rate determining step. It can therefore be implied that kynureninase also has a proton in 
flight in the rate determining step. Interestingly, for the HIV-1 proteinase the value of 
^(V/K) was 1.0 and pH independent while decreased from 2.2-3.2 to 1.5-1.7 as the pH 
was decreased. The lack of effect on ^(V/K) results from a high foiward commitment. Also 
the attenuation of the forward commitment is highly pH dependent. The peptide substrates 
are thought to be able to bind only to the correctly protonated form and chemical steps cannot 
be made fully rate limiting at a non optimal value of pH(D). The values of indicate that 
also in this case a proton transfer is at least partially rate limiting for these substrates. The 
rate limiting proton transfer step occurs either in the formation or breakdown of the enzyme 
bound tetrahedral adduct or substiate and water.
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Scheme 4.19
For the solvent isotope effect of kynureninase ^Y/K  is quite large implying that C f  and C r  are 
not very big, from the equation:
D (V/K) = + Cf + c.
1 + C f  +  C j
is also quite large implying that Cyf is also quite small from the equation:
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D(V) = ^ + Cyf + Cf
1 + Crf + Cj
The solvent isotope effect could arise as a result of changes in the rate of a number of 
different steps. These include formation of the external aldimine (k^), attack of water on the 
y-carbonyl group (ky), reprotonation at C-p (kg) and hydrolysis to produce the product. The 
magnitude of the observed solvent isotope effect is high for transfer of a hydrogen atom 
between oxygen and nitrogen atoms (usually 2-4). However, for transfer to or fi*om carbon 
higher values can be obtained (up to 8 ).
As the effect on is not suppressed, this implies that there are no subsequent slow steps 
insensitive to changes in the solvent i.e. product debinding.
One possibility for the solvent sensitive step is reprotonation of the aminoacrylate 
intermediate (kg). It is known^^ that this intermediate has sufficient lifetime to be trapped out 
by added aromatic aldehydes. This is consistent with slow protonation of the intermediate, 
which could be responsible for suppression of the isotope effect for a-H  abstraction. One 
interesting question is the degree of reversibility of this step. Experiments to produce, and 
trap out, the aminoacrylate from alanine were unsuccessful."^^ This would imply that 
abstraction of the p-proton from alanine does not talce place.
Attack of a water molecule on the y-carbonyl would also be expected to be a solvent sensitive 
step. This occurs too soon after a-H cleavage to be responsible for suppression of ^ V. The 
rate constant ley also appears in the term for Cr and if it were small would increase Cr and 
therefore reduce ^^(V/K) aswell. The reversibility of this step is also open to question. There 
is no evidence to show trapping of the aminoacrylate intermediate with aromatic acids, only 
the more reactive aldehydes. Indeed if kg is proposed to be the slow step then in order for it
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to appear only in Cyf and not Q , for the a-deuterium isotope effect, this would require k? to 
be the first irreversible step in the reaction.
However, as yet the evidence provided here is not complete and further experiments are 
required to elucidate the mechanism in more detail. Firstly, it is important to determine both 
isotope effects at different pH's to establish if they are dependent or independent of pH. A 
pH dependence may arise because the commitments have two parts. Firstly, there is the 
internal commitment which involves rate constants for steps other than reactant release. This 
does not vary with the levels of other substiates and is independent of pH for most 
mechanisms. Secondly, there is an external commitment involving rate constants for reactant 
release steps. The external protonation may become very small at pH values where V/K is 
decreasing by a factor of about ten per pH unit. This is because incorrect protonation reduces 
rate constants for the chemical reaction but not rate constants for reactant release. Thus it is 
possible to eliminate the external commitments by changing the pH and so enhance the 
observed isotope effect. Thus if the observed Y/K  isotope effect increases when the pH is 
changed from the optimum and hence V/K decreases, it implies that the overall commitment 
was essentially caused by the external commitment.
It would also be necessary to carry out the measurement of the a-kinetic isotope effect in 
^H2 0 . This should determine whether the two isotope effects are independent or mutually 
dependent. If they are independent then the two processes are performed in the same step 
and the reaction is concerted. On the other hand, if the a-kinetic isotope effect and solvent 
kinetic isotope effect are mutually dependent this provides evidence for a stepwise 
mechanism and the result may give some information on the order of these steps.
Also, the preparation and testing of the p,p-dideuteriated kynurenine should complete the 
isotope effect measurements. For example, Faleev et al. determined the isotope effect for 
p,p-dideuteriated 3-fluoro-25-tyrosine to determine the relative significance of the p-
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elimination stage of tyrosine phenol lyase. When interpreting the p-ldnetic isotope effect 
the two stages involved in the p-elimination process were considered.
(i) The p-elimination stage leading to a-aminoacrylate formation and
(ii) Subsequent protonation of this intermediate wliich begins the aminoacrylate hydrolysis. 
The rate of the later stage should be the same for all substrates of tyrosine phenol lyase. The 
elimination stage is accompanied by rehybridisation of the p-carbon atom from sp  ^to sp^ and 
consequently is slowed down on passing from the normal to the p,p-dideuteriated substrate. 
The observed value of the p-kinetic isotope effect (1.1) is comparable with the normally 
observed secondary kinetic isotope effect in other reactions with sp3 to sp2  hybridisation 
changes and therefore it was concluded that for p,p-dideuteriated 3-fluoro-25'-tyrosine, p- 
elimination is partially rate limiting.
A similar aminoacrylate formation has been proposed in the reaction catalysed by 
kynureninase so the comparison should be useful.
4.4.4.9 Conclusion.
The isotope effect measurements have shown that for the kynureninase catalysed reaction a- 
H abstraction is partially rate limiting. The observation of = 0.98, whereas ^(V/K) = 3.6 
implying that there is a subsequent slow step in the mechanism, which suppresses the isotope 
effect on V. The solvent isotope effect was ^V= 4.4 and ^(V/IC)= 4.6. These show that a 
proton transfer is also partially rate limiting. In this case there is almost no suppression of 
the value of ^ V.
The results have begun to shed some light on the chemical mechanism and an indication of 
which chemical steps are important to the rate but further experiments ar e requir ed to get a 
detailed understanding of the mechanism of tire enzyme catalysed reaction.
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5 PARTIAL PURIFICATIO N OF KYNURENINASE FROM
PSEUDOMONAS FLUORESCENS.
5,1 Purification Method.
Kinetic studies were carried out with partially purified kynureninase from Pseudomonas 
fluorescens (Strain ATCC 11250), which was obtained as a freeze dried sample from 
NCIMB (the National Collection of Industrial and Marine Bacteria). The method for the 
isolation and purification of the enzyme outlined by Moriguchi et al. was followed and as 
there were few experimental details given each step of the procedure was optimised.^
As the enzyme is on the tryptophan metabolic pathway the bacteria are grown in a medium 
containing a high percentage of tryptophan. The bacteria must metabolise this as a food 
source to grow and this, therefore, encourages expression of the enzymes on the pathway.
Initially resuscitation of the freeze dried culture was unsuccessful in minimal media and so it 
was first incubated in nutrient broth which was richer in nutrients. This contained 'Lab.- 
Lemco' powder 0.1%, yeast extract 0.2%, peptone 0.5% and NaCl 0.5% at pH 7.4. Small 
bottles of nutrient broth were sterilised and the freeze dried culture divided amongst them. 
After incubation at 28 °C for eighteen hours these suspensions were kept refrigerated. This 
was then sub-cultured into the minimal media which contained 0.1% 25-tryptophan, 0.2% 
peptone, 0.1% glycerin, 0.05% yeast extract, 0.1% KH2 PO4 , 0.2% K2 HPO4 , and 0.01% 
MgS0 4 .7 H2 0  at pH 7.0. The flasks were completely cooled before inoculation, which was 
carried out using a sterilised wire loop. Each flask was inoculated twice. The cultures were 
then grown at 28 °C for eighteen hours under aeration. If the flasks are not shalcen then only 
approximately five per cent growth resulted.
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The harvested cells were washed twice with 0.85% sodium chloride solution and 
subsequently with 0.01 M potassium phosphate buffer (pH 7.2). All buffers used contained 
20 |iM PLP and 0.01% 2-mercaptoethanol. The yield of cells was approximately'4g (wet 
weight) per litre of the medium. The washed cells were mixed in a small amount of buffer 
and sonication was carried out in eight thirty second bursts. The resultant slurry was 
centrifuged in order to separate the cell-free extract from the cellular debris. It was possible 
to judge by eye if sonication had been completely successful as the slurry became thinner and 
darker in colour. This was confirmed by running an assay to check for kynureninase 
activity. The pellet obtained on centrifugation could be re-extracted into potassium phosphate 
buffer and showed no kynureninase activity if sonication was complete. Any pellets that 
were kept to be checked for kynureninase activity were stored at -78 °C until required.
1% Protamine sulphate in 0.01 M potassium phosphate buffer (pH 7.2) was added to the cell 
free extract with stirring to remove nucleic acids. The mixture was centrifuged and the bulky 
inactive precipitate was discarded. The protamine sulphate was added slowly and efficient 
stirring maintained throughout the addition. It was observed that if the addition was too rapid 
then complete precipitation of the protein resulted. It was possible to re-extract the protein 
into potassium phosphate buffer (pH 7.2) and repeat the procedure, however this was not as 
efficient. This process could readily be followed by monitoring for kynureninase activity.
The enzyme solution was brought to 20% saturation with ammonium sulphate and the 
precipitate removed by centrifugation. The ammonium sulphate was added slowly in 
portions which were allowed to dissolve before a further portion was added. This required 
efficient but not too vigorous stirring as the protein could be denatured (shown by the 
presence of white froth). Ammonium sulphate was then added to the supernatant to 55% 
saturation. The precipitate, collected by centrifugation, was dissolved in 0.01 M potassium 
phosphate buffer (pH 7.2) and the resulting enzyme solution was dialysed overnight against
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one hundred volumes of the same buffer to remove the ammonium sulphate. The dialysed 
enzyme solution was centrifuged to remove particulates. It was important to assay for 
kynureninase activity and also to determine the protein content at this stage so that the 
efficiency of the column chromatography could be evaluated.
5.2 Assay for Kynureninase Activity.
Kynureninase activity was measured from the decrease in absorbance at 360 nm (e= -4500 
cm‘ )^ upon the conversion of kynurenine to anthranilic acid. The reaction mixture 
contained 0.4 mM (25)-kynurenine in 0.04 M potassium phosphate, pH 7.0 containing 40 
llM PLPat25
5.3 Determination of Kinetic Parameters.
Determination of inhibition of kynureninase by various compounds was performed by 
variation of the concentration of (25)-kynurenine at several fixed values of the inhibitor 
concentration. Km and Vmax values were calculated by fitting of initial rate data to the 
Michaelis-Menten equation with the ENZFTTTER^^  ^programme on a PC.
5.4 Ion Exchange Chromatography of Enzyme Solution.
The dialysed enzyme solution was purified by DEAE-cellulose chromatography using the 
apparatus illustrated overleaf.
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Prior to running the column chromatography, test tube experiments were carried out using 
aliquots of enzyme and beads. It was hoped to demonstrate that enzyme was indeed 
absorbed onto the beads removing the activity from the solution. Several washes were then 
carried out to remove the protein from the beads. Therefore, enzyme solution (3.4 units in 
10 ml) was diluted with 0.01 M potassium phosphate buffer (pH 7.2) and ion exchange 
beads (1.5 g) were added. This was stirred and allowed to settle. When the supernatant was 
checked for kynureninase activity, none was observed, confirming that the enzyme did bind
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to the beads. The supernatant was poured off and replaced with the same buffer containing
0.1 M, 0.2 M and 0.5 M sodium chloride respectively. The ion exchange beads were 
washed a few times with each buffer and the supernatant checked for activity. 
Unfortunately, there was no sharply defined point when activity was released into the 
supernatant. Therefore, careful monitoring of the fractions eluted from the column was 
required.
The DEAE cellulose was mixed with potassium phosphate buffer and the column was packed 
under gravity and then connected to the pump. Buffer was run through the column at eighty 
ml per hour to compress the column. The UV detector was zeroed using distilled water 
which was run through the system (minus the column) until the trace on the chart recorder 
was stabilised. The baseline was set using 0.01 M potassium phosphate buffer (pH 7.2). 
The complete system was reconnected and the enzyme solution was applied via the peristaltic 
pump to the top of the colunm. The column was washed with approximately two bed 
volumes of 0.01 M potassium phosphate buffer (pH 7.2) to remove any unabsorbed protein. 
It was then washed with the same buffer containing 0.1 M sodium chloride for one and a half 
bed volumes. The enzyme was eluted using the buffer supplemented with 0.2 M sodium 
chloride and the trace was recorded (see example p 194). From the trace of absorbance at 
280 nm pealcs due to proteins being eluted from the column were observed. The fractions 
containing protein were assayed for Icynureninase activity and the active fractions pooled and 
brought to seventy percent saturation with ammonium sulphate. The precipitate was collected 
by centrifugation and suspended in 0.01 M potassium phosphate buffer (pH 7.2). Finally, 
ultrafiltration using an AMICON stirred cell (50 ml) fitted with a filter (YM 10, 43 mm) was 
used to concentrate the sample to a few millilitres, which was stored in Epindorph tubes (1.5 
ml) at -78 °C until required.
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From the early column purifications it was found that the protein obtained from the 0.1 M 
elution had negligible kynureninase activity when analysed. This confirmed that some 
purification had taken place as an inactive protein was removed from the sample. The 
column length was optimised at 20-25 cm in length and 2.5 cm in diameter with an enzyme 
loading of 10 ml (40-45 units of activity).
The activity and protein content was calculated for each step in the procedure (See Table 5.1). 
From 19.9 g of cells
Step of Procedure Activity(units) Protein Content (mg) Specific Activity (units mg“l)
%
Purification^
Sonication 81.5 1522 0.0535 0  (0 )
1% Protamine Sulphate 76.0 1458 0.0521 6.7 (2)
20% Aiiunonium Sulphate Cut 72.0 1155 0.0623 1 2  (1 0 )
Dialysis 47.1 812 0.0580 42 (-)b
ColumnChromatography 2 0 . 2 131 0.154 75 (79)
 ^ Figures in brackets denote literature values.^
 ^Literature value not quoted.
Table 5.1
The literature procedure shows comparable purity to the method outlined above for the final 
partially purified enzyme. Some steps showed slightly greater purity than the literature 
values possibly because these were easier to monitor and control on a small scale.
5.5 Determination of Kinetic Parameters for Kynurenine,
The partially purified enzyme was used to determine the kinetic parameters for kynurenine 
under the standard conditions (0.4 mM (2S)-kynurenine in 0.04 M potassium phosphate, pH 
7.0 containing 40 jiM PLP at 25 °C), Km was found to be 25.5 jiM and Vmax was 1.07 x
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10-3 mol dm-3 min-i (see Appendix). The Km is in excellent agreement with literature data
i.e. Km is 25 The enzyme was then used in further kinetic studies and in the
evaluation of new compounds as substiates and inhibitors.
196
FURTHER WORK.
The work described in the thesis has allowed some preliminary investigation into the 
elucidation of the enzyme catalysed reaction.
The synthesis of a novel phosphinic acid transition state analogue has been carried out and its 
interaction with kynureninase has been determined. It was found to be a poor competitive 
inhibitor of the enzyme, with a Kj of 4.19 mM. Preparation of the corresponding methyl 
ester of the phosphinic acid improved the inhibitory properties and this compound had a Ki of 
0.88 mM. It is proposed that méthylation of the acid removes a destabilising interaction 
between the negative charge of the ionised phosphinic acid and some group at the active site. 
Due to the poor inhibition observed the separation of diastereomers or synthesis of the 
compounds with the addition of the ortho-màno group are not of primary importance at this 
stage.
Synthetic routes towards an epoxide analogue, a putative irreversible inhibitor of 
kynureninase, were examined. Examination of the inhibitory properties of this compound 
would provide a useful comparison with those of the phosphinic acid analogues. This 
inhibitor is designed to alkylate the putative active site nucleophile and probe for the 
nucleophile mediated mechanism. If the inhibitors do become irreversibly attached to the 
protein, preparing them in radioactively labelled form and digestion of the inactive enzyme 
formed would give some structural information on the active site.
A number of kynurenine analogues have also been prepared in order to obtain information on 
the specificity of the enzyme and these have begun to give an understanding of the interactions 
at the active site. A racemic mixture of desaminokynurenine was found to have a Kj of 23.2 
pM. Cyclohexyl and naphthyl amino acid derivatives prepared by the same method were 
found to be wealc competitive inhibitors of the enzyme with Kj values of 844 pM and 
207 pM, respectively. Further analogues are required in order to gain more information on
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the specificity of the enzyme. Introducing the ortho-diwmo group into both the cyclohexyl and 
naphthyl amino acid derivatives may allow further examination of these compounds as 
substrates of kynureninase. A further interesting analogue (235) would be that prepared from 
a-tetralone. If this binds at the active site cleavage of the p,y-carbon carbon bond could take 
place. However, there is now an extra covalent linkage between the aromatic ring and the 
alanine fragment. This may result in improved inhibition.
(235)
Stereospecific syntheses and /  or methods of separation of the enantiomers, for all the 
analogues prepared maybe useful for further study in this area.
a-Deuteiiated kynurenine has been prepared for the first time by two complementary synthetic 
routes. Diacetylation /  racémisation of racemic kynurenine in deuterium oxide followed by 
acylase catalysed resolution is the most direct route. This labelled compound has then been 
used in isotope effect studies to gain an understanding of the mechanism of the enzyme 
catalysed reaction. The primary deuterium isotope effect, = 0.98 and ^(V/IQ = 3.6, 
showed that for the kynureninase catalysed reaction, a-H abstraction is partially rate limiting.
The solvent isotope effect, = 4.4 and ^(V/K) = 4.6, showed that a proton transfer is also 
partially rate limiting. Further work is required to elucidate the mechanism in more detail. 
Double kinetic isotope effect studies of the primary and solvent isotope effects should 
distinguish between stepwise and concerted proton transfers. The preparation and testing of 
the p,p-dideuteriated kynurenine would then complete the isotope effect measurements. This 
would give the secondary deuterium isotope effect and assess the kinetic importance of 
carbon-carbon bond cleavage. Finally, all of the measurements need to be carried out at 
different pHs to establish whether each isotope effect is dependent or independent of pH.
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6. EXPERmENTAL.
Melting points were determined using a Gallenkamp melting point apparatus and are 
uncorrected.
Elemental analyses were carried out in the departmental microanalytical laboratory.
Optical rotations were measured at room temperature using an Optical Activity Ltd, AA 1000 
polaiimeter, 1 0  cm path-length cells were used.
Infrared spectra were recorded on a Perldn-Elmer series 1420IR spectrometer. The samples 
were prepared as Nujol mulls or thin films between sodium chloride discs, Absoiption 
maxima are given in wavenumbers (cm"l) relative to a polystyrene standard,
NMR spectra were recorded on a Bruker AM-300 f,t. spectrometer (iH, 300 MHz;
74,76 MHz; 31p, 121.49 MHz) and a Varian Gemini f,t. spectrometer ( %  200 MHz; Hq , 
50,31 MHz), They were also obtained at Merck Sharp and Dohme Research Laboratories 
using a Bruker AC-250 f,t, spectrometer (^H, 250 MHz), a Bruker AM-360 f,t, spectrometer 
(1H, 360 MHz; 90.52 MHz) and a Bruker AMX-500 f,t. spectrometer (IH, 500 MHz;
125,70 MHz). iH NMR spectra were referenced on chloroform, TMS, methanol or d^ * 
DMSO, NMR spectra were referenced on chloroform, methanol or d^’DMSO and ^Ip 
spectra on external H3PO4 , NMR spectra are described in parts per million downfield shift 
from TMS and are reported consecutively as position (5H or SC), relative integral, multiplicity 
(s-singlet, d-doublet, t-triplet, q-quartet, m-multiplet, dd-doublet of doublets and b-broad), 
coupling constant (Jx,yHz if applicable) and assignment.
Mass spectra and accurate mass measurements were recorded on a Kratos MS50, obtained on 
an EPSRC service basis at the University of Swansea using a VG ZAB E and at Merck Sharp
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and Dohme Research Laboratories using a VG Quattro. Major fragments are given as 
percentages of the base peak intensity. Fast atom bombardment (FAB) spectra were recorded 
using glycerol as a matrix.
Flash chromatography was performed according to the procedure of Still^ ^^  using Sorbisil 
C60 (40-60 mm) silica gel and Kieselgel 60.
Analytical thin layer chromatography was carried out on 0.25 mm precoated silica gel plates 
(Whatman SIL G/UV2 5 4) or on 0.1 mm precoated cellulose plates (CEL Macherey-Nagel 
3 OO/UY2 5 4). Compounds were visualised by UV fluorescence, iodine vapour, aqueous 
potassium permanganate, bromocresol green in ethanol or ninhydrin.
Ozonolysis was carried out using a Fischer Ozon Ozon-generator 500.
Protein concentrations were measured by the method of Bradford.
Sonication was canied out with a Heat Systems-Ultrasonics Inc. Europa W-220F sonicator. 
Centrifugation was carried out in a Kontron Centrikon T-124 centrifuge.
Assays were carried out using a UVICON 932 spectrophotometer.
All equipment used in protein purification (peristalic pumps, UV detectors, fraction collector 
etc.) were purchased from Pharmacia.
Solvents were dried and purified according to the methods of Perrin and Armarego.*^^
Pseudomonas fluorescens (Strain ATCC 11250) was obtained from NCIB in Aberdeen.
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6.1 COMPOUNDS SYNTHESISED.
iV-(Beiiz:yloxycarlboiiyl)“(2S)“Serme (101a).
HO C O 2H 
\  /
NH
A solution of 2^-serine (10 g, 93 mmol) in water (100 ml) containing potassium bicarbonate 
(23.5 g, 0.24 mol) was stirred vigorously. Benzylchloroformate (15 ml, 0.105 mol) was 
added in small portions over fifteen minutes. The reaction was then stiiTed for three hours. 
The solution was extracted with diethyl ether (2 x 100 ml). The aqueous layer was then 
acidified with conc. HCl to pH 2 and extracted with diethyl ether (3 x 100 ml). The diethyl 
ether extracts were washed with brine (50 ml) and dried (Na2 S0 4 ). Concentration under 
reduced pressure yielded a white solid which was recrystallised from ethyl acetate/petroleum 
ether to give (22.73 g, 77%) of white crystals, m.p. 116-118 °C (lit.,^®  ^ 117-119 °C); 
[a]g’+2.6° (c 3 in MeOH) (lit.,™ [a]”  +5.8° (c 6  in AcOH)); a)max (nujol)/cnr‘ 3450-3200 
(OH and NH). 1750 (CO carbamate), 1695 (CO acid); Bh (200 MHz; d^-DMSO), 3.65 (2H, 
d, /  5.6 Hz, CHz), 4.08 (IH, m, a-H), 5.05 (2H, s, OC%Ph), 6.95 (d, J  7.5 Hz, NH), 
7.40 (5H, s, aromatic); 5c (50.31 MHz; d^-DMSO), 56.34 (s, a-C), 62.01 (s, p-CHi),
66.15 (s, CH2 -PI1), 128.42 and 129.03 (s, aromatic), 137.65 (s, quat. aromatic), 156.73 (s, 
NHÇO), 172.86 ( s, CO2 H); m/z (Cl) 257 ([M+NH41+, 100%), 240 (53, [M+H]+), 149 
(95, [M +H-CH2Ph]+, 108 (36, [PhC H 20H ]+).
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^"(Be]nizyloxycarboiiyl)“(2S)“Seriinie p-lactone (102a).
yPo — r
u . . . H
NH
A solution of recrystallised triphenylphosphine (2.2 g, 8.4 mmol) in dry THF (40 ml) was 
cooled to -78 °C using solid carbon dioxide/acetone and stirred under nitrogen. Diethyl 
azodicarboxylate (DEAD) (1.46 g, 1.64 ml, 8.4 mmol) was added dropwise over ten minutes. 
The reaction was left stining for ten minutes then A-(Benzyloxycarbonyl)-(25)-serine (2 g,
8.2 mmol) in dry THF (40 ml) was added dropwise over one hour, with shaldng, to prevent 
the solution from solidifying. The reaction mixture was left stirring for twenty minutes at -78 
°C and then allowed to warm to room temperature and stirred overnight (18 hours). The 
solvent was evaporated under reduced pressure and the product was purified by column 
chi'omatography (silica, ethyl acetate: petroleum ether, 45: 55). The product was obtained as 
white needles (0.70 g, 39%), m.p. 127-128 "C (lit.,'^» 133-134 "C); [a]”  -26° (c 1 in 
CH3CN) (lit., >30-26.6° (c 1 in CH3 CN)); n„,ax (nujol)/cm > 3380 (NH), 1840 (CO lactone), 
1690 (CO carbamate); 8h (200 MHz; C^HCls), 4.45 (2H, d ,J  7.5 Hz, CH2 ), 5.15 (3H, m, 
OCHjPh, aH), 5.62 (IH, br d, J 7.5 Hz, NH), 7.24-7.50 (5H, m, aromatic); 6 c (50.31 
MHz; C^HCls), 60.04 (s, a-C ), 66.81 (s, CHiPh), 68.25 (s, GHz), 128.87, 129.03,
129.14 (3x s, aromatic), 135.94 (s, quat. aromatic), 155.83 (s, £ 0  lactone), 169.58 (s, 
COzCHzPh); m/z (Cl) 239 ([M+NH4 ]+, 100%), 222 (8 , [M+H]+), 178 (7, [M-COzH]+), 
108 (48, [PhCH20H]+).
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(2S)“Methyl 7V-(Benzyloxycarbonyl)-2-ammO"3-(0-methyl phenyl
phosplîiîîo)“propanoate ( 122).
O C0 2Me
OMe NH 
CBz
Serine p-lactone (0.5 g, 2.44 mmol) was dissolved in phenyldimethylphosphonite (5 ml, 29.4 
mmol) and the solution heated at 40-50 °C under nitrogen for forty eight hours. The reaction 
was followed by tic (silica, ethyl acetate: petroleum ether; 1: 1). On completion of reaction, 
excess solvent was distilled off at reduced pressure on the Kiigelrohr apparatus at 80 °C (0.1 
mmHg). The product was obtained as a pale yellow oil (0.81 g, 85%) and was partially 
purified by column chromatography (silica, isopropanol: dichloromethane, 5: 95). Two 
diastereomers can be seen, ôjj (200 MHz; C^HCls) 2.50 (2H, m, P-CH2 ), 3.55 (3H, s, 
CO2 CH3), 3.75 (3H, 2x d, /  11 Hz, POCH3 ), 4.60 (IH, m, a-H), 5.05 (2H, s, OCH2Ph), 
6.10 and 6.25 (IH, d, J 7.5 Hz NH, diastereomers), 7.20-7.85 (lOH, m, aromatic); ôc 
(50.31 MHz; C^HCfy), 31.49 (d, g-C, 7pc 100 Hz), 49.84 (s, a-C), 51.87 (s, CO2ÇH3),
53.16 (d, POÇH3 , /pc 4.6 Hz), 67.30 (s, 0 £H 2Ph), 128.32-133.27 (aromatic), 129.31 (d, 
orf/io-aromatic, 7pc 12.6 Hz), 132.03 (d, mefa-aromatic, 7pc 10 Hz), 132.27 (s, para- 
aromatic), 134.99 (quat. aromatic, 7pc 172 Hz), 156.16 (s, NHÇO), 171.86 (s, C0 2 Me); 
m/z (El) 392 ([M+H]+, 10%), (391 (28, M+), 332 (24, [M-C0 2 Me]+), 256 (15, [M- 
PhCH20C0]+), 108 (19, [PhCH20H]+), 77 (100, [Ph]+).
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(2S')“2=Amleo«3“(plheiniyI phosphmo)-propanoic acid (96).
CO 2
The partially purified (25)-methyl iV-(benzyloxycarbonyl)“2-amino-3-(0-methyl phenyl 
phosphino)-propanoate (0.1 g, 0.26 mmol) was heated at reflux in 6  M HCl (10 ml) for 
twelve hours. After cooling, the mixture was evaporated under reduced pressure and then 
taken up in isopropanol (1 ml) containing a small amount of RS-dithiothieitol. This was 
neutralised with propylene oxide (0.07 g, 1.28 mol). Diethyl ether was added and a white 
solid precipitated out of solution. This was then filtered under nitrogen and recrystallised 
from acetone/water to give a white solid (0.03 g, 50%), m.p. 210-212 °C; (Found: C, 47.45; 
H, 5.45; N, 6.03; [Mh-H]+, 230.0573. C9 H 13NO4 P requires C, 47.17; H, 5.28; N, 6.11%; 
[M+H]+, 230.0582); [a]“  +10.1° (c 0.4 in H2 O); Umax (nujol)/cm-> 1680 (CO acid), 1130, 
1150 (P=0, R2 (0 H)P=0 ); 5 h  (200 MHz; ^HzO) 2.00 (IH, m, p-CH (Half of ABX system)) 
and 2.30 (IH, m, p-CH (Half of ABX system)), 3.70 (IH, m, a -H ), 7.50 (5H, m, 
aromatic); 8 p (121.49 MHz; % 2 0 ) 29.43; 8c  (74.76 MHz; % 2 0 ) 31.68 (d, P-CH2 , / p c  90 
Hz), 50.07 (s, a-C), 129.50 (d, ort/io-aromatic, 7 pc  12 Hz), 131.63 (d, raeto-aromatic, J 
PC 10 Hz), 132.69 (s, para-aromatic), 135.17 (d, quat. aromatic, Jpc 130 Hz), 172.46 (s, 
ÇO2 H); m/z (FAB) 230 ([M +H]+, 12%).
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(2lîS)“Mêtliyl i¥“(A€etyl)“2»amniio-3'-(0°methyI pheitiyl phosp5ilno)"propanoate 
(125).
COaMe 
H
Phenyl dimethylphosphonite (21.76 g, 128 mmol) and 2-acetamidoacrylic acid (1.90 g, 14.8 
mmol) were combined and heated at 70 °C for seventy two hours. The product was distilled 
at reduced pressure on the Kiigelrohr to give a pale yellow oil (4.10 g, 94%). The oil was 
dissolved in diethyl ether (50 ml) and washed with 5% sodium bicarbonate (2  x 50 ml) to 
remove any residual phenyl dimethylphosphonite. The aqueous phase was then evaporated at 
reduced pressure, acidified with HCl to pH 3 and extracted into ethyl acetate (3 x 50 ml). The 
product was obtained as a pale yellow oil and used without further purification. Data is given 
for the impure mixture of diastereomers and some tiaces of phenyl dimethylphosphonite are 
also visible in the spectrum (2.26 g, 51%), Dmax (nujol)/cm"l 1725 (CO ester), 1210 (P=0, 
R2 (R’0 )P=0 ); ÔH (200 MHz; C^HCls), 1.60 (3H, 4 x s, CH3CON), 2.55 (2H, m, p-CHg), 
3.25, 2.60 (3H, s, COiCHa), 3.45 (3H, 2 x d, /  11 Hz, POCH^), 4.80 (IH, m, a-H), 7.00 
(IH, dd, J 7.5Hz, NH), 7.70 (5H, m, aromatic); 6? (121.49 MHz; C ^C lg) 43.56, 43.30 
(1:1 mixture of diastereomers); §c (50.31 MHz; C^HCls), 23.51 (s, NHCOGH3), 30.68 (d, 
P-CH2 , /PC lOlHz), 48.45 (s, a -Q , 51.74 (s, CO2CH3), 53.27 (d, POCHs, / p c  5.6 Hz), 
128.52-133.51 (aromatic), 170.45, 170.57 (s, GOCH3 and s, CO^Me); miz (El) 299 (M+, 
8 %), 240 (87, [M-C0 2 Me]+), 155 (91, [PhPOOCH3 ]+), 140 (21, [PhPOO]+), 77 (84, 
[Ph]+), 43 (97, [CH3C01+).
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(2i^S)“2“Ammo->3“(pheiiyl phosphieo)“pFopanoic acid (127).
COgH 
-H
OH
(2jR5)-Methyl A^-(acetyi)-2-amino-3-(0-methyl phenyl phosphino)-propanoate (1.1 g, 3.72 
mmol) was dissolved in 6  M HCl (73 ml) and heated under reflux for twelve hours. The 
solution was concentrated at reduced pressure and taken up in isopropanol (8.5 ml) containing 
a small amount of RS-dithothreitol. This was then neutralised with propylene oxide (1.00 g, 
18.6 mmol) and a white solid precipitated out of solution. Diethyl ether was added and more 
white solid precipitated out of solution. This was then filtered under nitrogen and washed 
with dry diethyl ether. Reciystallisation from acetone/water to give (0.34 g, 54% yield) of a 
white solid, m.p. 211-213 °C (decomp.); (Found: C, 47.46; H, 5.21; N, 6.05; [M+H]+ 
230.0566. C9 H 12NO4 P requires C, 47.17; H, 5.28; N, 6 .1 1 % ; [M+H]+, 230.0582); Umax 
(nujol)/cm-l 1680 (CO acid), 1125, 1145 (P=0, R2 (H0 )P=0 ); 0h (200 MHz; ^ O ) ,  1.80 
(IH, m, p-CH (Half of ABX system)), and 2.10 (IH, m, p-CH (Half of ABX system)), 
3.30 (IH, m, a-H ), 7.60 (5H, m, aromatic); 6 p (121.49 MHz; ^H2 0 ) 29.83; §c (74.76 
MHz; 2 H2 O / 2HC1) 28.85 (d, P-ÇH2 , / p c  90 Hz), 47.20 (s, a-C ), 126.74 (d, ortho- 
aromatic, 7 p c  12 Hz), 128.87 (d, mgfa-aromatic, 7 pc  10 Hz), 130.00 (s, para-aromatic),
132.15 (d, quat. aromatic, Jpc 129 Hz), 169.59 (s, ÇO 2 H); m/z (FAB) 230 ([M+H]+, 
100%), 252 (25, [M+ Na]+).
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Methyl pheeylphosphinate (133).
MeO^
A solution of methanol ( 6  ml, 0.25 mol) and pyridine (12 g, 12.4 ml, 0.152 mol) in toluene 
(24 ml) was added dropwise over one and a half hours to a stirred solution of 
dichlorophenylphosphine (21.48 g, 16.4 ml, 0.12 mol) in toluene (140 ml) cooled to 0 °C. 
The pyridinium hydrochloride, formed within one hour, was vacuum filtered from solution 
and water (30 ml) was added dropwise to the filtrate. The organic layer was extracted with 
saturated sodium bicarbonate (50 ml) and water (50 ml) and the aqueous layer was back 
extracted twice with dichloromethane (2 x 30 ml). The combined organic layers were dried 
(Na2 S0 4 ) and concentrated at reduced pressure. The product was purified by distillation to 
give a colourless liquid (8.24 g, 43%), bp 82 °C/ 0.2 mmHg, (lit.,^ "^^  72 °C/ 0.1 mmHg); 
Umax (C%Cl3 )/cm-l 2380 (PH), 1230 (P=0); 8 h (250 MHz; C^HCla) 3.80 (3H, d, /  12 Hz, 
POCH3 ), 7.42-7.85 (5H, m, aromatic), 7.55 (IH, d, J 565 Hz, P-H); 6 c  (90.18 MHz; 
C^HCla) 52.00 (d, OÇH3 , / p c  6.4 Hz), 128.74 (d, orf/zo-aromatic, 7pc 14 Hz), 130.86 (d, 
mera-aromatic, 7 p c  12 Hz), 132.43 (d, quat. aromatic, 7 p c  126 Hz), 133.13 (s, para- 
aromatic); m/z (El) 157 ([Af+H]+, 90%), 313 (100, [M+M+H]+).
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Benzyl-(25?)“iV°(Be8i2yloxycarboiîyI)=2-l]>roïïiîciialaiîmô benzyl ester (130),
Br. COgCHgPh 
\ —
N ^O C H g P h
O
Carbon tetrabromide (1.47 g, 4.4 mmol) and triphenyl phosphine (1.16 g, 4.4 mmol) were 
dried in a desiccator over P2O5 for twelve hours. They were then dissolved in Na-dry toluene 
(20 ml) and #-CBz serine benzyl ester (1 g, 3 mmol) was added in several portions over 
thirty minutes. This was then left to stir overnight. Precipitated triphenyl phosphine oxide 
was removed by filtration through celite and purification was carried out by column 
chromatography (silica, ethyl acetate: dichloromethane 2: 8 ) to give (0.89 g, 75%) of white 
crystals, m.p. 85-87 °C 84-85 °C); [a f^  -18.1° (c 1 in MeOH) (lit.,!^^ (c
1 in MeOH)); Umax (nujol)/cm-l 1730 (CO ester), 1680 (CO amide), 695 (C-Br); Ôh (200 
MHz; C^HCls) 3.80 (2H, m, CH2 -ABX system), 4.85 (IH, m, a-H), 5.10 (2H, s, CHz of 
Cbz), 5.20 (2 H, s, CHl of ester), 5.70 (IH, d, J  7.5 Hz, NH), 7.35 (lOH, s, 2  x aromatic), 
5c (50.31 MHz; C^HClg), 34.3 (s, P-C.H2 ), 55.0 (s, a-C), 67.8, 68.5 (benzyl CH2 *s),
128.7, 129.0, 129.1, 129.2, (aromatics), 135.3, 135.5 (quat. aromatics), 156.0 (CO Cbz), 
169.3 (CO ester), m/z (HI) 409, 411 ([M+NH4 J+. 95, 100%), 392, 394 (14, 38, [M+H]+).
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Benzyl-(2&)-7V=(benzyloxycarbonyl)-2-am ino-3-(0-methyB phenyl
phosphIiîo)»pa*®panosite (129).
\ = /  OUe n - ^ O C H a P h
C02CH2Ph
^Butyl lithium (2,41 mmol, 1.1 eq, 0.96 ml, 2.5 M solution in hexanes) was added dropwise 
to methyl phenylphosphinate (343 mg, 2.19 mmol) in THF (4 ml) at -78 °C under nitrogen. 
This was then stirred at -78 °C for thirty minutes. The A^-CBz-2-bromo alanine benzyl ester 
was then added (0.85 g, 2.19 mmol) in THF (5 ml) at -40 °C. This was stined at -40 °C for 
one hour and then allowed to warm to room temperature. The reaction was quenched with a 
saturated solution of ammonium chloride ( 8  ml) and extracted into dichloromethane (3 x 20 
ml). The solvent was then removed at reduced pressure. Purification was carried out using 
column chromatography and a gradient solvent system (silica, initially ethyl acetate: 
petroleum ether, 1:1, then 3: 1 then pure ethyl acetate). It was therefore possible to separate a 
small amount of pure product (100 mg, 11%), 'Umax (nujol)/cm‘l 1720 (CO ester), 1680 (CO 
amide), 1225 (P=0, R2 (R'0 )P=0 ); %  (250 MHz; C^HCl]) 2.60 (2H, m, (I-CH2 ), 3.65 (3H, 
d j  12 Hz, POCH3 ), 4.60 (IH, m, a-H), 5.05 (4H, m, OCI^Ph), 6.18 and 6.25 (IH, d, J
7.5 Hz, NH), 7.24-7.80 (15H, m, aromatic); 6 c  (74.76 MHz; C^HCls), 30.99 (d, p-£, / p c  
100 Hz), 49.67 (s, a-Q), 51.25 (d, POCH3 , J p c  5.4 Hz), 66.96, 67.15 ( 2  x s, 0 £ H 2 Ph), 
128.13-132,94 (aromatics), 128.70 (d, orr/io-aromatic /  pc 15 Hz), 132.00 (d, mem-aromatic 
7 PC II  Hz), 132.94 (s, para-aromatic), 134.06 (quat. aromatic / p c  170 Hz), 135.43, 
136.42 (quat. aromatic), 156.00 (s, N H £0), 170.69 (s, £ 0 2 CH2 Ph ester), m/z (El) 468 
([M+H]+, 100%), 506 (26, [M+K]+).
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(2S)-2-Am m ®-3-(0-m ethyl-phenyl phosph:no)-propano:c acîd (124).
O  C O :
P>
OMe NH3^
Benzyl-(25)-iV-(benzyloxycarbonyl)-2-amino-3-((9-methyl phenyl phosphino)-propanoate 
(100 mg, 0.24 mmol) was dissolved in methanol (10 ml) and Pd/C (100 mg) was added. 
Hydrogenation was then carried out overnight at atmospheric pressure using the 
hydrogenation apparatus. The catalyst was removed by filtration through a celite bed and the 
methanol removed under reduced pressure. This gave the desired product (23 mg, 38%), 
m.p. 188 °C (decomp.); [«]“  -6 .6 ° (c 0.25 in H2 O); «max (nujol)/cm-l 3320 (OH acid), 1690 
(CO acid), 1225 (P=0, R2 (R'0 )P=0 ); 8 h (200 MHz; % 2 0 ) 2.50 (2H, m, II-CH2 ), 3.60 (3H, 
d , . /  10 Hz POCH3 ), 4.10 (IH, m, a-H), 7.35-7.80 (5H, m, aromatic); Sp(121.49 MHz; 
7H2 0 ) 48.58, 47.94 (2:1 mixture of diastereomers), 8c  (74.76 MHz; 7 h 2 0 ) 29.63 (d, p -C ,/ 
PC 100 Hz), 49.45 (s, a-£), 52.57 (d, POCH3 , /  pc 5.6 Hz), 128.74 (d, ortfto-aromatic, /  
PC 12 Hz), 130.83 (d, raeto-aromatic, J  pc  10 Hz), 131.76 (s, para-aromatic), 133.06 (d, 
quat. aromatic, 7 PC 169 Hz), 172.27 (s, ÇO2H), m/z (Cl) 244 ([Af+H]+, 100%).
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(2S)=iV"(BerazyloxycaFbo!iyl)=2=ammO“3"(0"met]hyI phenyl phosphino)-
propanoate (128).
  O COgH
\ = /  owe H -^O C H ,Ph  
o
(25)-Methyl A^-(benzyloxycarbonyl)-2-amino-3-(0-methyl phenyl phosphino)-propanoate 
(210 mg, 0.54 mmol) was dissolved in a mixture of THF: water (1: 1, 10 ml) with stirring at 
0 °C. This was then treated with lithium hydroxide monohydrate (0.023 g, 0.54 mmol) in 
THF: water (10 ml) which was added dropwise at 0 °C. This was then stirred for three hours 
and followed by mass spectrometry. The solution was then poured into IM HCl (5 ml) and 
extracted into ethyl acetate (3 x 20 ml). The ethyl acetate extracts were dried (MgSO^) and 
concentrated under reduced pressure to give a colourless oil (40.6 mg, 20%); 5h (250 MHz; 
C^HCIs) 2.70 (2H, m, p-Cgz), 3.75 (3H, d,,7 11 Hz, POCH3 ), 4.60 (IH, m, a-H), 5.05 
(2H, m, OCH2 Ph), 5.95 and 6.11 (IH, d, J  7.5 Hz, NH), 7.25-7.84 (lOH, m, aromatic); 
m/z (El) 378 ([M+H]+, 60%), 187 (100, [PhP(0 )0 Me2]+).
212
(2S)“i¥“(BenzyIoxycarboiniyl)“2=amiiiO“3"(0“methyi phenyl phosphino)-
propanoate (128).
COgH
OMe N-^OCHaPh
o
(25)-2“Amino-3-(0-methyl-phenyl phosphino)-propanoic acid (244 mg, 0.622 mmol) was 
dissolved in acetone ( 6  ml) and O.IM potassium phosphate buffer (60 ml, pH 8 ) was added. 
(This had previously been prepared using di-potassium hydrogen orthophosphate which was 
buffered to pH 8  using dilute phosphoric acid). Then pig liver e s te ra s e ^ (5 mg in 3.2 M 
(NH4 )2 S0 4 , 1150 units) was added and the mixture incubated at 38 °C, Once NMR showed 
the reaction to be complete the mixture was acidified to pH 4 with 2 M HCl and extracted with 
ethyl acetate (3 x 15 ml). The organic layer was washed with water, dried (MgS0 4 ) and 
concentrated at reduced pressure to give a pale yellow oil (104 mg, 44%), Umax (nujol)/cm'l 
1690 (CO acid), 1680 (CO amide), 1225 (P=0, R2 (R'0 )P=0 ); ô r (200 MHz; ^HiO) 2.60 
(2H, m, p-CHa), 3.70 (3H, d,, /  10 Hz, POCH3 ), 4.60 (IH, m, a-H), 5.05 (2H, m, 
OCHiPh), 6.05 and 6.20 (IH, d, J  7.5 Hz, NH), 7.20-7.90 (lOH, m, aromatic); 5c (50.31 
MHz; 2 H2 O) 29.53 (d, p-C, J  pc 108 Hz), 49.50 (s, a-C), 52.68 (d, POÇH3 , /  pc 5.3 Hz), 
67.02 (2x s, OCH2Ph), 127.87-133.06 (aromatics), 128.48 (d, orfAo-aromatic, / p c  10 Hz), 
132.26 (d, mern-aromatic, J p c  9 Hz), 132.30 (d, quat. aromatic, J pc 129 Hz), 132.65 (s, 
para-aromatic), 156.39 (s, NHCO), 173.40 (s, CO2 H), m/z (Cl) 395 ([M+NH4 +J+, 21%), 
378 (11, [M+H]+).
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(2S)-2-A m m o-3-(0-m ethyl-phenyl phospHilMo)-propanoic acid (124).
o CO:
(2iS)-iV"(Benzyloxycarbonyl)-2-aimno-3-(<9-methyl phenyl phosphino)-propanoate (150 mg, 
0.40 mmol) was dissolved in methanol (10 ml) and Pd/C (100 mg) was added. 
Hydrogenation was then carried out overnight at atmospheric pressure using the 
hydrogenation apparatus. The catalyst was removed by filtration through a celite bed and the 
methanol removed under reduced pressure. The yellow oil isolated was dissolved in water 
and washed with diethyl ether (2 x 10 ml) and ethyl acetate (2 x 10 ml). The aqueous phase 
was then lyopholised to give a pale yellow solid and recrystallised from acetone /  water (60 
mg, 67%), m.p. 188 °C, [a]^ -6 .6 ° (c 0.25 in H2O); Umax (nujol)/cm-l 3320 (OH acid), 
1690 (CO acid), 1225 (P=0, R2 (R’0 )P=0 ); S r (200 MHz; % 2 0 ) 2.50 (2H, m, P-CH2 ),
3.60 (3H, d , /  10 Hz POCH3 ), 4.10 (IH, m, a-H), 7.35-7.80 (5H, m, aromatic); 6 p (121.49 
MHz, %20), 48.58, 47.94 (2:1 mixture of diastereomers), 8 c (74.76 MHz; % 2 ^) 29.63 (d, 
P-Ç, J  PC 100 Hz), 49.45 (s, a-C), 52.57 (d, POCH3 , J  pc 5.6 Hz), 128.74 (d, ortho- 
aromatic, 7 pc 12 Hz), 130.83 (d, mem-aromatic, / p c  10 Hz), 131.76 (s, para-aromatic),
133.06 (d, quat. aromatic, / p c  169 Hz), 172.27 (s, ÇO2 H), m/z (El) 244 ([M+H]+, 100%).
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i¥“(Bensyloxycarbo]niyi)“(2S)»serm e 3“îîiethyI“3“(hydroxym ethyl) oxetane 
ester (179).
NH-Cbz
N-CBz serine (1.13 g, 4.47 mmmol) was dissolved in dichloromethane (125 ml) and added 
dropwise over three hours to a stirred solution of DCC (1.47 g, 7.11 mmol, 1.5 equiv.), 
DMAP (29.0 mg, 0.237 mmol, 0.05 equiv.) and 3-methyl-3-(hydroxymethyl)-oxetane (9.68 
g, 94.8 mmol, 20 equiv.) cooled to 0 °C under a nitrogen atmosphere. The solution was 
allowed to warm to room temperature and stirred for a further twelve hours. The solution 
was then filtered to remove dicyclohexylurea (DCU). The filtrate was washed with 1% 
NH4 CI (2 X 125 ml), 5% NaHCOg (1 x 125 ml), dried (MgS0 4 ) and evaporated under 
reduced pressure, yielding a white solid. The product was purified by column 
chi'omatography (silica, ethyl acetate/petroleum ether; 2 : 1), to give a white solid (0 . 8 8  g, 
57%). (The aqueous fractions were saved for recovery of oxetane alcohoT^^), m.p. 84-85 
°C; m/z (Found: [M+H]+ 324.1441. C16H2 1 NO6 requires 324.1447); Dmax (nujol)/cm'l 
3310-3410 (OH and NH), 1675 (CO); Sh (200 MHz; C^HClg), 1.30 (3H, s, CH3 ), 3.20 
(IH, br s, OH), 3.90 (IH, m, a-H), 4.10 (2H, d, J 10 Hz, CH2 OH), 4.50 (6 H, m, CH2  
oxetane), 5.05 (2H, s, OCHgPh), 5.85 (IH, d, J  7.5 Hz, NH), 7.35 (5H, s, aromatic); §c 
(50.31 MHz; d^-DMSO), 21.25 (s, oxetane ÇH3 ), 40.10 (s, quat. oxetane), 56.88 (s, a-C), 
63.81 (s, oxetane C.H2 OCO), 67.65 (s, CH2 Ph), 69.39 (s, p-Q, 79.97 (s, oxetane ÇH2 O), 
128.63, 128.75, 129.05 (s, aromatic), 136.60 (s, quat. aromatic), 156.73 (s, NHCO), 
171.24 (s, C0 2 -oxetane); m/z (Cl) 324 ([M+H]+, 27%), 306 (10, [M+H-H2 0 J+), 280 (8 , 
[M+H-C021+), 233 (100, [M4.H-CH2PW+), 216 (72, [M+H-HOCH2Ph]+).
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Attempted preparation of A "(benzyloxycarbonyl)-(lS)”l “a]nriinO"2» 
lbiydroxyethyI“4“metfeyI“2,657“trnoxabicyclo[2.2.2]octane, iV-Cbz-ortho ester 
( 180).
OH
fffiii..
NH-Cbz
The oxetane ester (0.43 g, 1.32 mmol) was dissolved in freshly distilled (off CaH2 ) 
dichloromethane (8.2 ml) and cooled to 0 °C under nitrogen. A solution of Bp3 .Et2 0  (22 jiL 
of a 20% (v/v) solution in CH2 CI2 , 0.033 mol, 0.027 equiv.) was then added. The solution 
was stirred and allowed to warm to room temperature. After twenty four hours, tic (silica, 
ethyl acetate/petroleum ether; 2 : 1) showed reaction to be incomplete and a further portion of 
BP3 .Et2 0  ( 2 2  pL of a 2 0 % (v/v) solution in CH2 CI2 , 0.033 mol, 0.027 equiv.) was added. 
The reaction was left to stir for a further twenty four hours, then EtsN (108 pL, 0.78 mmol, 
0.58 equiv.) was added and the solution evaporated to dryness under reduced pressure. The 
product was (0.379 g, 8 8 %) of a white solid which was found to be starting material.
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i¥“(9“FIuc5reiiiylmethyIoxycarboBiyI)»(2S)“Serlne (159),
OH ÇOgH
Fmoc chloride (1.45 g, 5.25 mmol) in dioxane (5 ml) was added dropwise over thirty 
minutes to a cooled stirred solution of serine (0.525 g, 5 mmol) dissolved in a mixture of 
dioxane (5 ml) and 10% NaiCOg (13.5 ml). The reaction was then stirred for forty eight 
hours. The dioxane was evaporated at reduced pressure and water (62.5 ml) was added to the 
remaining aqueous solution. Extraction was carried out with ether (3 x 75 ml). On 
acidification of the aqueous layer with HCl the product precipitated and was extracted into 
ethyl acetate (3x40ml). The combined organic extracts were washed with brine (50ml) and 
dried (Na2 S0 4 ). The ethyl acetate was evaporated at reduced pressure and recrystallisation 
was caiTied out using ethyl acetate/petroleum ether giving pale yellow crystals (1.23 g, 
71.3%), m.p. 84-90 °C (lit.,‘55 7 4 - 8 6  “C); [al^Oo +16.1° (c 1 in MeOH), (lit.,2»l [a]20o 
+13.3° (c 1 in EtOAc); Vmax (nujol)/cm-l 3310 (OH and NH), 1670 (CO); 8 h (200 MHz; d®- 
DMSO); 3.75 (2H, m, p -C H i), 4.08 (IH, m, Fmoc CECH 2 O), 4.30 (2H, m, Fmoc 
CHCE2 O), 5.04 (IH, br m, a-H ), 7.30-7.94 (8 H, m, Fmoc=CH); 8 c  (50.31 MHz; d®- 
DMSO); 46.87 (s, Fmoc ÇHCH2 ), 56.93 (s, a -Q , 64.03 (s, p-Q , 66.0 (s, Fmoc CH2 O), 
120.39, 125.58, 127.37, 127.92 (s, Fmoc=£H), 144.11, 145.46 (s, Fmoc=C=), 156.35 (s, 
CONH), 172.44 (s, CO2 H); m/z (Cl) 345 ([M+NH4 ]+, 44%), 328 (30, [Mn-H]+), 179 (76, 
[C6H4CH(CH2)C6H4]+).
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i¥“(9“FIuoreïiyInnietibiyIoxycarboniyl)"(2S)“SeFi!ie 3=met!îyl“3»(hydroxy“îmiethyI) 
oxetane ester (160).
NH-Fmoc
Fmoc-(25)-serine (1.23 g, 2.96 mmol) was dissolved in CH2CI2  (31 ml) and added dropwise 
over an hour to a stirred solution of DCC (0.92 g, 4.44 mmol, 1.5 eq), DMAP (18.0 mg, 
0.148 mmol, 0.05 eq) and oxetane alcohol (6.04 g, 59.2 mmol, 20 eq) cooled to 0 °C under 
nitrogen. The reaction solution was allowed to warm up to room temperature and stirred for a 
further twelve hours. The solution was then filtered to remove dicyclohexylurea (DCU). The 
filtrate was washed with 1% NH4CI (2 x 125 ml), 5% NaHCOs (1 x 125 ml), dried (MgS0 4 ) 
and evaporated under reduced pressure to dryness. The product was purified by column 
chi'omatography (silica, ethyl acetate/petroleum ether; 2: 1), to give a pale yellow foam (1.05 
g, 8 6 %), m.p. 104-106 °C (lit.,‘55 106-107 “Q ; Omax (nujol)/cm-> 3320 (OH and NH), 1675 
(CO); 6 h (200 MHz; C^HCl;); 1.28 (3H, s, CHs oxetane), 3.65 (IH, br s, OH), 3.86 (IH, 
m, P-CHH), 4.10 (2H, m, a -C E , p-CH E), 4.20 (IH, t; 7 5 Hz, Fmoc CECHz), 4.30-
4.60 (8 H, m, Fmoc CH9 O. 3 oxetane CE2 O), 6.12 (IH, br d, 7 5 Hz, NE), 7.24-7.79 (8 H, 
m, Fmoc=CE); 8 c  (50.31 MHz; C % C 1;); 21.34 (s, oxetane CEH3 ), 39.88 (s, oxetane 
CCHs), 47.55 (s, Fmoc CHCH2 ), 56.93 (s, a-C). 69.43 (s, p-C), 67.57 (s, Fmoc CH2 O),
69.45 (s, oxetane CH2 OCO), 79.93 (s, oxetane CH2 O), 120.46, 125.63, 127.57, 128.21 (s, 
Fmoc=CH), 141.72, 144.21, 144.33 (s, Fmoc=£=), 156.89 (s, £ONH), 171.38 (s, £ 0 2 - 
oxetane); m /z  (Cl) 429 ([M + N H 4 ] + , 3%), 412 (12, [M + H] + ), 179 (30, 
[C6H4CH(CH2)CeH4]+).
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Attempted preparation of i¥"(9-FluorenyImethyIoxycarboeyl)“(lS)“l ”ami8io»2" 
hydroxyethyl-4-methyl-2,6,7-trloxab:cyclo[2.2.2]octane, Fmoc-S-Serine 
Ortho ester (161).
O H ° ^ °
|" '-H
NH-Fmoc
This was prepared in an identical manner to that described for the A^Cbz ortho ester, however 
l^C NMR showed that only starting material was isolated.
A/'“(^er^-Bntosycarhoiriyl)“(2S)“kynnrenme.
O CO gH
"H O
Di-ferr-butylpyrocarbonate (0.38 g, 1.738 mmol) was added to a solution of 2^-kynurenine 
(0.48 g, 1.58 mmol) and sodium bicarbonate (0.44 g, 5.21 mmol) in THF: water, (1: 1, 50 
ml). The solution was then stiired at room temperature for twenty four hours after which time 
tic examination (cellulose, IP A: conc. aq NH3 : H2 O; 3: 6 : 10) showed reaction to be 
incomplete. A further (0.19 g, 0.869 mmol) di-rerr-butylpyrocarbonate was added and the 
solution stirred for a further eight hours. Hydrochloric acid (0.145 ml, 1.738 mmol, 12 M) 
was then added. The solvent was then evaporated under reduced pressure and 
reciystallisation cairied out from ethanol / water to give (0.2 g, 41%) of yellow crystals, m.p.
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170 °C; Dmax (nujoI)/cm-l 1685 (CO acid), 1660 (CO amide); ôr (200 MHz; d^-DMSO), 1.38 
(9H, s, mu), 3.32 (2H, m, (i-CH^), 4.48 (lH,m, a-H ), 6.55 (IH, t, J  1 0  Hz, 5'H), 6.78 
(IH, d, J  10 Hz, 3'H), 6.95 (IH, d, J  7.5 Hz, NH), 7.25 (3H, m, 4'H,NH2), 7.75 (IH, d, 
J  7.5 Hz, 6 ’H); 6c (74.76 MHz; d^-DMSO), 28.40 (s, CHa’s), 41.69 (s, Ç-3), 49.92 (s, Ç- 
2), 78.70 (s, C(CH3 )3 ), 115.00 (s, 3'C), 116.81 (s, I'C), 117.33 (s, 5'C), 131.37 (s, 6 ’C), 
134.64 (s, 4'C), 136.99 (s, 2'C), 151.29 (s, C0 2 C(CH3 )3 ), 173.70 (s, Ç-1), 198.78 (s, Ç- 
4); m /z  (Cl) 309 ([M +H] + , 32%), 265 (9, [M + H -C 0 2 1  + ), 253 (100, [M + H- 
CH2 =C(CH3)2 ]+), 192 (15, M+H-(CH3)3C0C0NH2]+), 57 (20, [(CH3 )3C]+).
2“AcetylaminO"2“(2“OxO“2“phenyl“etlbyl) maionîc acid diethyl ester (192).
Q COsEtU nhao
COgEt
Diethylacetamidomalonate (12.2 g, 56.16 mmol) in redistilled DMF (74 ml) was added to 
sodium hydride (60% weight in oil) (2.25 g, 56.25 mmol) at 0 °C under a nitrogen 
atmosphere. Stirring was continued for three hours after which a solution of a -  
bromoacetophenone (10 g, 50.24 mmol) in redistilled DMF (22 ml) was added, and the 
resulting dark mixture was stirred for a further five hours. The reaction was then poured into 
distilled water (740 ml), acidified with 1 M HCl, extracted with diethyl ether (5 x 150 ml), 
washed with brine (250 ml) and dried (MgSO^). The solvent was then removed under 
reduced pressure and the residue triturated four times with diethyl ether/dichloromethane (3: 
1) to give a white crystalline solid (8.56 g, 25.53 mmol, 51%); m.p. 118-122 *"C (lit.,*^^ 
118-119 °C); Dmax (nujol)/cm-l 3200 (NH), 1750 (ester), 1725 (C=0), 1680 (CO amide); 6 h 
(200 MHz; C^HCb) 1.25 (6 H, t, J  7.5 Hz, 2 x CO2 CH2 CH3 ), 2.00 (3H, s, COCH3 ), 4.25
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(6 H, m, 2 X CO2 CH2 CH3 , P-CH2 ), 7.10 (IH, s, NH), 7.50 (3H, m, 3'H, 4'H, 5'H), 7.90 
(2 H, d, J  7.5 Hz, 2'H, 6 'H); Sc (50.31 MHz; C^HCls) 14.39 (s, CO2 CH2 CH3 ), 23.40 (s, 
NHCOCH3 ). 42.76 (s, p-Ç), 63.34 (s, CO2 ÇH2 CH3), 64.43 (s, a-Ç), 128.67 (ÏC , 5'Ç), 
129.17 (2'£, 6 'Q , 134.21 (4'Ç), 136.49 ( l 'Q ,  167.74 (s, Ç 0 2 Et), 169.98 (s, ÇOCH3 ), 
197.35 (s, ÇOCH2 ); m/z (CI) 336 ([M+H]+, 1 %), 262 (19, [M-C0 2 Et]+), 105 ( 1 0 0 , 
[PhCO]+).
(i?S)“2“ammo>«>4°oxO“4-pheiîyl“bety rîc  acid (27).
O COgH
A suspension of diethyl (phenacyl) acetamidomalonate ( 8  g, 23.86 mmol) in 6  M HCl (225 
ml) was heated at reflux for five hours. Upon cooling, the mixture was washed with ethyl 
acetate (2 x 50 ml), concentrated under reduced pressure. Trituration with acetone gave the 
pure hydrochloride salt which was then neutralised with 5% sodium hydrogen carbonate to 
afford the free base. Recrystallisation from acetone / water gave a white crystalline solid (2.6 
g, 56%); m.p. 189-191 °C, (Iit.,l® 190-200 °C); (Found: C, 61.88; H, 5.65; N, 7.15. Calc, 
for C 1 0HUNO 3 : C, 62.17; H, 5.74; N, 7.25%); SH (300 MHz; ZH2 O) 3.50 (2H, m, p- 
CHz), 4.15 (lH,.m, a-H ), 7.50 (2 H, m, 3'H, 5'H), 7.35 (IH, m, 4'H), 7.70 (2H, d, J 7.5 
Hz, 2'H, 6 'H); Sc (50.31 MHz; 2 H2 O) 55.09 (s, a-C), 131.02 (s, 3'C, 5'C), 131.64 (s, 
2'C, 6 'Q , 136.93 (s, 4 'Q , 138.83 (s, I 'Q , 184.14 (s, CO2 H), 205.45 (s, ÇOCH2 ); m/z 
(Cl) 194 ([A/+H]+, 100%). The compound was poorly soluble in a wide variety of NMR 
solvents; thus it was not possible to see all the signals in the NMR spectium.
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2“Bromo»l“CycloîîexylethanoMe (195).
A solution of bromine (2 mi, 37 mmol) in redistilled methanol (5 ml) was added slowly to 
cyclohexylethanone (4.25 g, 33.7 mmol) which was dissolved in redistilled methanol (20 ml) 
and cooled to 0 °C. The reaction mixture was maintained at 5-6 °C during the reaction. Once 
the red colour disappeared, distilled water ( 1 0  ml) was added and the mixture stirred at room 
temperature overnight. Distilled water (30 ml), was then added and the reaction mixture 
extracted with diethyl ether (4 x 30 ml). The organic layers were combined and washed with 
10% potassium caibonate (15 ml), distilled water (2 x 15 ml) and then dried (Na2 S0 4 ). The 
solvent was removed under reduced pressure to give (6.58 g, 96%) of a pale yellow liquid 
which was purified by distillation to give a colourless liquid (5.83 g, 85%), b.p. 90 °C/ 0.25 
mmHg (lit.,^°^ 78 °C/ 0.05 mmHg); Umax (C^HCl3)/cm l 2670 (cyclohexane); 1706 (C=0); 
ÔH (250 MHz; C^HClg) 1.10-1.90 (lOH, 2 x m, 2 ’CH2 , 3 CH2 , 4 '% ,  5 CH2 , 6’CH2),
2.70 (IH, m, TÇH), 3.90 (2H, s, CHaBr); 8 c (50.31 MHz; C^HClg) 25.95 (s, 3'C, 5'C), 
26.1 (s, 4'C), 29.2 (s, 2 'C, 6 'C), 34.1 (I'C), 48.5 (CH2 Br), 205.1 (COCH2 Br), m/z (El) 
205, 207 ([M+H]+, 16, 12%), 226, 228 (25, 23, [M+Na]+).
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2“AcetylamiEîO"2«(2°oxO“2»cydolTiexyl°etlîyI) m aloeic acid diethyl ester (196).
Q ÇÛ2EtNHAc
Diethylacetamidomalonate (2.44 g, 11.2 mmol) in dried redistilled DMF (15 ml) was added to 
sodium hydride (60% weight in oil, 0.45 g, 11.2 mmol) in DMF (2 ml) at 0 °C under a 
nitrogen atmosphere. Stirring was continued for three hours, after which time a solution of 2- 
bromo-1 -cyclohexylethanone (2.14 g, 10.48 mmol) in redistilled DMF (4 ml) was added and 
the resulting mixture stirred overnight. The reaction mixture was poured into distilled water 
(15 ml), acidified with IM HCl, extracted into diethyl ether (5 x 20 ml), washed with brine 
(25 ml) and dried (MgSO^). The solvent was then removed at reduced pressure and the 
residue triturated four times with diethyl ether/ dichloromethane (3: 1) to give a white 
crystalline solid (3.14 g, 84%), m.p. 232 °C; Umax (C2HCl3)/cm-l 3350 (NH), 1750 (C=0), 
1725 (CO ester), 1680 (CO amide); 8h (250 MHz; C2HCI3 ) 1.20 (1 IH, m, 2 x CO2 CH2 CH3 
-h 5 cyclohexyl H's), 1.70 (5H, m, 5 cyclohexyl H's), 1.95 (3H, s, COCH3 ), 2.30 (IH, m, 
TH), 3.70 (2H, s, P-CH2 ), 4.20 (4H, q, /  7 Hz, 2 x CO2 CH2 CH3 ), 7.00 (IH, s, NH); 8 c 
(90.52 MHz; C^HCb) 13.86 (s, CO2 CH 2ÇH 3 ), 22.92 (s, NHCOÇH3 ), 25.40 (s, 3'C, 
5'C), 25.69 (s, 4'C), 28.01 (s, 2'C, 6 'C), 43.92 (s, p-C), 50.64 (s, I ’C), 62.76 (s, 
CO 2 Ç H 2 CH 3 ), 63.72 (s, a-C), 167.16 (s, C 0 2 Et), 169.29 (s, Ç O C H 3 ), 211.14 (s, 
ÇOCH2 ); m/z (El) 342 ([M+H]+, 100%).
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(i?iS)“2“aimiimo°4“OxO"4=cyclohexyl“foell;yric acid (182).
2-Acetylamino-2-(2-oxo-2-cyclohexyl-ethyl) malonic acid diethyl ester (1.663 g, 5.0 mmol) 
was refluxed for five hours in 6  M HCl (48 ml). Upon cooling the solution was washed with 
ethyl acetate (2 x 20 ml) and then concentrated under reduced pressure. Trituration with 
acetone gave a the hydrochloride salt which was neutralised with 5% sodium hydrogen 
carbonate solution to afford the free base. This was then recrystallised twice from acetone/ 
water to give white crystals (0.73 g, 74%), m.p. 194 °C; (Found: C, 60.23; H, 8.45; N, 
6.81. Calc, for CioHnN Og: C, 60.28; H, 8.60; N, 7.03%); Umax (nujol)/cm-l 2670 
(cyclohexane), 1690 (CO acid); 6h  (250 MHz; % 20) 120 (5H, m, 5 cyclohexyl H's), 1.75 
(5H, m, 5 cyclohexyl H's), 2.50 (IH, m, I'H), 3.20 (2H, d ,7  6  Hz, P-CH2 ), 3.90 (IH, t, /  
6  Hz, a-H ); Sc (74.76MHz; 2 H2 O) 25.00 (s, 3'C, 5'C), 25.29 (s, 4'C), 27.91 (s, 2'C, 
6 'C), 39.87 (s, (3-Ç), 49.49 (s, I'C), 50.28 (s, a-C), 172.77 (s, CO 2 H), 215.88 (s, 
ÇOCH2 ); m/z (FAB) 200 ([M4-H]+, 1 0 0 %).
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2“Bromo=l“Scet:oHiaphthoiie (197),
2-Acetonaphthone (5.74 g, 33.7 mmol) was dissolved in redistilled methanol (70 ml) and 
cooled to 0 °C. Bromine (2 ml, 37 mmol) was added slowly as a solution in methanol (5 ml). 
The reaction mixture was maintained at 2-3 during the reaction. This was then stirred for 
two hours below 10 until the reaction mixture was a pale yellow colour. Distilled water 
(10 ml) was then added and the mixture stirred at room temperature overnight. To the 
solution was added distilled water (30 ml). This was extracted with diethyl ether (4 x 30 ml). 
The organic layers were combined and washed with 10% potassium carbonate (15 ml), 
distilled water (2 x 15 ml) and then dried (Na2 S0 4 ). The solvent was removed under reduced 
pressure and the product recrystallised from ethyl acetate to give (7.65 g, 91%) of a pale 
brown solid, m.p. 80-81 °C (lit.,^03 80-81 °C); 0)max (nujol)/cm"l 1650 (C=0); Ôh (250 
MHz; C^HCls) 4.60 (2H, s, CH^Br), 7.30 (2H, m, 6 ’H, 7’H), 7.66 (4H, m, 3’H, 4'H, 
5’H, 8 ’H), 8.50 (IH, s, I'H); ôc (90.52 MHz; C^HCls) 30.89 (s, CH2 Br), 124.16 ( s, 
3’C), 127.07 (s, 6 ’C), 127.85 (s, 7'C), 128.82 (s, 5'Ç), 129.04 (s, 8 ’Ç), 129.69 (s, 4'Ç),
130.95 (s, l'Ç), 131.31 (s, lO’Ç), 132.40 (s, 9’Ç), 135.89 (s, 2’Ç) 191.28 (s, ÇOCH2 Br); 
m/z (El) 249, 251 ([M+H]+, 95,100%), 171 (90, [M+H]+-Br).
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2-Acetylam!mo-2-(2-oxo-2-naphthyE-ethyl) maEonk acid diethyl ester (198),
COeEt 
NHAc
C0 2 Et
Diethylacetamidomalonate (2.44 g, 11,2 mmol) in redistilled DMF (15 ml) was added to 
sodium hydride (60% weight in oil, 0.45 g, 11.2 mmol) at 0 °C under a nitrogen atmosphere. 
Stirring was continued for three hours after which time a solution of 2-bromo-l- 
acetonaphthone (2.61 g, 10.48 mmol) in redistilled DMF ( 8  ml) was added and the resulting 
mixture stirred overnight. The reaction mixture was poured into distilled water (15 ml), 
acidified with IM HCl, extracted into diethyl ether (5 x 30 ml), washed with brine (50 ml) 
and dried (MgSO^). The solvent was then removed under reduced pressure and the residue 
triturated four times with diethyl ether/ dichloromethane (3:1), giving a dark brown oil (3.98 
g, 99%). The prcxiuct was purified by column chromatography (ethyl acetate: hexane; 45: 55) 
to give a pale yellow solid (3.45 g, 8 6 %), m.p. 89-90 °C; 'Umax (nujol)/cm-i 1730 (C=0 
ester), 1680 (C=0 amide); 5h (250 MHz; C^HClg) 1.28 (6 H, t, /  7 Hz, CO2 CH2 CH3), 1.98 
(3H, s, COCH3 ), 4.34 (2H, q, /  7 Hz, COCH2 CH3), 4.42 (2H, s, P-CH2 ), 7.20 (IH, s, 
NH). 7.60 (2H, m, 6 ’H, 7'H), 7.92 (4H, m, 3'H, 4’H, 5’H, 8 ’H), 8.52 (IH, s, I ’H); &C 
(90,52 MHz; C % C l3 ) 13.87 (s, CO2 CH2 ÇH 3 ), 22.90 (s, NHCOÇH3 ), 42.25 (s, p-C), 
62.86 (s, CO2 CH 2 CH 3 ), 64.06 (s, oc-Ç), 123.36 ( s, 3’C), 126.91 (s, 6 'C), 127.70 (s, 
7’C), 128.51 (s, 5’Ç), 128.79 (s, 8 ’Ç), 129.67 (s, 4’Ç), 130.43 (s, l ’Ç), 132.39 (s, lO’Ç), 
133.34 (s, 9Ç ), 135.79 (s, 2’Ç), 167.31 (s, C0 2 Et), 169.48 (s, ÇO CH 3 ), 196.77 (s, 
ÇOCH2 ); m/z (El) 386 ([M+H]+, 100%), 403 (20, [M+H]++NH4 ), 771 (20, [M+M+H]+).
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(l£S)~2-aniino-4-oxo-4-naphthyl-butyric acid (183).
2-Acetylainino-2-(2-oxo-2-naphthy 1-ethyl) malonic acid diethyl ester (1.00 g, 2.68 mmol) 
was refluxed for eight hours in 6  M HCl (28 ml) and dioxan (20 ml). Upon cooling the 
solution was washed with diethyl ether ( 2  x 2 0  ml) and then concentrated under reduced 
pressure. This was then triturated with acetone to give the hydrochloride salt which was 
neutralised with 5% sodium hydrogen carbonate solution to afford the free base. This was 
recrystallised from methanol to give off white crystals (0.42 g, 65%), m.p. 201 °C; (Found: 
C, 69.00; H, 5.55; N, 5.78. Calc, for C 14H 13NO3 : C, 69.12; H, 5.39; N, 5.76%); Omax 
(nujol)/cm-l 1690 (C=0), 1650 (C=0 acid), 1580 (aromatic); %  (200 MHz; C2H3O2 H),
3.95 (2H, m, p-CHa), 4.50 (IH, m, ot-H), 7.65 (2H, m, 6 'H, 7'E), 8.05 (4H, m, 3'E, 
4'H, 5’H, 8 ’H), 8 . 6 8  (IH, s, I'H); 5c (74.76 MHz; C ^ O ^ H )  39.42 (s, 3-£), 50.01 (s, a - 
£ ),  124.44 ( s, 3'C), 128.34 (s, 6 'C), 128.96 (s, 7'£), 129.89 (s, 5'Ç), 130.33 (s, 8 'C),
130.95 (s, 4'Ç), 131.87 (s, l'Ç ), 134.08 (s, lO'Ç), 134.31 (s, 9Ç ), 137.62 (s, 2'C),
171.45 (s, Ç O 2 H), 197.82 (s, ÇO CH 2 ); m/z (FAB) 266 ([M+Na]+, 25%), 244 (65, 
[M+H]+).
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Preparation of (2S)'-[2“2H]“kyEiarenine.
I) Acétylation / deuteriation,
TV, TV’-Diacetyl'-[2“^H]“kynurenine (213).
'  ^ CH
( 2/?5)-Kynurenine (1 g, 4.8 mmol) was dissolved in deuterium oxide (10 ml). Sodium 
(0.46 g, 0.02 mol) was added carefully after washing in petroleum ether and ethanol. Acetic 
anhydride (3 ml, 31.8 mmol) was added slowly, and the solution was shaken vigorously. 
The solution was then stirred at room temperature for three hours. Sulphuric acid (1 M, 10 
ml) was added and the solution concentrated at reduced pressure. The residue was extracted 
with dichloromethane (4 x 50 ml). The combined organic extracts were dried (Na2 S0 4 ) and 
concentrated under reduced pressure to give a pale yellow solid (1.17 g, 98%), m.p. 194 °C, 
Dmax (nujol)/cm-l 3320 (OH), 1675 (CO acid), 1645 (CO amide); ôh (200 MHz; d^-DMSO) 
1.85 (3H, s, NHOCH3 ), 2.15 (3H, s, NHOCH3 aromatic), 4.70 (IH, d, J  7.5 Hz, NH, 
aromatic), 7.25 (IH, t, J  10 Hz, 4'H), 7.62 (IH, t, J  7.5 Hz, 5'H), 8.00 (IH, d, J  10 Hz, 
6 ’H), 8.21 (IH, d, J  7.5 Hz, 3'H), 8.28 (IH, s, NH); ôc (50.31 MHz; d^-DMSO) 22.64 (s, 
NHCOÇH3 ), 24.96 (s, NHCOÇH3 aromatic), 41.57 (s, p-C), 48.27 (s, a-C), 121.26, (s, 
3'C), 123.42 (s, 5'C), 124.96 (s, I'C), 130.78 (s, 6 'C), 134.28 (s, 4'C), 138.85 (s, 2'C),
169.08, 169.42 (NHÇOCH3 ), 173.20 (s, ÇO2 H); m/z (Cl) 310 ([M+NH4J+, 17%), 293 
(100, [M+H]+), 275 (24, [M+H-H20J+), 162 (5, [M+H-CH2C(C02H)(2H)NHC0CH3]+).
228
) Resolution / deacetyîation. 
'’"AcetyI“(25)"[2“2H]"kyiiuremne (214).
NH
O
H3C
N, ISP Diacetyl-[2-^H]-(2/?5)-kynurenine (0.2 g, 0.68 mmol) was added to water (10 iTil) and 
solution was effected by adjusting the pH to 7.5 with concentrated NH4 OH. Acylase from 
Aspergillus meleus (100 mg, 0.47 units/mg) was added and the solution incubated at 38 °C 
for eighteen hours. Examination by tic (cellulose, IP A: conc. aq NH3 : H2 O; 3:6: 10) gave no 
indication if the reaction was complete. A further portion of acylase (100 mg) was added and 
the reaction incubated for eighteen hours. As the two tics were comparable an NMR was run 
which showed that the reaction had occured to completion. The acylase and other protein 
fragments were filtered off and the product evaporated to approximately one ml. Ion 
exchange column chromatography was carried out using strongly basic anion exchanger 
(DOWEX 1). The product was obtained as a pale yellow solid (0.045 g, 62.5%); 
m.p. 156 °C; m/z (Found: [M+H]+ 252.1102. Ci2 H i3 0 4 N2 ^H requires 252.1095); 'Umax 
(nujol)/cm-l 3320 (OH), 1680 (CO acid), 1650 (CO amide); §H (200 MHz; % 0 )  2.05 (3H, 
s, NHCOCH3 ), 3.55 (2H, s, P-CH2 ), 7.18 (IH, t, J  7.5 Hz, 4’H), 7.45 (IH, t, J  7.5 Hz, 
5’H), 7.70 (2H, 2 X d, 7 10 Hz, 6’3'H); ôc (50.31 MHz; 2 H2 O) 26.42 (s, NHCOCH3  
aromatic), 42.91 (s, p-C), 53.21 (s, a-C), 125.93 (s, 3'C), 127.91 (s, 5’C), 128.94 (s, 
I ’C), 133.10 (s,6 ’C), 137.44 (s, 4’C), 139.29 (s, 2’C), 175.66 (s, ÇO2 H); m/z (FAB) 252 
([M+H]+, 100%), 274 (50.5, [M+Na]+).
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Hi) (2g;).[2.2H].Kynuren:ne (199).
N'Acetyl-(2S)-[2-2H]-kynurenine (0.14 g, 0.56 mmol) was dissolved in 2  M HCl (15 ml) 
The solution was heated under reflux for one hour then evaporated to dryness under reduced 
pressure. Isopropanol (1.25 ml) was added containing a small amount of /?5-dithiothreitol. 
The dark orange solid which resulted was neutralised with propylene oxide (0.15 g, 2.75 
mmol). Diethyl ether was added and a pale yellow solid precipitated out of solution. After 
filtration more solid was seen to precipitate out of the diethyl ether. On filtering this became a 
yellow oil and was talcen up in water and the resulting pale yellow solution was freeze dried to 
give (0.05 g, 42%) of a yellow solid; m.p. 188 °C; m/z (Found: [M+H]"^ 210.0986. 
CioHiiNaOs^H requires 210.0989); +25.5° (c 0.5 in H2O); Dmax (nujol)/cm"l 3320
(OH), 1730 (CO), 1650 (CO acid); ôh (200 MHz; ^ O )  3.75 (2H, s, p-CH2 )> 7.30 (IH, d, 
J  7.5 Hz, 3'H), 7.40 (IH, t, J  7.5 Hz, 5'H), 7.62 (IH, t, J  7.5 Hz, 4’H), 8.02 (IH, d, J  7.5 
Hz, 6 'H); ÔC (74.76 MHz; % 0 ) ,  36.95 (s, p-C), 47.98 (t, a -Q , 117.78 (s, 3’Q ,  117.89 
(s, 5 'Q , 129.53 (s, 6 'Q , 133.80 (s, 4 'Q , 171.07 (s, CO2 H), 197.73 (s, ÇOCH 2 ); m/z 
(FAB) 210 ([M+H]"^, 100%), 232 (35, [M+Na]+). Chiral hplc showed an enantiomeric 
excess of 97.4%.
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(2S)»Tryptopham ethyl ester hydrochloride (215).
COgEt
p. NH3+CI
T 7 a 'N i '
Tryptophan (5 g, 24.5 mmol) was dissolved in dry redistilled ethanol (100 ml) cooled in ice. 
Redistilled thionyl chloride (1.9 ml, 1.1 eq) was added and the solution was heated at reflux 
for one hour. The solvent was evaporated under reduced pressure to obtain a white solid 
which was recrystallised from ethanol to give white crystals (4.43 g, 78.3%), m.p. 226-227 
"C (lit.,'®'* 225-226 °C); (Found: C, 58.24: H, 6.19; N, 10.52. Calc, for C 1 3H 16N2 O2 CI: 
C, 58.25, H, 5.97, N, 10.46%); [ci]20d +11.8° (c 1 in MeOH) (lit.,'®'* + 1 2 ° (c 1 in
MeOH)); umax (nujol)/cnr' 3300 (indole NH) and 1730 (C02Et); %  (200 MHz; d^-DMSO) 
1.10 (3H, t, 7 7 Hz, CO2 CH2 CH3 ), 3.20 (2H, dd, J 1 Hz, P-CH 2 ), 4.10 (2H, q, 7 7 Hz, 
CO2 CH2 CH3 ), 4.30 (IH, m, a-H), 7.05 (2H, 2x t, 7 7 Hz, 5'H, 6 'H), 7.38 (IH, d, 7 7 Hz, 
7'H), 7.50 (IH, s, 2'H), 7.54 (IH, d, 7 7 Hz, 4'H), 8.50 (3H, s, indole NH); Sc (50.31 
MHz; dS-DMSO) 13.97 (s, CO2 CH2 ÇH 3 ), 26.40 (s, p -£ ), 52.92 (s, a-C), 61.85 (s, 
CO2 GH2 CH3 ), 106.68 (s, 3 'Q , 111.78 (s, 7'C), 118.28 (s, 5 'Q , 118.79 (s, 6 'Q , 121.38 
(s, 4 'Q , 125.20 (s, 2 'Q , 127.19 (s, 7a'Q , 136.41 (s, 3a'Q , 169.61 (s, C0 2 Et); m/z (Cl) 
268 ([M+H]+, 36%), 130 (100, [CH2 -indole]+).
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^/"(BeM ylosycarbonyl)»(2S)"tryptophaîî ethyl ester (202).
COgEtH O
A , Ph
Sodium carbonate (2.2 eq, 32.33 mmol, 7.9 g) and benzylchloroformate (1.2 eq, 17.6 mmol,
2 . 6  g, 2.17 ml) were added to tryptophan ethyl ester hydrochloride (3.4 g, 14.7 mmol) in 
water (566 ml). The solution was left to stir overnight at room temperature. The reaction was 
followed by tic (silica, ethyl acetate: petroleum ether 3: 7). The white product which had 
precipitated out of solution was filtered off. The product was obtained as white crystals 
(4.11 g, 77%), m.p. 84 °C (lit.,'®: 84-85 °C); (Found; C, 68.96; H, 6.07; N, 7.70. Calc, 
for C2 1 H2 2 N2 O4 : C, 68.84; H, 6.05; N, 7.65%); -8 .8 ° (c 1 in EtOH) (lit.,'®: [a]25o
-6.7° (c 2 in EtOH); Umax (nujol)/cm- ' 3310 (indole NH), 1720 (ester CO) and 1690 
(carbamate CO); Sh (200 MHz; d^-DMSO) 1.10 (3H, t, 7 7 Hz, CO2 CH2 CH3 ), 3.10 (2H, 
m, p-CEz), 4.05 (2H, q, 7 7 Hz, CO2 CH2 CH3), 4.30 (IH, m, a-H), 5.00 (2H, s, CH2 PI1), 
7.00 (lH,t, 7 7 Hz, 5'H), 7.10 (IH, t, 7 7 Hz, 6 'H), 7.20 (IH, s, 2'H), 7.30 (5H, m, 
aromatic), 7.50 (IH, d, 7 7 Hz, 7'H), 7.55 (IH, d, 7 7 Hz, 4'H); Sc (74.76 MHz; d®- 
DMSO) 14.06 (s, CO2 CH2CH3 ), 27.06 (s, p -Q , 55.26 (s, a -Q , 60.63 (s, CO2ÇH2 CH3 ), 
65.54 (s. ÇH 2 PI1), 109.74 (s, 3 'Q , 111.59 (s, 7 'Q , 118.12 (s, 5 'Q , 118.58 (s, 6 'Q ,  
121.11 (s, 4 'Q , 123.98 (s, 2 'Q , 127.18 (s, 7a 'Q , 127.74, 127.92, 128.47 (3x s, 
aromatic), 136.26 (s, 3a'Q, 137.05 (s, quat. aromatic), 156.11 (PI1CH2 OCO), 172.36 (s, 
C 0 2 Et); m /z (El) 367 ([M+H] + , 3%), 258 (5, [M -PhC H 2 0 H ]+), 215 (1, [M- 
PhCH2 0 C0 NH2 ]+), 130 (99, [CH2 -indole]+), 108 (5, [PhCH2 0 H]+), 77 ( 1 1 , [Ph]+).
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"Formyl, N-(benzyloxycarbonyl)-(2S)-kynurenine ethyl ester (216).
COoEt O
/V-(Benzyloxycarbonyl)-(25)-tryptophan ethyl ester (0.88 g, 2.4 mmol) was dissolved in dry 
redistilled methanol (110 ml). The solution was cooled to -78 “C with stirring and then treated 
with ozone for one hour, the reaction was then quenched by the addition of dimethyl sulphide 
(10 ml). The reaction was checked by tic (silica, ethyl acetate: dichloromethane, 1: 9) and left 
to stir for a further hour at -78 °C. The solution was then evaporated to a dark orange oil. 
The product was dissolved in diethyl ether (25 ml) and washed with brine (2 x 50 ml) and 
water (2 x 50 ml). The solution was then dried (MgS0 4 ) and the solvent removed at reduced 
pressure to give an orange oil. Purification was caiiied out by column chr omatography (silica, 
ethyl acetate: petroleum ether, 1: 2). The product was reciystallised from ethyl acetate giving 
a pale yellow solid (0.26 g, 28%), m.p. I l l  °C; (Found: C, 63.31; H, 5.57; N, 7.03. Calc, 
for C2 1 H2 2 N 2 O6 : C, 63.10; H, 5.47; N, 6.91%; [a]2»D +3.4° (c 1 in MeOH); Umax 
(nujol)/cm‘l 3305 (indole NH), 1725 (ester CO), and 1680 (ainide CO); 5h (200 MHz; d^- 
DMSO) 1.20 (3H, t, 7 7  Hz, CO2 CH2 CH3 ), 3.50 (2H, d, 7 7 Hz, P-CH2 ), 4.10 (2H, q, 77  
Hz, CO2 CH2 CH3 ), 4.60 (IH, m, a-H), 5.10 (2H, s, CH2 Ph), 7.20 (lH,t, 7 7 Hz, 5'H); 
7.50 (5H, m, aromatic), 7.65 (lH,t, 7 7 Hz, 4'H), 7.80 (IH, d, 7 7 Hz, 3'H), 8.05 (IH, d, 7 
7 Hz, 6 'H), 8.50 (IH, m, NgCOH), 8c  (74.76 MHz; d^-DMSO) 13.91 (s, CO2 CH2CH3 ), 
41.32 (s, P-Ç), 50.02 (s, a -Q , 60.85 (s, CO2 ÇH2 CH3 ), 65.62 (s, CH2 PI1), 121.24 (s, 
3 'Q , 123.40 (s, 5 'Q , 123.90 (s, I 'Q , 127.64, 127.81, 128.32 (3x s, aromatic), 130.83 (s, 
6 'Q , 134.27 (s, 4 'Q , 136.88 (s, quat. aromatic), 137.96 (s, 2 'Q , 155.87 (s, PhCH2 0 C0 ), 
161.16 (s, NHCOH), 171.39 (s, £ 0 2 Et), 200.13 (s, Ph£OCH2 ); m/z (Cl) 416 ([M+NH4 ]+,
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20%), 399 (78, [M+H]+), 371 (8 , [M+H-CO]+), 355 (22, [M-NHCO]+), 308 (8 6 , [M+H- 
CH2 Ph]+), 291 (84, [M-02CH2Ph]+), 108 (35, [PhCH20H]+).
■(BeiîzyIoxycaE’boMyfi)»(25?)“kyBîMreraine ethyl ester (217).
O COgEt O
1W.-H jl ^
Ph
A
NH 2
iV'Formyl, iV-(benzyloxycarbonyI)-(25)-kynurenine ethyl ester (1.54 g, 3.87 mmol) was 
dissolved in methanol (150 ml). 4 M HCl (16 ml, 7.7 mmol) and dioxane (45 ml) were 
added. The solution was then stirred at room temperature for one hour. After this time it was 
poured into saturated NaHCOg (300 ml) and extracted into ethyl acetate (250 ml). The 
organic extracts were then washed with water. They were dried (MgS0 4 ), filtered and 
evaporated under reduced pressure to obtain a yellow oil (1.28 g, 8 6 %) which crystallised on 
standing, m.p. 58 °C; (Found: C, 64.61; H, 6.11; N, 7.57. Calc, for C2 0 H2 2 N2 O 5 : C, 
64.85; H, 5.99; N, 7.56%); Umax (nujol)/cm'l 1725 (ester CO) and 1680 (amide CO); §h 
(200 MHz; d^-DMSO) 1.20 (3H, t, 7 7 Hz, CO2 CH2 CH3 ), 3.40 (2H, m, P-CH 2 ). 4.10 
(2 H, q, /  7 Hz, CO2 CH2 CH3 ), 4.65 (IH, m, a -H ), 5.10 (2 H, s, CH2 Ph), 6.65 (IH, t, 7 7 
Hz, 5'Hl, 6.80 (IH, d, 7 7 Hz, 6 'H), 7.20 (2H, s, NH2 ), 7.30 (IH, t, 7 7 Hz, 4'H), 7,40 
(5H, m, aromatic), 7.70 (2H, m, NH, 3'H); 8 c  (74.76 MHz; d^-DMSO); 13.85 (s, 
CO2 CH2CH3), 39.97 (s, p-£), 50.04 (s, a - Q ,  60.58 (s, CO2CH2 CH3 ), 65.46 (s, CH2 Ph),
114.40 (s, 3 'Q , 116.27 (s, I 'Q , 116.93 (s, 5 'Q , 127.54, 127.69, 128.23 (3x s, aromatic), 
131 02 (s, 6 'Q , 134.24 (s, 4 'Q , 136.89 (s, quat. aromatic), 151.15 (s, 2 'Q , 155.77 (s, 
PhCH2 0 £ 0 ), 171.68 (s, £ 0 2 Et) 197.68 (PhjQOCHi); m h  (Cl) 371 ([M+H]+, 100%), 263 
(95, [M-OCH2Ph]+), 108 (42, [PhCH20H]+).
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(Benzylo%ycarbonyE)-(25î)-kyiniurenine (218).
O CO2H O
■ " A Ph
iV-(Benzyloxycarbonyl)-(25)4cynurenine ethyl ester (1.28 g, 3.22 mmol), was dissolved in a 
1:1 mixture of THF and water (60 ml) and tieated with lithium hydroxide monohydrate (378 
mg, 9.0 mmol). The solution was warmed at 70 for four hours. The reaction was 
followed by tic (silica, ethyl acetate: petroleum ether 1:2). The solution was poured into IM 
HCl (30 ml) and extracted into ethyl acetate (150 ml). It was dried (MgSO^), filtered and the 
solvent removed at reduced pressure to give a bright yellow solid (0.96 g, 8 8 %); mp 169 °C; 
Umax (nujol)/cm"l 1720 (ester CO) and 1680 (amide CO); Sr (200 MHz; d^-DMSO) 3.35 
(2H, m, P-CH 2 ), 4.50 (IH, m, a -H ), 5.00 (2H, s, CH^Ph), 6.50 (IH, t, 7 7 Hz, 5'H),
6.70 (IH, d, /  7 Hz, 6 'H), 7.30 (IH, t, /  7 Hz, 4'H ), 7.40 (5H, m, aiomatic), 7.70 (IH, d, 
3'H); m/z (Cl) 343 ([M+H]+, 100%), 325 (18, [M+H-H2 0 ]+), 252 (18, [Af+H-CH2 Ph]+), 
235 (55, [M-PhCH20]+).
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(26T)-Kynurem:ne (1).
O CO2H(XA
W-(Benzyloxycarbonyl)-(2S)-kynurenine (359 mg, 1.05 mmol) was dissolved in 15 ml 
methanol and 5% Pd/C (359 mg) was added. This was hydrogenated overnight at 
atmospheric pressure using the hydrogenation apparatus then filtered through a celite bed. 
The methanol was evaporated under reduced pressure to afford kynurenine (153 mg, 70%). 
The pale yellow solid was taken up in water and freeze dried; mp 188 "C (lit.,*^‘* 191 °C); 
[a]20D -29.5° (c 0.5 in H2 O) (lit.,^24[g]25p .3 0 .5 » (c 1 in H2 O)); Umax (nujol)/cm-l 3320 
(OH), 1720 (CO), 1650 (acid CO); 8 h  (200 MHz; 2 R 2 0 ) 3.60 (2H, d, /  10 Hz, p-CHa),
4.05 (IH, m, a-H). 6.50 (IH, t, J  7.5 Hz, 5'Hl, 6.70 (IH, t, J  7.5 Hz, 4'H), 7.50 (IH, d, 
J  7.5 Hz, 6 'H), 7.70 (IH, d, J  7.5 Hz, 3'H); 8 c (50.31 MHz; d^-DMSO) 41.70 (s, p -£ ), 
53.19 (s, a - £ ) ,  120.67 (s, 3'£), 120.93 (s, 5'C), 121.39 (s, 6 'C), 134.12 (s, 4 '£), 138.43 
(s, l '£ ) . 151.51 (s, 2 '£), 176.57 (s, CO 2 H), 202.59 (s, CH2 £OPh); m/z (FAB) 209 
([M+H]+, 6 6 %).
236
-Acetyl (2S^)“[2“2H]4ryptopliiaE (219).
1 NJ'a
Tryptophan (5 g, 24.5 mmol) was added to 2 H2 O (50 ml) with stirring. Sodium (2.34 g,
105.6 mmol) was added carefully after washing in petroleum ether and ethanol. Acetic 
anhydride (15 ml) was added to the solution in 5 ml portions, shaking after each addition. 
The resulting dark orange solution was left stirring for two hours, after which time a white 
solid had precipitated from solution. A further amount of (5ml) was added and the 
solution was left to stir overnight. The resulting solution was cooled in the fridge for several 
hours and then the crystals were filtered off and washed with cold water. The residue was 
suspended in 0.2 M HCl, cooled, filtered and washed with cold water until free of the 
chloride ion. The pale pink crystals obtained (4.55 g, 75%) were dried, m.p. 278 °C; Dmax 
(nujol) /cm-l 3380 (indole NH), 1710 (CO ester), 1610 (CO amide); ô r (200 MHz; d^- 
DMSO) 1.85 (3H, s, NHCOCH3 ), 3.05 (2H, dd, J  15 Hz, P-CH2 ), 6.95 (2H, m, 5'H, 
6 'H), 7.15 (IH, s, 2'H), 7.30 (IH, d, J  7.5 Hz, 7'H), 7.50 (IH, d, J  7.5Hz, 4'H), 8.25 
(IH, s, indole NH); §c (50.31 MHz; d^-DMSO) 22.62 (s, CH3 ), 27.27 (s, p-Q , 52.94 (t, 
a -C ), 110.15 (s, 3'C), 111.65 (s, 7'C), 118.37 (s, 5'C), 118.65 (s, 6 'C), 121.20 (s, 4'C), 
123.78 (s, 2'C), 127.40 (s, 7a'C), 136.32 (s, 3a'C), 169.70 (s, CH3 CO), 173.81 (s, 
ÇO2 H); m/z (Cl) 265 ([M+NH4 ]+,1 2 %), 248 (100, [M+H]+), 230 (53, [M+H-H2 0 ]+), 130 
(1 0 0 , [CH2  ind]+).
237
(2S)"[2“^ H]"Tryptop!îaini (220).
H2N CO2H
iV-Acetyl (25'/?)-2-pH]-tryptophan (5.14 g, 20.8 mmol) was added to water (200 ml) and the 
pH adjusted to 7.5 using concentrated ammonia. Acylase îvom Aspergillus meleus (520 mg,
0.47 units/mg) was added and the solution incubated at 38 °C. After a few days it was seen to 
have reacted to completion by ^H NMR. The acylase was filtered off and the solution reduced 
in volume. Ion exchange chromatography (DOWEX 1) was carried out and the product 
fractions freeze dried to give a white solid (2.08 g, 97%), m.p. 232 °C (lit.,[Sigma L- 
Tryptophan sample] 228 °C); (Found; C, 64.60; H, 5.5.72; N, 13.61. Calc, for 
C 1 1H 1 1N2 O2 2 H: C, 64.375; H, 5.89; N, 13.65%); [a]^^D -10.4° (c 0.5 in H2 O) (lit.,204 
-33.4° (c 1 in EtOH); \)max (nujol) /cm-1 3370 (indole NH), 1645 (CO ester); §h (200 MHz; 
2 H 2 O) 3.20 (2H, dd, J 15 Hz, P-CH2 ), 7.00 (IH, t, J  7.5 Hz, 5'H), 7.15 (2H, m, 2'H, 
6 'H), 7.40 (IH, d, J  7.5 Hz, 7'H), 7.60 (IH, d, J  7.5 Hz, 4'H); Sc (74.76 MHz; d^-DMSG)
24.40 (s, P-Ç), 53.19 (s, a-C), 105.62 (s, 3'C), 110.03 (s, 7'C), 116.54 (s, 5'C), 117.55 
(s, 6 'C), 120.22 (s, 4'C), 123.10 (s, 2'C), 124.76 (s, 7a'C), 134.43 (s, 3a'C), 172.59 (s, 
ÇO2 H); m/z (FAB) 433 ([2M+Na]+, 2%), 411 (9, [2M+H]+), 228 (14, [M+Na]+), 206 
(100, [M+H]+), 160 (16, [M-C0 2 1 +), 130 (53, [CH2 -indole]+).
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(25!)-[2-^H]-Tryptophan ethyl ester hydrochloride (221).
2- NH3+CI-
® 'f7a=-j^r
(2iS)-[2-2H]-Tryptophan (3.12 g, 15.16 mmol) was dissolved in dry redistilled ethanol (60 
ml) cooled in ice. Redistilled thionyl chloride (1.2 ml, 1.1 eq) was added and the solution 
was refluxed for one hour at approximately 100 °C. The solvent was concentrated in vacuo 
and recrystallisated from ethanol to give an off white solid (2.53 g 72%), m.p. 224 “C; [apO[) 
+12.25° (c 1 in MeOH); u^ax (nujol)/cm’l 3250 (indole NH) and 1725 (CO ester); 5h (200 
MHz; d^-DMSO) 1.10 (3H, t, 7 7 Hz, CO2 CH2CH3 ), 3.20 (2H, m, P-CH2 ), 4.10 (2H,q, J  
1 Hz, CO2 CH2 CH3 ), 7.10 (3H, m, 2'H, 5’H, 6 ’H), 7.60 (IH, d, 7 7 Hz, 7'H), 7.80 (IH, 
d, 7 7 Hz, 4'H), 8.70 (IH, s, indole NH); 6 c (50.31 MHz; d^-DMSO) 13.96 (s, 
CO2 CH2 CH3 ), 26.32 (s, P-Ç), 61.85 (s, CO2 ÇH2 CH3 ), 106.69 (s, 3'C), 111.79 (s, 7'C), 
118.28 (s, 5'C), 118.81 (s, 6 '0 ,  121.39 (s, 4 '0 ,  125.18 (s, 2 '0 ,  127.20 (s, 7a'C), 
136.44 (s, 3a'C), 169.56 (s, C0 2 Et); m/z (El) 233 ([M+H]+, 10%), 130 (100, [CH2 - 
indole]+) 103 (13, [M+H-CH2 -indole]+).
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i¥“(Beinizylosyca6’bo]nyI)“(2S)“[2“2H]“tryptophan ethyl ester (222).
CO oEt
(25)-Tryptophan ethyl ester hydrochloride (3.54 g, 15.2 mmol) was dissolved in water (80 
ml). Sodium carbonate (2.2 eq, 33.40 mmol, 3.52 g) was added followed by 
benzylchloroformate (1.2 eq, 18.24 mmol, 2.6 g, 2.7 ml) The solution was left to stir 
overnight at room temperature. The reaction was followed by tic (silica, ethyl acetate: 
petroleum ether 3:7). A pale brown precipitate was seen and the solid was filtered off to give 
(4.54 g, 82%) of an off white solid, m.p. 76-78 “C; [a]^®D -9.0° (c 1 in EtOH); 'Omax 
(nujol)/cm-l 3300 (indole NH), 1720 (ester CO) and 1680 (amide CO); §h (200M Hz; d^- 
DMSO) 1.10 (3H, m, CO2 CH 2 C H 3 ), 3.10 (2H, m, P -C H 2 ), 4.05 (2H, q, /  7 Hz, 
CO2 CH2 CH3 ), 5.05 (2H, s, CHiPh), 7.05 (2H, m 5'H, 6 'H), 7.15 (IH, s, 2'H), 7.35 (6 H, 
m, 7'H, aromatic), 7.55 (IH, d, /  7 Hz, 4'H) 7.80 (IH, s, NH indole); §c (50.31 MHz; d^- 
DMSO) 14.20 (s, CO2 CH 2ÇH 3 ), 27.11 (s, p-C), 60.72 (s, CO2 ÇH 2 CH 3 ), 65.66 (s, 
CH2 Ph), 109.84 (s, 3'C), 111.71 (s, 7'C), 118.24 (s, 5'C), 118.68 (s, 6 'C), 121.23 (s, 
4'C), 124.11 (s, 2'C), 127.30 (s, 7a'C), 127.88, 128.05, 128.60 (3x s, aromatic), 136.37 
(s, quat. aromatic), 137.19 (s, 3a'C), 157.22 (s, COCH2 Ph), 172.49 (s, C0 2 Et); m/z (El) 
367 (M+, 28%), 216 (10, [M-PhCH2 0 C0 NH2 ]+), 130 (100, [CH2 -indole]+), 77 (15, 
[Ph]+).
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iV’Formyl, N-(benzyloxycarbonyl)-(2S)-[2-^H ]-kynurenine ethyl ester (223).
O COgEt O
Ph
7V-(Benzyloxycarbonyl)-(25)-[2-^H]-kynurenine ethyl ester (2.2 g, 2.0 mmol) was dissolved 
in dry distilled methanol (100 ml). The solution was cooled to -78 ”C with stirring and then 
treated with ozone for one hour, the reaction was then quenched with dimethyl sulphide (10 
ml). The reaction was checked by tic (silica, ethyl acetate: dichloromethane, 1: 9) and left to 
stir for a further hour at -78 °C. The solution was then evaporated to a dark orange oil. The 
product was dissolved in diethyl ether (50 ml) and washed with brine (2 x 100 ml) and water 
(2 X 100 ml). The solution was then dried (MgS0 4 ) and evaporated under reduced pressure 
to an orange oil. Purification was carried out by column chromatography (silica, ethyl acetate: 
petroleum ether, 1: 2) giving the product (786 mg, 33%), m.p. 111-112 °C; (Found: C, 
63.35; H, 5.81; N, 6.96; [M+H]+ 400.1619. C2 1 H2 1 N2 O6 2 H requires C, 63.15; H, 5.55; 
N, 7.01%; [M+H]+ 400.1613); +3.2° (c 1 in MeOH); Umax (nujol)/cm"l 3305 (indole
NH), 1725 (ester CO), and 1680 (amide CO); 6 5  (200 MHz; d^-DMSO) 1.15 (3H, t, 7 7 Hz, 
CO2 CH2 CH2 ), 3.45 (2 H, s, P-CH 2 ), 4.10 (2 H, q, 7 7 Hz, CO2 CH2 CH3 ), 5.05 (2H, s, 
CH2 Ph), 7.25 (lH,t, 7 7 Hz, 5'H); 7.35 (5H, m, aromatic), 7.65 (lH,t, 7 7 Hz, 4’H), 7.75 
(IH, s, NHCOH), 7.80 (IH, d, 7 7 Hz, 3'H), 8.00 (IH, d, 7 7 Hz, 6 'H), 8.45 (IH, m, 
NHCOH); 8c  (74.76 MHz; d^-DMSO) 14.03 (s, CO2 CH2ÇH3), 41.16 (s, p-C), 60.91 (s, 
CO 2 ÇH 2 CH 3 ), 65.64 (s, CH 2 Ph), 121.25 (s, 3'C), 123.45 (s, 5'C), 123.87 (s, I ’C), 
127.82, 127.94, 128.43 (3x s, aromatic), 130.94 (s, 6 'C), 134.37 (s, 4'C), 136.93 (s, quat. 
aromatic), 137.99 (s, 2'C), 155.92 (s, PhCH2 0 C0 ), 161.34 (s, NHCOH), 171.57 (s, 
£ 0 2 Et), 200.07 (s, PhCOCH2 ); m/z (Cl) 417 ([M+NH4 J+, 100%), 400 (55, [M+H]+), 372
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(6 , [M+H-C01+), 356 (10, [M-NHCO]+), 309 (32, [M+H-CH2 Ph]+), 292 (12, [M- 
O2CH2PW+), 108 (19, [PhCH20H]+).
'-(Benzyloxycssrbony!)-(2S)-[2-^H]-kyiiurenine ethyl ester (224).
O C O jE t  O 
■■ ■ Ph
The protected kynurenine (362 mg, 0.91 mmol) was dissolved in methanol (45 ml). 4 M HCl 
(4 ml, 3.44 mmol) and dioxane (15 ml) were added to the solution. The solution was stirred 
at room temperature for one hour. It was poured into saturated NaHCOg (120 ml) and 
extracted into ethyl acetate (150 ml). The organic extracts were then washed with water (2 x 
50ml). They were dried (MgSO^), filtered and evaporated at reduced pressure to obtain a 
yellow oil (33 mg, 98%) which crystallised on standing, m.p. 60 °C; Umax (nujol)/cm~l 1725 
(ester CO) and 1680 (carbamate CO); 6 h (300 MHz; d^-DMSO) 1.15 (3H, t, 7 7 Hz, 
CO2 CH2 CH3 ), 3.40 (2H, m, P-CH2 ), 4.10 (2 H, q, 7 7 Hz, CO2 CH2 CH3 ), 5.10 (2H, s, 
CH2 Ph), 6.65 (IH, t, 7 7 Hz, 5’Hl, 6.80 (IH, d, 7 7 Hz, 6 ’H), 7.15 (2H, s, NH2 ), 7.30 
(IH, t, 7 7 Hz, 4'H), 7.35 (5H, m, aromatic), 7.55 (IH, s, NH) 7.70 (IH, d, 7 7 Hz, 3’H); 
8c  (74.76 MHz; d^-DMSO) 13.91 (s, CO2 CH2ÇH3 ), 60.63 (s, CO2 CH2 CH3 ), 65.50 (s, 
CH2 Ph), 114.46 (s, 3'C), 116.30 (s, I'C), 116.98 (s, 5'C), 127.62, 127.76, 128.30 (3x s, 
aromatic), 131 09 (s, 6 'C), 134.33 (s, 4'C), 136.95 (s, quat. aromatic), 151.22 (s, 2'C), 
155.83 (s, PhCHiOCO), 171.77 (s, C0 2 Et), 197.75 (PhCOCHi); m/z (Cl) 372 ([M+H]+, 
100%), 264 (57, [M-PhCH20]+), 108 (15, [PhCH20H]+).
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■(Benzyloxycarbonyil)“(2S)“[2“2H]“kyiiiiiireBme (225),
O C O 2 H O
■■ ■ " > ^ 0 Ph
iV-(Benzyloxycarbonyl)-(25)-[2-2H]-kynurenine ethyl ester (291 mg, 0.78 mmol), was 
dissolved in a 1: 1 mixture of THF and water (14 ml) and treated with lithium hydroxide 
monohydrate (91 mg, 2.18 mmol). The solution was warmed at 70 “C for four hours. The 
reaction was followed by tic (silica, ethyl acetate: petroleum ether 1:2). The solution was 
poured into 1 M HCl (7 ml) and extracted into ethyl acetate (125 ml). It was dried (MgS0 4 ), 
filtered and concentrated under reduced pressure to give a yellow oil. This was then dissolved 
in ethanol and concentrated under reduced pressure to give a bright yellow solid (267 mg, 
95%); m.p. 169-170 °C; + 44.8° (c 0.13 in MeOH); Umax (nujol)/ cm~l 1725 (ester
CO) and 1680 (amide CO); 5h (300 MHz; d^-DMSO) 3.40 (2H, m, P-CH2 ), 5.05 (2H, s, 
CH2 Ph), 6.55 (IH, t, 7 7 Hz, 5'Hl, 6.75 (IH, d, 7 7 Hz, 6 'H), 7.10 (2H, br s, NH2 ), 7.25 
(IH, t, 7 7 Hz, 4'H), 7.35 (5H, m, aromatic), 7.40 (IH, m, NH), 7.70 (IH, d, 7 7 Hz, 
3'H); Sc (74.76 MHz; d^-DMSO) 65.58 (s, CH2 Ph), 114.65 (s, 3’C), 116.51 (s, I'C), 
117.11 (s, 5'C), 127.73, 127,87, 128.43 (3x s, aromatic), 131 22 (s, 6'C), 134.42 (s, 4'C),
137.06 (s, quat. aromatic), 151.28 (s, 2'C), 156.01 (s, PhCH2 0 C 0 ), 173.40 (s, ÇO2 H), 
198.21 (PhCOCH2 ), m/z (El) 343 (M+, 5%), 235 (5, [M-PhCH2 0 H]).
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(2S)-[2-^H]-Kynuremme (199).
O COgH
iV-(Benzyloxycarbonyl)-(25)-[2-2H]-kynurenme (235 mg, 0.69 mmol) was dissolved in 
methanol (15 ml) and 5% Pd/C (235 mg) was added. This was hydrogenated overnight at 
atmospheric pressure and filtered through a celite bed. The methanol was evaporated under 
reduced pressure and isopropanol (1.50 ml) was added containing a small amount of RS- 
dithiothreitol. The dark orange solid which resulted was neutralised with propylene oxide 
(0.18 g, 3.39 mmol). Diethyl ether was added and a pale yellow solid precipitated out of 
solution. After filtration more solid was seen to precipitate out of the diethyl ether. On 
filtering this became a yellow oil and was taken up in water and the resulting pale yellow 
solution was freeze dried to give (0.05 g, 42%) of a yellow solid (65 mg, 45%); m.p. 188 °C; 
[aj^Op -25.5° (c 0.5 in HgO); Umax (nujol)/cm-l 3320 (OH), 1720 (CO), 1650 (acid CO); 6h 
(200 MHz; % 20) 3.60 (2H, d, J 10 Hz, P-CH2 ), 4.05 (IH, m, a -H ), 6.50 (IH, t, J  7.5 
Hz, 5’m , 6.70 (IH, t, J  7.5 Hz, 4'H), 7.50 (IH, t, J 7.5 Hz, 6 'H), 7.70 (IH, d, J  7.5 Hz, 
3'H); §c (50.31 MHz; d^-DMSO) 41.70 (s, p-C), 53.19 (s, a -C ), 120.67 (s, 3'C), 120.93 
(s, 5'C), 121.39 (s, 6 'C), 134.12 (s, 4'C), 138.43 (s, I'C), 151.51 (s, 2'C), 176.57 (s, 
CO2 H), 202.59 (s, CHgCOPh); m/z (FAB) 209 ([M+H]+, 6 6 %). The material was identical 
in all respects to that obtained from the first method, with an enantiomeric excess of 98%.
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6.2 Partial Purification of Pseudomonas fluorescens^
The freeze diied culture of Pseudomonas fluorescens was grown in nutrient broth containing 
'Lab. Lemco' powder (meat extract) 0.1%, yeast extract 0.2%, peptone 0.5% and sodium 
chloride 0.5% (0.26 g in 20 ml distilled water). The cultures were grown at 28 ”C for 
eighteen hours under aeration and then kept refrigerated until required. This was then sub­
cultured to a media containing 0 .1 % 25'-tryptophan, 0 .2 % peptone, 0 .1 % glycerin, 0.05% 
yeast extract, 0.1% KH2PO4 , 0.2% K2 HPO4 , and 0.01% MgS0 4 .7 H2 0  (3 1). The cultures 
were grown at 28 “C for eighteen hours under aeration.
The harvested cells were washed twice with 0.85% sodium chloride solution (10 ml) and 
subsequently with 0.01 M potassium phosphate buffer (10 ml, pH 7.2). All operations were 
carried out at 4 °C. All buffers used contained 20 fxM PLP and 0.01% 2-mercaptoethanol. 
After each wash, centrifugation was carried out at 6  500 g and 4 °C.
Step 1
The washed cells (28.8 g) were mixed with 0.01 M potassium phosphate buffer (pH 7.2) (35 
ml) and sonication was carried out in eight thirty second bursts with two minutes between 
bursts. The resultant sluriy was then centrifuged (32 000 g for twenty minutes at 4 °C).
Step 2
To the cell free extract (35 ml), 1 ml of 1 % protamine sulphate in 0.01 M potassium 
phosphate buffer (pH 7.2) was added per 100 mg of protein (17 ml) with stirring over ten 
minutes. The mixture was then stirred for a further thirty minutes and centrifuged (32 000 g 
for twenty minutes at 4 ”C) and the buUcy inactive precipitate was discarded.
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The enzyme solution (60 ml) was brought to 20% saturation with ammonium sulphate (6.84 
g) added over twenty minutes and then stirred for a further thirty minutes. The precipitate 
was removed by centrifugation (32 000 g for twenty minutes at 4 °C).
Ammonium sulphate (13.5 g) was added to the supernatant to 55% saturation over 
approximately thirty minutes and stirring was continued for thirty minutes. The precipitate 
was collected by centrifugation (32 000 g for twenty minutes at 4 °C).
The precipitate was dissolved in 0.01 M potassium phosphate buffer (pH 7.2) (10 ml) and 
then dialysed overnight against 100 volumes (1000 ml) of the same buffer. After dialysis the 
enzyme solution was centrifuged (32 000 g for twenty minutes at 4 “C).
The dialysed enzyme solution (10 ml, 25-30 units activity) was placed on a DEAE-cellulose 
column, (2.5 x 20 cm) and equilibriated with 0.01 M potassium phosphate buffer (pH 7.2). 
The column was washed thoroughly at a flow rate of 80 ml per hour (120 ml) with the same 
buffer followed by the buffer containing 0.1 M sodium chloride (120 ml). The enzyme was 
eluted with the buffer supplemented with 0.2 M sodium chloride. The active fractions were 
pooled (55 ml) and brought to 70% saturation with ammonium sulphate (25.96 g) added over 
about thirty minutes and then stirred for a further thirty minutes. The precipitate was collected 
by centrifugation (32 000 g for twenty minutes at 4 °C).
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step 7
The precipitate was suspended in 0.01 M potassium phosphate buffer (pH 7.2) (10 ml) and 
concentrated by ultrafiltration (4.5 ml) using a filter (AMICON, YM 10, 43 mm). This was 
then stored in the freezer ready for use.
6.2.1 Preparation of dialysis tefoing.
Dialysis tubing was prepared by boiling for five to ten minutes in distilled water (200 ml) 
containing EDTA (0.2 g). Prepared dialysis tubing was kept in a solution of ethanol: water 
(1 : 1) and rinsed with distilled water before use.
6.2.2 Regeneration of DEAE cellulose.
The DEAE cellulose was washed with hydrochloric acid (0.5 M, 1000 ml) followed by 
distilled water (1500 ml) five times or until the pH was the same as distilled water. The 
DEAE cellulose was washed with sodium hydroxide (0.5 M, 1000 ml) followed by distilled 
water (1500 ml) ten times or until the pH was the same as distilled water. Most of the water 
was then removed and 0.01 M potassium phosphate buffer added. This was decanted and 
more buffer added in order to pack the column.
6.3 ASSAY OF ECYNURENINASE ACTIVITY.
The activity of kynureninase was determined by measuring the rate of decrease in absorbance 
at 360 nm (e= -4500 mol~l dm^ cm - )^ due to the conversion of kynurenine to anthranilic 
acid. Incubation was carried out at 25 ± 0.1 °C in the thermostated housing of the UV 
spectrophotometer using a 1 cm path length cuvette (1.2 ml). Reaction was initiated by the 
addition of 30 |il of enzyme solution to the assay buffer (1 ml). The assay buffer contained
0.4 mM kynurenine, 40 p,M PLP in 0.04 M potassium phosphate and was brought to pH 7.0 
using 4 M potassium hydroxide. Enzyme activity was measured in units where one unit is
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defined as the amount of enzyme required to convert one pmol of substrate per minute under j 
standard conditions.
From the Beers law,
A = eel, therefore c = A/el 
volume = 1 ml + 30 |Xl 
= 1.03 ml
The rate for one unit under assay conditions is 
dc , , 1 0 0 0
= 9.709 X lO"'^  mol dm"3 min~l
This is then converted to rate in absorbance units per minute for one unit.
^  = 9.709 X 10-4 X 1 X -4500 dt
= -4.369
The number of units of enzyme activity can, therefore, be calculated.
_ absorbance per minute from assayno. of units = ---------------   —absorbance per minute for one unit
» gradientno. of units =  --------4.369
The number of units per ml can then be calculated.
248
6.3.1 Determination of Kinetic Param eters.
Determination of inhibition of kynureninase by various compounds was performed by 
variation of the concentration of (25)-kynurenine, from 0.1 to 0.5 mM, at several fixed values 
of the inhibitor concentration ranging from 0.05 mM to 2.0 mM. The reactions were linear 
over the time course measured and the rate was measured in duplicate or in triplicate. Km and 
Vmax values were calculated by fitting of initial rate data to the Michaelis-Menten equation via 
non linear regression with the ENZFITTER^^^ programme on a PC. The analysis for each 
compound was carried out at three inhibitor concentrations. Each compound was compared 
to a standard assay of kynurenine from 0.1 to 0.5 mM (For example, see Table 6.1 and 6.2).
Change in 
Absorbance for 0.4 mM K ynurenine 
(min -1 )
K ynurenineconcentration
(mM)
Change In Absorbance for 
Standard Assay 
(min -1 )
Average Change
in Absorbance for Standard 
Assay (min “l)
0.2403 0 . 1 0.2107
0 . 2 1 1 0
0.21085
0.2346 0 . 2 0.2280
0.2290
0.2288
0.2286
0.20685 0.3 0.2065
0.2063
0.2064
0 . 2 0 0 0 0.45 0.2078
0.2083
0.2076
0.2079
0.1970 0.5 0.1881
0.1880
0.18805
Table 6.1
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Before each run an assay was carried out in normal assay buffer (0.4 mM kynurenine) so that 
the change in absorbance, of the standard assay, could be corrected for one unit of enzyme 
activity.
Change in Absorbance for 0.4 mM Kynurenine 
(min -1 )
Number of units of enzyme activity
Average ChangeIn Absorbance for Standard 
Assay (min “1)
Average Change in Absorbancecorrected for one unit of enzyme 
activity (min "1 )
0.2403 0.0550 0.21085 3.83
0.2346 0.0537 0.2286 4.26
0.2068 0.0473 0.2064 4.36
0.0458 0.0458 0.2079 4.54
0.1790 0.0410 0.18805 4.59
Table 6.2
The data was then fitted to the Michaelis-Menten equation by non-linear regression using the 
ENZFITTER^^^ programme. This provided values of Km and Vmax with calculated errors. 
A Lineweaver-Burk plot was also drawn (Graph 6.1).
The rate generally follows saturation kinetics with respect to the concentration of the 
substrate. At sufficiently low [S], V increases linearly with [S] but as [S] is increased, this 
relationship brealcs down and V increases less rapidly than [S] until, at sufficiently high or 
saturating [S], V tends towards a limiting value termed Vmax- This is expressed 
quantitatively in the Michaelis-Menten equation, the basic equation of enzyme kinetics.
V = ^So..t.?.I .!5:,cat Michaelis-Menten equation [S] +Km
where, ICcat [E]o = Vmax-
The concentration of substrate at which V = 1/2 Vmax is termed Km, the Michaelis constant.
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4.55
4.45
4.35
.25
10- i
2.55
®  4.15
m 2.45
£K 2.35V■H 2.25
4.05
3 . 9 5
3.85 0 . 4 0
C s u b s t i T ' a t e ]
Graph 6.1
For kynurenine Km was calculated as 25.1 jiM and Vmax as 4.78 min'l. This Vmax can be 
converted to standard units by dividing by the molar extinction coefficient. Therefore Vmax 
is equal to 1.06 x lO'^ mol dm'^ mimk
The complete set of results are shown in the Appendix.
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6.4 Protein determ ination.
Protein was determined by the method of Bradford^using bovine serum albumin as a 
standard (0-10 |ig in 0.1 ml). Bradford reagent (1 ml) was added to each sample (0.1 ml) 
and the mixture left to react for thirty minutes before the optical density was recorded at 
595 nm. A calibration curve was plotted and used to determine the amount of protein in each 
sample.
6.4.1 Specific activity.
Specific activity is expressed as units per milligram of protein and is defined as:
VC- units of activityspecific activity = -------------------mass of protein
6.5 Determination of Substrate Properties.
Determination of the substrate properties of compounds was performed by tic (cellulose, IPA: 
conc. NH3 : H2 O; 36: 6 : 10).
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K m Determination for Kynurenlne.
3 Buffer at pH 7.0 
^ Buffer at pH 7.8
Num ber KM (|4M) E rro r (pM) Vmax(m in-l)
E rror 
( x l 0 ”2  lîiin"!)
1 » 25.26 ±1.17 4.79 ±2.34
2 a 25.03 ±0.597 4.80 ± 1 . 2 0
3» 25.22 ±9.80 4.82 ±19.8
4 a 26.12 ±8.70 4.88 ±17.6
5 a 26.13 ± 1 0 . 1 4.83 ±2 0 . 2
5 a 25.15 ±6.52 4.80 ±13.1
7 a 25.91 ±7.28 4.85 ±14.7
ga 25.39 ±1.60 4.79 ±3.20
9 b 25.10 ± 1 . 0 1 4.78 ±2.03
Table 7.1
Average Km = 25.48 ± 0.6 |iM 
Average Vmax = 4.82 ± 0.06 min ^
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Phosphlnic Add Analogue. 0.5 mM Fhosplitîik Add
[Substrate] (mM)
3.770.10
4.170.20
4.290.30
4.560.45
4.600.50
4.60
4.50
4.40
4.30
41 4.20
10-1
2.604.10
2.50
4.00 flj 2.40 US
^  2.303.90
2.20
3.80 0.800.40
Kinetic Param eters for 0.5 mM Phosphinic Acid
Variable 
Vmax (min-i)
Value Error
4.81 ±0.0739
Km (MM) 28.6 ±3.78
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Phosphietc A dd Asialogue. 1 mM Phosphinic A dd
[Suhstfate] (mM)
0.10 3.70
0.20 4.12
0.30 4.25
0.45 4.53
0.50 .61
4.55
4.45
4.35
.25
4.15
.05
0, 2.503.95
3.05 2.30
3.75
0.40
siBbsü: r  aik e 3
Kinetic Param eters for 1 mM Phosphinic Acid
Variable Value Error
Vmax (lïlin 4.82 ±0.0905
Km (itM) 31.6 ±4.73
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Phosphinic Acid Analogue. 2 mM Phosphinic Acid
Rate (min°^) 
4.04
[Substrate] (mM)
0.20
4.410.45
4.490.50
4.40
4.44
4.40
4.36
4.32
4.28
2.44
2.40Of-s^  2.36 
Ç  2.32 
2.20 
2.24
4.20
4.16
4.12
4.08
2.50 3.50 4.504.04
2.20 2.60 3.00 3.40CsajOjsflrD-'-aittielD3.80 4.20 4.60
Kinetic Parameters for 2 mM Phosphinic Acid
Variable Value Error
Vmax (niin 4.81 ±0.0576
Km (M-M) 37.7 ±4.27
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Methyl Phosphimate Analogue. 0.5 mM Methyl Phosphlnate
V'
Rate (min-^) 
3.50
[Substrate] (mM)
0.10
4.140.20
4.290.30
4.460.45
4.570.50
4,50
4.40
4.30
4.20
4.10
f? 4.00IS
3.90 2.70
3.80
3.70
2.30
3.50
10
Kinetic Parameters for 0.5 mM Methyl Phosphlnate
Variable 
^max (min
Value Error
4.89 ±0.0522
Km (pM) 39.0 ±2.84
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Methyl Phosphlnate Analogue. 1 mM Methyl Phosphlnate
[Substrate] (mM)
0.10 3.15
0.20 3.98
0.30 4.25
0.45 4.43
0.50 4.50
4.40
4.20
4.00
3.80C£ 3.10
3.60 2.90
2.70
3.40
2.30
3.20 0.40  AXES 3
Kinetic Parameters for 1 mM Methyl Phosphlnate
Variable Value Error
Vmax (min 4.89 ±0.0522
Km ( m ) 39.0 ±2.84
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Metliyl PbosphÊnate Analogue. 2 mM Methyl Phosphlnate
Rate (min°^)[Substrate] (mM)
0.10 2.86
0.20 3.69
0.30 4.10
0.45 .41
0.50
4 . 3 0
4 . 1 0
3 . 7 0
K  3 . 5 0
3 . 2 03 . 3 0
é  2.003 . 1 0
2 . 4 0
2 . 9 0
0 . 4 0
ICmetic Param eters for 2 mM Methyl Phosphmate
Variable Value Error
Vmax (min"^) 5.23 ±0.131
Km (liM) 83.1 ± 8 . 6 6
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Methyl Phosphmate Analogue. 2 mM Methyl Phosphmate
[Substrate] (mM)
2.790.10
3.770.20
4.250.30
4.440.50
4.590.60
4.40
4.20
4.00
3.80
û£
3.40 3.20
3.20
■H 2.403.00
0.402.80
5.503.50 4.502.50E sasftos'it e 31.50
lOïietîc Param eters for 2 mM Methyl Phosphlnate
V a r ia b le Value Error
V m a x  (min-1) 5.27 ±0.143
Km (M-M) 83.7 ±9.66
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Substrate Analogue. 0.05 mM Cyclohexyl Amino Acid
Rate[Substrate] (mM)
0.10 3.72
4.020.20
4.240.30
4.400.45
4.490.50
.45
4.35
.25
4.15
4.05
2.60
3.95
3.85
2.30
3.75 0.40 0.80
s t r a t e ]
Kinetic Param eters for 0.05 mM Cyclohexyl Amino Acid
Variable Value Error
V m a x  ( m in - 1 ) 4.66 ±0.0703
Km (fxM) 26.9 ±3.66
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Substrate Analogue. 0.1 mM Cyclohexyl Amino Acid
[Substrate]
0.10 3.65
0.20 3.96
0.30 4.15
0.45 4.39
0.50 4,45
4.40
4.30
.20
4.10
es 4.00
2.603.50
esV  2.40 «H3.00
3.70
0.80
ICInetic Param eters for 0.1 mM Cyclohexyl Ammo Acid
Variable Value Error
Vmax (min-1) 4.64 +0.0927
Km (|xM) 29.0 ±4.93
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Substrate Analogue. 0.2 mM Cyclohexyl Amino Acid
[Substrate] (mM)
3.580.10
3.890.20
4.130.30
0.45 4.38
4.420.50
4.40
4.30
.20
4.10
.00
10-1
3.30
3.80
2.403.70
3.60 0.40
10sttfltîst: r a t e
Kinetic Param eters for 0.2 mM Cyclohexyl Amino Acid
Variable Value Error
Vmax (min i) 4.64 ±0.0985
Km ([iM) 31.8 ±5.36
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Substrate Analogue. 0.05 mM Naplithyl Amino Acid
[Substrate] (mM)
3.820.10
4.270.20
4.360.30
4.670.45
4.700.50
4.65
4.55
4.45
4.35
.w 4.25
.15 2.50
4.05
F  2.30■H3.95
2.103.85
Kinetic Param eters for mM Naphthyl Amino Acid
Variable Value Error
Vmax (min-1) 4.93 ±0.0876
Km ({iM) 30.2 ±4.42
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Substrate Analogue, 0.1 mM Naphthyl Amino Acid
[Substrate] (mM)
0.10 3.56
0.20 4.04
0.30 4.26
0.45 4.52
0.50 4.56
4.50
4.40
4.30
.20
4.10
10-1
2.703.90
2.503. BO
3.70 2.30
3.60 0.40IX ES 3
Kinetic Param eters for 0.1 mM Naphthyl Amino Acid
Variable Value Error
Vmax (min-1) 4.87 ±0.0651
Km (pM) 38.1 ±3.54
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Substrate Aealogee. 0.15 mM Naphthyl Amimo Acid
Rate (mm-1) 
3.36
[Substrate] (mM) 
0.10
0.20
4.090.30
0.45 4.38
0.50 4.42
4.40
4.30
4.10
^  3T.OO
2.803.70
2.403,50
0.40
C siatost a~ab4
Kinetic Param eters for 0.15 mM Naphthyl Amino Acid
Variable Value Error
Vmax (niin 4.77 ±0.0625
Km (M-M) 43.4 ±3.60
281
Substrate Analogue. 0.05 mM Desaminokynurentne
[Substrate] (mM)
0.8910.10
0.9830.20
1.300.30
1.350.45
1.470.50
1.46
1.42
1.38
1.34
1.30
1.26
1.22
1.14
1.051.10
1.06 & 0.95
1,02 K  0.85
0.98 0.75
0.94
0.90 0.40
ICInetic Param eters for 0.05 mM Desaminokynurenlne
Variable Value Error
^max (min 1.74 ±0.169
Km (P-M) 113 ±38.3
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Substrate Analogue. 0.2 mM Desaminokynurenlne
Rate (mln“^ ) 
0.380
[Substrate] (mM)
0.10
0.6810.20
0.9080.30
0.9470.45
0.9920.50
0.98
0.34
0.90
0.86
0.82
0.78  
0.74  
Cj 0.70
0.62 2.40
0.58 2.00
0.54
p : 1.600.50
0.46 1.20
0.42
0.38
siBlîsfS: fl-'S't © 3
Kinetic Parameters for 0.2 mM Desaminokynurenlne
Variable Value Error
Vmax (min-1) 1.52 ±0.205
Km ([iM) 252 ±78.5
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Substrate Analogue. 0.3 mM Desaminokynurenlne
Rate (mln-i) 
0.187
[Substrate] (m M )
0.10
0.3600.20
0.4410.30
0.5260.45
0.5610.50
5.20
4.80
4.40
4.00
3,20 4.50
2.80 3.50
2.502.40
2.00 0.40
S 3
C siJibstr'ate '
Kinetic Parameters for 0.3 mM Desaminokynurenlne
Variable Value Error
Vmax (min-1) 0.976 ±0.838
Km ([iM) 371 ±62.0
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Primary Isotope Effect Studies on a-Deutehated Kymurenine
1 [Substrate] (mM) Rate (mln 1)
0 ,10 2.5%
1 0.15 Z.97
1 0 .20 3.45
1 0.25 3.66
0.30 3.79
0.35 3.89
0.40 3.99
0.45 4.08
0.50 4,13
3.40
±0^ -1 
3 .CO^  3.20
3.00
2.60 0.40&XÆS3
Kinetic Parameters for 0.4 mM a-Deuterlated Kynurenlne
Variable Value Error
Vmax (min”^ ) 4.94 ±0.0726
Km (liM) 93.6 ±5.32
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Solvent Isotope Effect Studies on Kynurenlne
[Substrate] (mM) Rate (mln-%)
0 . 1 0 0.869
0.15 0.923
0 .2 d 0.966
1 0.30 1 . 0 11 0.45 1.041 0.50 1.04
1.02
1.00
0.98
0.96
1.14
1.10
0.92
t !  1.06
V  1.020.90
0.98
0.88
0.40
0 .86
E S M b s t r a te 3
Kinetic Parameters for 0.4 mM Kynurenlne
Variable Value Error
Vmax (min-1) 1 . 1 0 ±0.0456
Km (m-M) 27.0 ±0.946
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Solvent Isotope Effect Studies on Kynurenlne
[Substrate] (mM) Rate (min-i)
0 . 1 0 0.873
0.15 0.920
0.25 0.989
0.30 1 . 0 1
0.50 1.04
1.04
1.02
1.00
0.98
® 0.96
1.140.94
1.10
0.92 ■iJ 1.06
0.90
0.98
0 .88 0.40 0.80
Kinetic Parameters for 0.4 mM Kynurenlne
Variable Value Error
Vmax (min-1) 1.09 ±0.0877
K m ([iM ) 26.2 ±1.72
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Solvent Isotope E ffe c t Studies on Kynurenlne
[Substrate] (mM)
0.10 0.871
0.15 0.929
0.9660.20
0.30 1.01
0.45 1.03
0.50 1.04
1.04
1.02
1.00
0.98
Q; 0.96
1.140.94
1.10
0.92 1.06flj
V  1.020.90
0.98
0 . 88 0.40
.40C s u b s t r a t e 1
Kinetic Parameters ffoD* 0.4 mM Kynurenlne
Variable Value Error
Vmax (min"l) 1.09 ±0.0323
Km (M-M) 26.2 ±0.667
